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Abstract
Proteins are the main functional components of all cellular processes, and most of them fold into unique
three-dimensional shapes guided by their amino-acid sequence. Discovering the structure of a protein, or
protein complexes, can provide important clues about how they perform their function. However, the
chemical, physical or architectural properties of many proteins impede traditional approaches to structure
determination. Two such proteins, the tumor suppressor p53 and the cholesterol processing enzyme
endothelial lipase, are prime examples of problematic proteins that defy structural investigation via
crystallographic methods. Therefore, new techniques must be developed to gain valuable structural insights,
such as: computationally assisted protein design strategies, more efficient crystal screening, or a combination
of both.
We applied a statistical computationally assisted design strategy to stabilize a p53 variant consisting of two
independently folding domains. The re-engineered variant retained normal DNA-binding activities, and
allowed us to experimentally determine the first structure of a physiologically active multi-domain p53
tetramer bound to a full-length DNA response element. We then demonstrated how computational
methodology can be used to gain functional detail of proteins in the absence of experimentally determined
structures. By creating comparative models of endothelial lipase, we discovered structural features that
describe function and regulation, and gained a better understanding of the mechanisms conferring substrate
specificity.
Additionally, traditional methods for protein structure determination, such as X-ray crystallography, require
relatively large amounts of purified sample in order to screen a sufficient variety of conditions. To improve this
process, we developed a novel method for protein crystal screening using a microfluidics platform. We show
how it is possible to use smaller quantities of protein to screen larger varieties of conditions, in turn increasing
the probability of success in obtaining crystals. Furthermore, in contrast to current crystallographic
approaches, all steps from screening to crystal growth to data collection were performed within the same
reaction chamber, without any manipulation of the crystal, dramatically increasing the efficiency of both time
and sample required to realize the structure. Collectively, these results demonstrate how advances in
computational and experimental approaches can provide structural detail for proteins in circumstances where
traditional methodology fails.
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ABSTRACT 
PROBABILISTIC PROTEIN DESIGN, COMPARATIVE MODELING, AND THE 
STRUCTURE OF A MULTIDOMAIN P53 OLIGOMER BOUND TO DNA 
Thomas John Petty II 
Thanos D. Halazonetis & Jeffery G. Saven 
  
 Proteins are the main functional components of all cellular processes, and most of 
them fold into unique three-dimensional shapes guided by their amino-acid sequence. 
Discovering the structure of a protein, or protein complexes, can provide important clues 
about how they perform their function. However, the chemical, physical or architectural 
properties of many proteins impede traditional approaches to structure determination. 
Two such proteins, the tumor suppressor p53 and the cholesterol processing enzyme 
endothelial lipase, are prime examples of problematic proteins that defy structural 
investigation via crystallographic methods. Therefore, new techniques must be developed 
to gain valuable structural insights, such as: computationally assisted protein design 
strategies, more efficient crystal screening, or a combination of both. 
 
We applied a statistical computationally assisted design strategy to stabilize a p53 
variant consisting of two independently folding domains. The re-engineered variant 
retained normal DNA-binding activities, and allowed us to experimentally determine the 
first structure of a physiologically active multi-domain p53 tetramer bound to a full-
length DNA response element. We then demonstrated how computational methodology 
can be used to gain functional detail of proteins in the absence of experimentally 
v 
 
 
 
determined structures. By creating comparative models of endothelial lipase, we 
discovered structural features that describe function and regulation, and gained a better 
understanding of the mechanisms conferring substrate specificity.  
 
 Additionally, traditional methods for protein structure determination, such as X-
ray crystallography, require relatively large amounts of purified sample in order to screen 
a sufficient variety of conditions. To improve this process, we developed a novel method 
for protein crystal screening using a microfluidics platform. We show how it is possible 
to use smaller quantities of protein to screen larger varieties of conditions, in turn 
increasing the probability of success in obtaining crystals. Furthermore, in contrast to 
current crystallographic approaches, all steps from screening to crystal growth to data 
collection were performed within the same reaction chamber, without any manipulation 
of the crystal, dramatically increasing the efficiency of both time and sample required to 
realize the structure. Collectively, these results demonstrate how advances in 
computational and experimental approaches can provide structural detail for proteins in 
circumstances where traditional methodology fails.  
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General Introduction 
 The structural characterization of proteins provides knowledge that can be used to 
help deduce a protein's role in human health and disease, as well as aid in drug 
development. Traditional approaches to structure determination, such as protein 
crystallography and nuclear magnetic resonance [NMR], are dependant upon the 
availability of pure, soluble protein. However, many proteins are modified and/or exist in 
complexes with other factors in vivo and can become unstable when removed from their 
native environment during experimental purification, preventing subsequent structural 
analysis.
 
 Structure determination by traditional techniques is a complicated process that 
involves producing the protein of interest in large quantities for subsequent purification 
and concentration, followed by screening against hundreds of conditions, characterization 
of crystals, crystal optimization, leading eventually to the generation of high quality X-
ray diffraction data. Numerous experimental challenges at each step, coupled to the need 
to maintain the protein in soluble form, make structure determination a long and 
problematic process. However, various approaches can be used to address these problems 
such as: creation of stable variants of the protein of interest, computational analysis and 
re-design of the protein, optimization of the crystal growth and screening process, or a 
combination of these approaches. In the what follows, advances in each of these topics 
are presented.  
 
 
 
 
- 2 - 
Organization and overview of chapters 
 This dissertation is divided in two parts. Part one (chapters 1-3) describes the first 
multi-domain crystal structure of the human tumor suppressor p53, made possible 
through selective mutagenesis and computational re-design of the protein. Given that p53 
is the most frequently mutated gene in all cancers, that it is implicated in many cellular 
processes affecting cell fate, and that the majority of the thesis work was dedicated to this 
investigation, the detailed introduction and discussion are centered on the p53-related 
discoveries and are presented in the first three chapters. 
 
Part two (chapters 4-7) is focused on describing recent developments in 
experimental and computational approaches used in determining protein structures. Each 
chapter is a self-contained module reflecting the associated scientific investigation 
containing a specific set of hypotheses, methods and corresponding bibliography 
sections. The figures and tables, however, are numbered in the context of the entire 
dissertation. 
 
Chapter 1  
INTRODUCTION: p53 through history, function and structure 
 
 The most frequently mutated gene in cancer encodes the tumor suppressor p53. 
This transcription factor has the crucial function of responding to cellular stress and 
eliciting responses that can change the cell cycle dynamics and initiate DNA damage 
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repair, or in situations when the damage is beyond repair, induce more drastic measures 
that lead to senescence or cell death. 
 
 Thirty years after its discovery in 1979, research continues to reveal novel p53 
functions. At the base of all known functions, however, lies the requirement for p53 to 
recognize and bind DNA response elements of effector genes, subsequently regulating 
their expression, in turn affecting various cellular responses. The vast majority of cancer-
causing mutations are located in the DNA-binding domain, demonstrating how altered 
DNA-binding capabilities lead to tumorigenesis. 
 
 The history of p53 is described in chapter one, starting with the discovery and the 
initial classification of p53 as an oncogene and how continued research led to the 
understanding that p53 is a tumor suppressor. Next, the multitude of well-documented 
functions are described, followed by a review of currently understood modes of 
regulation. Finally, after a description of the DNA response element sequence, the 
available p53-DNA structures are discussed, illustrating the contributions of each 
structure to current knowledge, and highlighting why more comprehensive p53-DNA 
structures are needed.  
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Chapter 2  
RESULTS: structure of a multidomain p53 oligomer bound to DNA 
 
 The critical function of p53 is the ability to recognize and bind to response 
element sequences of effector genes. Although previous p53-DNA structures have 
provided some insight into the details of DNA binding, there is still debate concerning 
various aspects of the p53-DNA interaction. Here we present the first structures of p53 
variants containing both DNA binding and oligomerization domains, made possible 
through selective mutagenesis and the computational protein design strategies described 
in chapter five. 
 
 In the absence of DNA, the p53 variants dimerize through the oligomerization 
domains, but the DNA-binding domains do not interact with each other. When incubated 
with dsDNA containing the full-length consensus p53 response element, the p53 dimers 
form tetramers on the DNA, creating robust protein-protein interfaces that induce a shift 
within the DNA. The structure reveals novel base-specific contacts and provides a more 
detailed understanding of cooperative binding interactions.  
 
Chapter 3  
DISCUSSION: p53 DNA-binding 
 
 The tetrameric p53-DNA complex reported here answers key questions regarding 
specific aspects of DNA binding. The architecture of the DNA binding and 
oligomerization domains is further described, with more discussion on how the DNA 
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binding domains come together on the response element to form relatively large protein-
protein interfaces involving conserved surface residues. Furthermore the most frequently 
mutated residue of p53 in cancer, Arg248, is discussed in more detail demonstrating how 
this residue interacts with invariant bases within the p53 response element sequence.  
Chapter 4  
Microfluidics, protein crystallization and in situ X-ray diffraction 
 
 Protein crystal screening is a rate-limiting step to the discovery of novel protein 
structures. Many combinations of salts, buffers and precipitants must be sampled before 
discovering the conditions promoting crystal growth, and conditions initially promoting 
growth usually require refinement in order to generate diffraction-quality crystals. 
Additionally, the limited amounts of purified protein can restrict the screening search 
space. Although liquid-handling robots are able to rapidly set up a large number of 
screening conditions using small volumes of sample, the choice of crystallographic 
method is limited. Furthermore, there are many subsequent time-consuming steps; the 
plates must be separately observed and cataloged, and crystals must be harvested or re-
grown, and finally stabilized and cryo-prepared for X-ray exposure.  
 
 We demonstrate an automated approach that can develop intricate custom 
screening buffers using fluid combinatorics, accurately distribute protein sample volumes 
of 50 to 100 nanoliters, grow crystals, and facilitate the collection of X-ray diffraction 
data to solve a structure to 1.5 Å with 100% completeness, all within the same reaction 
chamber and without direct manipulation of the crystal. Furthermore, unlike other 
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automated screening systems with limited flexibility, the system can replicate various 
well-established crystallographic protocols such as microbatch, vapor diffusion, and free 
interface diffusion. The methods developed here demonstrate the basis for a self-
contained, cost-effective, high-throughput (hundreds to thousands of unique simultaneous 
reactions), crystal screening system that streamlines all aspects of protein crystallization 
including data collection. 
 
Chapter 5  
Computational protein design: tailoring sequence, structure, and folding 
properties 
 
 While protein crystallization is an important means for obtaining atomic detail of 
macromolecules, often times this approach is not tractable due to protein insolubility or 
insufficient quantities of protein after purification, rendering experimental manipulation 
(expression, purification, crystallography) difficult or impossible. While the traditional 
methodology of sequence selection and mutagenesis can help to stabilize proteins, it 
involves a lengthy process of cloning, expression, screening and finally experimental 
characterization of the protein variants.  
 
 Here we present excerpts from a book chapter that we developed, published by 
the Royal Society of Chemistry in 2008, focusing on computational protein methodology. 
We present the current state of computational protein design and describe the underlying 
theories of these design approaches. Computational protein design strategies have been 
successfully used to solubilize trans-membrane proteins, modify substrate specificity of 
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enzymes, and to create self assembling polypeptides. We used some of the methods 
described in this chapter, namely the statistical computationally assisted design strategy 
[SCADS], to stabilize a human tumor suppressor p53 variant that led to determination of 
the first X-ray crystal structures of multi-domain p53 dimers and p53 tetramers bound to 
DNA. 
 
Chapter 6  
The active form of endothelial lipase: a homodimer in a head-to-tail 
conformation 
 
 Strategies other than probabilistic protein design, such as comparative protein 
modeling, can also be implemented to generate theoretical three-dimensional models of 
proteins in the absence of X-ray crystal structures. This technique uses the structural 
coordinates of a homologous protein as a sequence-structure template, to which the 
protein of unknown structure (the target) is then aligned, in order to generate initial 
structural models. A final step calculates a set of spatial restraints from the sequence 
alignment and three-dimensional template coordinates and applies them to protein 
backbone distances and dihedral angles. These restraints then serve as the basis of a 
global optimization step, leading to iterative refinement of the positions of atoms from 
the residues of the target sequence, resulting in an energy minimized three-dimensional 
model of the target protein. In this investigation, the existing pancreatic lipase [PL] 
structures served as the basis for modeling endothelial lipase [EL].  
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 Because endothelial lipase is a pharmacologic target for inhibition as a strategy to 
raise HDL cholesterol levels in humans, detailed structural information regarding the 
active forms of endothelial lipase could be important to the optimal design of EL 
inhibitors. Here we present comparative models of human endothelial lipase that grant 
the first structural details of this enzyme and provide evidence that it functions as a 
homodimer.  
Chapter 7  
Functional analysis of positively charged regions of endothelial lipase  
 
 The role of endothelial lipase in lipoprotein metabolism and in the development of 
atherosclerosis in humans continues to be an important area of study. Based on its ability 
to hydrolyze high density lipoprotein [HDL] and its reported association with coronary 
artery disease, endothelial lipase is a potential therapeutic target. Understanding key 
structural, substrate and surface binding domains can contribute to the efforts to regulate 
EL pharmacologically. 
 
 The endothelial lipase models presented in chapter six provided the basis to 
investigate experimental observations that various regions within endothelial lipase, when 
mutated or deleted, alter the activity towards lipid hydrolysis. We demonstrate that four 
regions map to the surface and can create motifs of local charge capable of recruiting 
factors regulating function. We also describe the implications of one region important for 
heparin-binding and another carboxy-terminal region implicated in regulation of the 
active EL conformation. 
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CHAPTER 1 
Introduction: p53 through history, function and structure 
 
 
History  
Discovery of p53 
 Two experimental investigations, one virologic and the other serologic, led to the 
near simultaneous discovery of p53 in 1979 by independent research groups (Fig. 1.1) 
(Lane DP & Crawford LV 1979; Linzer DIH & Levine AJ 1979). This early work 
probing either murine cells transformed by simian virus 40 [SV40] infection, or 
uninfected embryonic carcinoma cells, revealed an increased synthesis or stability of an 
approximately 53-54 kilodalton [kDa] cellular protein. A few months after these initial 
reports another group confirmed that p53 is a cellular tumor antigen by demonstrating 
that animals immunized with non-virally transformed cells produced antibodies to the 
same 53 kDa protein. This immunologic study detected an antigen that cross-reacted in 
two different cancers and could be linked to transformation, the ability of a cell to 
become immortal. The antigen was a protein 53,000 Daltons in size, was subsequently 
named p53, and was found to be expressed in a variety of cells transformed either by 
tumor viruses, spontaneously by chemicals, or by irradiation (DeLeo et al. 1979).  
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Figure 1.1 
 
Highlights in p53 research since 1979. Numerous key discoveries leading to the 
classification of p53 as a tumor suppressor, and defining the various structural elements 
of this transcription factor, are listed above. The small brown circles in each text box on 
the timeline correspond to the number in the reference list in the gray box.  
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p53 as an oncogene 
 The observation that various types of cancers elicited an immune response to p53 
prompted similar studies in humans. Numerous reports in the early 1980s revealed that 
anti-p53 antibodies were found in a wide variety of human cancer types (Crawford et al. 
1982; Caron de Fromentel et al. 1987). The 53 kDa protein gained popularity as a 
potential oncogene, given that elevated protein levels were associated with increased cell 
proliferation. Multiple groups using different cell types showed that expression of p53 
was positively correlated to induction of cell growth (Milner & McCornick 1980; Reich 
& Levine 1984; Mercer et al. 1984). However, during this period of discovery and 
characterization, the p53 protein detected in the aforementioned studies was believed to 
be wild-type. 
 
 In one investigation though, a p53 clone was unable to activate transformation, 
raising the question as to why this particular p53 clone could not transform cells (Finlay 
et al. 1989). Available cDNA clones were compared in attempts to find the reasons for 
this difference, and sequences of p53 previously classified as polymorphic were re-
classified at the realization that some sequence changes occurred in highly conserved 
regions (Fig. 1.2). After careful investigation of the sequences, it was understood that this 
particular non-transforming clone was actually wild-type p53, whereas the other clones 
previously characterized contained point mutations that enhanced transforming 
capabilities (Finlay et al. 1989; Soussi et al. 1990). This discovery led to the design of 
experiments introducing wild-type p53 into transformed cells. Subsequently, wild-type 
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p53 reduced or suppressed the proliferative effects of various cancer types, and so it was 
realized that p53 is indeed a tumor suppressor (Eliyahu et al. 1989; Finlay et al. 1989). 
 
p53 as a tumor suppressor 
 One of the first reports that p53 might be a tumor suppressor came from the 
observation that over 75% of colorectal carcinomas had allelic deletions of the short arm 
of chromosome 17 (Baker et al. 1989). The work of Baker et al. demonstrated that the 
wild-type p53 alleles were frequently lost or mutated and that the tumor cells no longer 
contained any wild-type p53. However, no gross alterations within p53 were discovered. 
But by following the hypothesis that p53 might still be somehow affected, a closer 
inspection revealed amino acid mutations in a highly conserved region of p53 that 
coincided with mutations found in murine cancers (Fig. 1.2). 
 
 It is expected then, as a tumor suppressor, organisms harboring germline 
mutations in p53 should have a higher susceptibility to cancer. Indeed, transgenic mice 
with germline mutations in p53 have an increased likelihood of developing different 
types of cancer, with a large proportion of sarcomas (Lavigueur et al. 1989). Similar 
results were found in human investigations carried out on patients with Li-Fraumeni 
syndrome, a disease characterized by a variety of early-onset cancers. The studies 
revealed that there is familial linkage conferring various cancer types, and that there is a 
strong correlation of transmission of the mutant p53 allele with the development of 
cancer (Malkin et al. 1990; Srivastava et al. 1990). 
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Activity & Function: DNA binding 
 At the time of the initial cloning and characterization of p53, little was known of 
its function (Oren et al. 1983). However, low amounts of p53 were also observed in non-
transformed cells with an extremely short protein half life, suggesting a potential 
regulatory role of p53 (Oren et al. 1981). An initial attempt was made to compare p53 to 
other known oncogenes at the time. The closest match was the myc oncogene, since both 
proteins accumulate in the nuclei of transformed cells (Donner et al. 1982; Rotter et al. 
1983), both bind DNA (Donner et al. 1982), both are involved in cell-cycle control 
(Reich & Levine 1984; Kelly et al. 1983; Campisi et al. 1984) and both appear to be 
induced at an early stage after mitogenic stimulation of resting cells (Mercer et al. 1982 
& 1984; Kelly et al. 1983). 
 
 Continued investigation uncovered more details of the structure, function, and 
regulation that helped define the role of p53 as one of the guardians of the genome. The 
393-residue polypeptide chain of p53 was shown to consist of four domains that confer 
functionality as a DNA-binding tetramer, and offer a wide range of regulation (Appendix 
II, Fig. a2.3). The marginally stable transactivation domain [TAD] (residues 1-44) is 
necessary for transcriptional activation of downstream target genes (Fields et al. 1990; 
Raycroft et al. 1990). The Proline-Rich Doman [PRD] (residues 60-100) (Walker & 
Levine 1996; Toledo et al. 2007) is indispensible for eliciting apoptosis (Baptiste et al. 
2002). The sequence-specific DNA binding activity resides in the structurally compact 
DNA-binding domain [DBD] (residues 102-292), is highly conserved across species and 
contains 97% of the p53 mutations found in cancers (Steinmeyer et al. 1988). The 
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oligomerization domain (residues 325-356) is required for efficient activity in vivo 
(Pietenpol et al. 1994) although not required for DNA-binding activity in vitro (Pavletich 
et al. 1993). The carboxyterminus contains a basic regulatory domain (residues 353-390) 
implicated in nonspecific interactions with DNA, as well as multiple nuclear localization 
signals [NLS] (Fig 1.2; Wang et al. 1993; Jeffrey et al. 1995). 
 
 In order to ensure rapid responses to a variety of cellular and genotoxic stress, p53 
is maintained at low levels in the cell at all times. The constant turnover and degradation 
is mediated through interactions with the E3 ubiquitin ligase MDM2 that targets p53 for 
proteosomic degradation. During periods of cellular stress, p53 is stabilized through 
inhibition of interaction with MDM2 and by a variety of post-translational modifications 
that in turn allow p53 to bind sequence specific response elements [RE] to regulate 
expression of target genes that affect cell cycle progression, DNA repair and apoptosis 
(Appendix II, Fig. a2.3). Once p53 is bound to DNA, gene expression may be further 
regulated through the basal transcription factor TFIID (Thut et al. 1995) or through 
coactivators such as CBP and p300 (Gu et al. 1997; Espinosa et al. 2001). Therefore p53 
regulation can lead to one of four main outcomes consisting of reversible cell cycle 
arrest, apoptosis, senescence or differentiation (Vousden et al. 2002). 
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Figure 1.2 
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Cellular effects of p53 activity 
 A wide variety of pathways within the cell involve many genes under the 
transcriptional control of p53 (Fig. 1.3). Currently p53 is known to regulate DNA repair, 
cell cycle, cell growth, cell adhesion, protein catabolism, apoptosis, metabolism, ion 
transport and transcription. The following section describes a subset of the many reported 
effects in order to demonstrate the functional diversity of p53. 
Apoptosis 
 Apoptosis via p53 occurs through regulation of many genes, some of the more 
characterized being: BAX, PUMA, SIVA, FOS, and FAS. BAX [Bcl-2-associated-X 
protein] encodes a pro-apoptotic protein that promotes cell death via cytochrome C 
release (Oltvai et al. 1993). The transcription level is upregulated when p53 binds to 
response elements located in the promoter and intronic regions of BAX (Miyashita et al. 
1995; Thornborrow et al. 2002). 
 
 PUMA [p53-Upregulated Modulator of Apoptosis] can mediate apoptosis induced 
via both nuclear and cytoplasmic p53 (Nakano et al. 2001). Upon activation by p53 in the 
nucleus, PUMA binds Bcl-2 and Bcl-XL (Yu et al. 2001 & 2003), relieving their 
inhibition of pro-apoptotic protein BAX (Ming et al. 2006). In the cytoplasm, PUMA can 
free p53 from Bcl-XL, allowing p53 activation of BAX, thus inducing mitochondrial 
permeabilization leading to cell death. There are two p53-binding sites in the promoter 
region of PUMA that can be directly bound and transactivated by p53 in vitro (Yu et al. 
2001 & 2003).  
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Figure 1.3 
 
From  Levine AJ & Oren M. The first 30 years of p53: growing ever more 
 complex. Nat Rev Cancer. (2009) 9:749-58. 
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 SIVA [named after the Hindu god of destruction] is yet another pro-apoptotic 
protein that shares features with TNFR [Tumor Necrosis Factor Receptor] and FAS, 
interacts with CD27 to induce apoptosis in a variety of cell lines (Prasad et al. 1997), and 
is a direct transcriptional target of p53 (Fortin et al. 2004). FOS, a constituent of the AP-1 
transcription factor complex, and implicated in cell proliferation, differentiation and 
apoptosis, is likewise under the regulatory control of p53. The FOS gene is positively 
regulated through a p53 response element located within the first intron, and studies show 
that in vivo induction of FOS after ionizing radiation is p53 dependent (Elkeles et al. 
1999). Likewise, multiple reports confirm that FAS-mediated apoptosis is dependent on 
the presence of functional wild-type p53 (Owen-Schaub et al. 1995; Li et al. 2003). 
 
Cell cycle modulation 
 Cell cycle regulation is affected by p53 through inhibition of cyclin-dependent 
kinases or PCNA [Proliferating Cell Nuclear Antigen] that results in G1/S cell cycle 
arrest governed by p21 (Gibbs et al. 1997). In response to stress, p53 regulates p21 levels 
through the six response elements located in the p21 promoter (Chin et al. 1997; Wei et 
al. 2006). Furthermore, p53 can regulate G2/M arrest via GADD45 (Chen et al. 1995; 
Chin et al. 1997), and phosphorylated p53 can increase transcription of APC 
[Adenomatous Polyposis of the Colon], in turn regulating not only cell cycle, but also 
chromosome segregation, mitotic spindle assembly, cell migration, cell adhesion and 
apoptosis (Narayan et al. 1997; Jaiswal et al. 2001). 
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 Cellular senescence, constituent cell cycle arrest, is also dependent upon p53 
function. One study demonstrates that when MDM2 activity is abolished by the small 
molecule nutlin, the p53-MDM2 interaction is disrupted, in turn stabilizing p53 leading to 
the induction of senescence in eight different cancer cell lines. Three days after the start 
of nutlin treatment, the cells adopt a senescence-like state, yet upon removal of nutlin, the 
cells regain proliferative capability (Huang et al. 2009). These findings suggest that p53 
activity is required not only for induction, but also for the maintenance of the senescent-
like state in human cancer cells.  
 
DNA damage repair 
 The nucleotide excision repair [NER] pathway is used to fix UV photoproducts or 
to remove large adducts on the DNA throughout the genome. Binding of p53 upregulates 
the genes DDB2 (DNA Damage Binding Protein 2) and XPC (Xeroderma Pigmentosum 
group C), whose products then recognize the DNA damage and initiate NER (Hwang et 
al. 1999; Tang et al. 2000; Tan et al. 2002).  
 
 Mismatch repair [MMR], used to recognize and repair insertion, deletion and 
misincorperated bases, is likewise under the control of p53 (Chen et al. 2005). Two gene 
products involved in MMR, PMS2 [yeast Postmeiotic Segregation increased 2] and 
MLH1 [MutL Homolog 1] contain p53 response elements and are upregulated upon p53 
binding. The finding of p53 targets in MMR-related genes creates a potential link 
between the p53-mediated control of growth arrest and apoptosis. Activated PMS2 
stabilizes p73, which is required for p53-dependent apoptosis following DNA damage 
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(Flores et al. 2002; Shimodaira et al. 2003). Therefore it is possible that upon DNA 
damage, activated p53 arrests cell growth via the p21/WAF pathway, while MLH1 and 
PMS2 are induced to begin DNA repair. If the extent of the damage is too great, then the 
stabilization of p73 by PMS2 could serve as a trigger for p53-mediated apoptosis. 
 
 Homologous recombination [HR] is a mechanism used to repair DNA double 
strand breaks via sister chromatid pairing. One protein responsible for strand pairing, 
RAD51 [RecA homolog, E. coli] (Sonoda et al. 1999), is down-regulated when p53 binds 
the RAD51 promoter (Arias-Lopez et al. 2006). This is consistent with the tumor-
suppressing role of p53, as cells with extensive DNA damage require repression of HR 
for apoptosis (Collis et al. 2001).  
 
Reactive oxygen species 
 Evidence exists that p53 regulates the intracellular redox state by monitoring 
reactive oxygen species [ROS], in turn protecting against the oxidation of protein, lipids 
and DNA (Johnson et al. 1996). Two metalloproteins involved in ROS scavenging, GPx1 
[Glutathione Peroxidase-1] and MnSOD [Manganese Superoxide Dismutase], are 
upregulated in a p53-dependent manner in doxorubicin-exposed human lymphoblasts 
(Tan et al. 1999; Hussain et al. 2004). However, contrary to anti-ROS activities, p53 can 
also up-regulate pro-oxidative genes such as PIG-3 [P53 Induced Gene] and POX 
[Proline Oxidase] to induce apoptosis via oxidative degradation of mitochondrial 
components (Polyak et al. 1997; Maxwell et al. 2008). Thus it is interesting to speculate 
that p53 regulates the fate of the cell by eliciting the appropriate response to intracellular 
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ROS levels. The p53-dependant upregulation of genes involved in ROS scavenging can 
help the cell manage the redox state as long as ROS concentrations are marginal. 
However, if ROS concentrations surpass a critical limit, the ROS levels can instead be 
supplemented via induction of pro-oxidative genes, in order to push the critically 
damaged cell towards apoptosis. 
 
Other effects 
 The following list provides a sampling of the growing number of cellular 
processes potentially affected by p53 activity. The significance, however, of the 
contribution of p53 to these processes has yet to be determined. 
 
Cellular autophagy 
 Autophagy, the lysosomal degradation of cellular organelles, can lead to cell 
atrophy or death and could serve as another level of tumor suppression. The mTOR 
[Mammalian Target Of Rapamycin] pathway controls autophagy, and recent reports show 
that activation of p53 can inhibit mTOR and increase autophagy (Stambolic et al. 2001; 
Feng et al. 2005). Another p53-inducible gene involved in metabolism, TIGAR [TP53 
Induced Glycolysis and Apoptosis Regulator], can limit autophagy via ROS regulation 
(Bensaad et al. 2009) 
 
Cellular metabolism 
 The regulation of cellular energy levels has a direct effect on ROS production, 
and as previously discussed, ROS levels must be controlled to prevent cellular and 
 
 
 
 
- 22 - 
genomic stress. Mitochondrial respiration is controlled in part by SCO2 [Synthesis of 
Cytochrome C Oxidase 2], and SCO2 is regulated by p53 (Matoba et al. 2006). Likewise, 
p53 can affect glycolysis by upregulating the TIGAR gene, leading to an inhibition of 
glycolysis and an overall decrease in intracellular ROS levels (Bensaad et al. 2006; Green 
et al. 2006). 
 
MicroRNA 
 Microarray and bioinformatics experiments estimate that approximately 30% of 
all genes are regulated, at least partially, by miRNAs [Micro RNA] (Lim et al. 2005). The 
small miRNAs, approximately 20 to 25 nucleotides in length after processing, form 
complexes with other proteins and downregulate expression of genes containing 
sequences complementary to the miRNA. The miR-34 family of miRNAs is implicated in 
regulation of apoptosis, cell cycle arrest and senescence. Recently, two miRNAs from 
this family, miR-34a and miR-34b/c, were found to contain p53 response elements and to 
be under transcriptional regulation by p53. These p53-regulated miRNAs in turn down-
regulate expression of genes that modulate cell cycle progression such as CDK4/6, Cyclin 
E2, MET and BCL-2 (Bommer et al. 2007; Corney et al. 2007; He et al. 2007). Given that 
p53 generally induces expression of target genes through DNA-binding, miRNA 
regulation could serve as a complementary mode of control via indirect gene repression. 
 
Indirect effects 
 Multiple reports demonstrate the ability of p53 to influence gene expression in the 
absence of DNA-binding. p53 has been shown to interact with Wilms Tumor 1 [WT1] to 
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induce GADD45 expression, (Zhan et al. 1998) and also to interact with the transcription 
factor SP1 [Sephacryl and Phosphocellulose Purification 1] to induce transcription of 
p21 (Koutsodontis et al. 2001). However, p53 can elicit an apoptotic response even in the 
absence of direct DNA-binding. There is evidence that a p53-SP1 complex can bind to 
the promoter region and down-regulate expression of MnSOD [Manganese Superoxide 
Dismutase], a gene product that protects against cell death (Dhar et al. 2006). 
 
Regulation of p53 
 The role of p53 as general mediator of cellular responses to genotoxic stress 
includes many functions (previously discussed) that lead to a host of different cellular 
outcomes. While p53 can control many different pathways, p53 itself is regulated by 
many different mechanisms. Although new modes of p53 regulation continue to be 
discovered, some well-characterized regulatory mechanisms are discussed in the 
following section. 
 
mRNA level 
 Currently ten variations of p53 are known to exist in human tissues as the result of 
alternative splicing, or translation from an alternative promoter or translation start sites 
(Appendix II, Fig. a2.2; Yin et al. 2002; Courtois et al. 2002; Bourdon et al. 2005). These 
variants contain the DNA-binding domain and maintain DNA-binding capabilities but 
differ in the amino and carboxyterminal regulatory domains. Some p53 variants are 
differentially expressed in a tissue-specific manner, suggesting expression can be 
selectively regulated. Although the significance of these isoforms has yet to be 
 
 
 
 
- 24 - 
determined, there is evidence for differential transcriptional activities among the p53 
variations.   
 
 Full-length wild-type p53 binds preferentially to MDM2 and p21 response 
elements whereas p53β preferentially binds p21 and BAX. Furthermore, p53 and p53β 
interact and enhance transcriptional activity at the BAX, but not the p21, promoter 
(Bourdon et al. 2005). Increased expression of p53/47 stabilizes p53 in the presence of 
MDM2 and alters expression of p53 effector genes (Yin et al. 2002). One other isoform 
lacking the N-terminal activation domain, ΔN-p53, has no known role in response to 
genotoxic stress but is implicated as a transient negative regulator of p53 during cell 
cycle progression (Courtois et al. 2002). Another p53 variant, lacking part of the DNA-
binding and oligomerization domains, is present during the intra S-phase cell cycle 
checkpoint (Rohaly et al. 2005). These variants could potentially play a role in buffering 
the p53 response by modulating the threshold of full-length p53 needed to bind and 
regulate effector genes. 
 
Cellular localization 
 The cellular localization of p53 is likewise critical for timely and effective 
regulation of the appropriate stress response. The shuttling of p53 between the nucleus 
and the cytoplasm is closely linked to cell cycle (Shaulsky et al. 1990), and the 
importation of p53 into the nucleus during the G1/S phase transition can dramatically 
impact the effectiveness of p53. The negative consequences of nuclear exclusion of p53 
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are demonstrated by the cytoplasmic localization of p53 observed in breast cancers and 
neuroblastomas (Moll et al. 1996). 
 
 Nuclear export of p53 during S-phase is another mode of regulation and involves 
the C-terminal nuclear export signal [NES]. Various models have been proposed that 
suggest either ubiquitination or dimeric forms of p53 can expose the NES (residues 340-
351) that is otherwise masked in tetrameric p53 (Stommel et al. 1999; Nie et al. 2007). 
Indeed mutations in this region can deregulate an otherwise fully functional p53. A small 
proportion of cancers have mutations in this area of p53 (Fig. 1.2). 
 
Degradation 
 Under normal non-stress conditions, the cell maintains steady but low levels of 
p53 by targeting it for constant proteolytic degradation through ubiquitination via 
MDM2. In response to genotoxic stress, however, MDM2 is auto-poly-ubiquitinated and 
subsequently degraded, allowing p53 levels to increase (Momand et al. 1992; Haupt et al. 
1997). This regulation occurs as a feedback loop, as MDM2 transcription is regulated by 
p53 (Fig. 1.3; Barak et al. 1993; Haupt et al. 1997). 
 
 The stability of p53 is also modulated by MDMX, a homologue of MDM2, as 
well as the ubiquitin ligases PIRH2, COP1 and CHIP. MDMX stabilizes MDM2 through 
direct binding, which in turn enhances ubiquitination and subsequent degradation of p53 
(Shvarts et al. 1996; Badciong et al. 2002). The ubiquitin-mediated degradation of p53 is 
supplemented through the actions of PirH2 (Leng et al. 2003), COP1 (Dornan et al. 
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2004), and CHIP (Esser et al. 2005), which are also part of the p53-controlled regulatory 
feedback loop. The presence of multiple feedback mechanisms might ensure that the p53 
circuit has backup measures in order to prevent uncontrolled or incorrect stress responses. 
Furthermore, the constant turnover ensures that functional p53 is available when needed 
for immediate action to elicit the appropriate cellular responses, and in the context of a 
damaged genome, avoids complete dependence on transcription from a potentially 
mutated p53 locus. 
 
Post-translational modifications 
 The post-translational regulation of p53 occurs mainly through modifications to 
the N-terminal transactivation domain [TAD] and C-terminal domain, with the 
modifications mostly affecting interactions with p53 negative regulator MDM2. In 
response to DNA damage, upstream kinases including ATM, ATR, Chk1, Chk2, CK1, 
DNA-PK, DYRK2, ERK1, ERK2, HIPK2, JNK, MAPK can phosphorylate various 
serine and threonine residues of p53 (Appendix II, Fig. a2.3; Bode et al. 2004, Olsson et 
al. 2007). The modifications can either affect p53 stability, or can reduce or abolish the 
effectiveness of protein-protein interactions with p53 and co-activators. MDM2 also 
plays a role in regulating post-translational modifications by concealing the TAD of p53 
upon binding, thus preventing modifications and interactions with co-activators such as 
p300 and CBP (Oliner et al. 1993). 
 
 Post-translational modifications specifically adapt p53 responses to the particular 
variety of stress. Although the majority of modifications are phosphorylation and 
 
 
 
 
- 27 - 
acetylation, the list also includes mono- and poly-ubiquitination, methylation, 
sumoylation, neddylation and proyl-isomerization as means to regulate p53 (Olsson et al. 
2007). The varieties of specific p53 modifications are well documented and involve 
various sets of residues to elicit particular responses to stress. For example, 
phosphorylation of serines 15, 20 and 37 are induced by gamma irradiation, whereas 
exposure to UV radiation leads to phosphorylation of the same three residues plus serines 
33 and 46. Treatment of cells with doxorubicin, a small DNA-intercalating 
chemotherapeutic molecule that inhibits DNA replication, leads to phosphorylation of 
serines 6 and 9. At the C-terminus of p53, acetylation is the primary form of 
modifications found on a range of lysine residues in response to UV and gamma radiation 
(Gu et al. 1997[Cell]; Sakaguchi et al. 1998). As some of these acetylated lysines are also 
targets of ubiquitination, the acetylation events could stabilize p53 by preventing 
proteasomal degradation (Brooks et al. 2003; Bode et al. 2004). 
 
Autoregulation 
 The N-terminal proline rich region [PRR] and the C-terminal basic region of p53 
are involved in auto-regulatory functions that modulate DNA-binding (Fig 1.2). Deletion 
of residues 80 to 93 that contain the PRR enhance the DNA binding activity of p53. 
Furthermore, synthetic peptides made from this region are able to activate sequence-
specific DNA-binding in vivo (Müller-Tiemann et al. 1998). Through NMR-based 
analysis using full-length p53 and various peptides sampling the PRR; complementary 
sources of experiment and simulation provide evidence for a stiffened chain extending 
away from the core DNA-binding domain. These structural studies suggest the extended, 
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relatively rigid conformation of the PRR could facilitate interactions with the SH3 
domains of p53 related regulatory kinases (Wells et al. 2008).  
 
 Relative to the N-terminal regulatory regions, there is more debate over the 
functional significance of the C-terminal basic region. This domain is believed to 
maintain p53 in a latent form, and that stress-induced modifications in this region create 
an active conformation with high sequence-specific DNA-binding activity. Various 
studies support this idea by demonstrating enhanced response element binding when 
residues 360-393 are deleted (Hupp et al. 1992), when residues 370 to 378 are masked by 
a monoclonal antibody (Halazonetis et al. 1993), when serine 378 is phosphorylated 
(Takenaka et al. 1995), and when lysines 373 and 382 are acetylated (Gu et al. 
1997[Cell]).  
 
There are conflicting reports, however, that suggest p53 is not a latent form 
structure that becomes activated through C-terminal modification and structural changes. 
One report shows that there is no noticeable structural change of latent and active forms 
of p53 (Ayed et al. 2001), and another report claims that the C-terminal domain is not 
inhibitory, but rather that it is required for p53 association with particular target sites 
(Espinosa et al. 2001). The ability of the C-terminal region to interact non-specifically 
with a variety of DNA forms (Nelson et al. 1994; May et al. 1999) leads to an alternative 
model. Given the evidence, it is possible that the C-terminal domain competes with the 
DNA-binding domain for interactions with DNA. In the absence of C-terminal 
modifications, p53 would be sequestered to non-specific DNA through the C-terminal 
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domain, rendering p53 functionally inactive. Modifications to the C-terminus could 
abolish the non-specific DNA interactions, thus freeing the DNA-binding domain to bind 
specific response elements. Currently more evidence is needed to uncover the functional 
implications of the auto-regulatory effects of the C-terminal domain. 
Other regulatory interactions 
 Various reports describe modulation of p53 binding affinity through direct 
protein-protein interactions, although the mechanistic details and functional significance 
of these interactions are not yet fully understood. Proteins such as ASPP1 and ASPP2 
interact with p53 and enhance p53 binding to promoters of pro-apoptotic genes BAX and 
PIG-3 (p53 Inducible Gene 3). Accordingly, p53-mediated apoptosis is suppressed when 
ASPP1 and ASPP2 are rendered non-functional (Samuels-Lev et al. 2001).  
 
 In a mouse cell line lacking the genes for p53 homologs p63 and p73, p53 binding 
to pro-apoptotic genes is reduced. Despite the presence of wild-type p53 in these double 
null cells, p53 is not able to induce apoptosis in response to DNA damage (Flores et al. 
2002). But exactly how these proteins enhance p53 binding to RE remains to be 
determined, as yet another observation is that p63, p73, ASPP1 and ASPP2 interact with 
p53 through the DNA-binding domain, which is somewhat counter-intuitive. 
Furthermore, p53 is also reported to modulate homologous recombination factors in a 
transcription-independent manner through direct interactions with hRAD51 and hRAD54 
(Linke et al. 2003). 
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Cancer: effects of altered p53 function 
 Because p53 is so often mutated in so many varieties of cancers, intense research 
over the past 30 years has helped in the understanding of how these mutations can affect 
p53 functionality. Below is a brief discussion of what happens when mutations in p53 
affect normal function. Approximately 97% of p53 missense mutations are localized to 
the DNA-binding domain and impair DNA binding, thus reducing or attenuating the 
transactivation activity (Petitjean et al. 2007). These mutations can be classified into one 
of two groups; 1) contact mutations, with minor effects on folding and stability that 
impair DNA-binding and 2) mutations affecting structural stability that can lead to 
unfolding of the DNA-binding domain (Cho et al. 1994; Yip et al. 2006). Over 60% of 
the mutated residues in the DNA-binding domain are either directly involved in binding 
DNA, or located close to the protein-DNA interface (Cho et al. 1994).  
 
Loss of function 
 The active form of p53 is a tetramer of four identical subunits, made of a dimer of 
dimers (Jeffrey et al. 1995). Mutations affecting residues involved in DNA binding or 
stabilization have a dominant negative effect within the tetramers. These mutations grant 
p53 a prolonged half-life relative to wild-type p53, which in turn reduces or abolishes 
transcriptional activities (Chan et al. 2004). However the extent of functional defects 
depends on the location of the mutation within p53, and can have different consequences 
for different effector genes. One such report describes that a mutation at residue Arg175, 
the third most common mutation in p53, renders p53 defective in its ability to induce 
apoptosis. A p53 variant with a proline at position 175, transfected into rat cells, acted in 
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a dominant-negative manner by suppressing the apoptotic ability of endogenous rat p53. 
However, the same Arg175Pro variant was able to induce normal cell-cycle arrest in two 
human tumor cell lines deficient in wild-type p53 (Rowan et al. 1996). 
 
 In a larger study, 2,314 different p53 clones containing point mutations 
representing >95% of the tumor-derived p53 amino acid substitutions listed in the IARC 
[International Agency for Research on Cancer] database R7 (2002), as well as randomly 
chosen mutations, were assessed for in vivo functionality using 8 different p53 effector 
gene promoters (Kato et al. 2003). In this yeast-based assay, 905 mutants (~39%) 
exhibited normal transactivation capabilities; correspondingly these mutants have not 
been reported in tumors. As expected, 361 mutants (~16%) were inactive for all 8 
promoters and have been reported at least once in tumors. However, of the remaining 
mutants, 635 (~28%) were inactive only for various promoter subsets. This work 
highlights the diversity of mutational effects and demonstrates that only subsets of p53 
downstream pathways might be affected upon mutation. These results further support the 
view that sequence-specific transactivation is the critical function in p53-dependent 
tumor suppression. 
 
 There is also growing evidence that mutations in the DNA-binding domain could 
affect binding to response elements in the effector genes only in a stress-dependant 
manner. A study on colon carcinoma cells showed that p53 with mutations in residues 
175 and 273 could not elicit the G1/S cell cycle arrest after gamma irradiation, whereas a 
mutant at residue 143 functioned normally (Pocard et al. 1996). In contrast, another study 
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performed with the same cell line revealed that upon treatment with a mitotic spindle 
inhibitor, nocodazole, the 273 mutant could induce G1/S arrest whereas the 143 and 175 
mutants could not (Dridi et al. 2003). Taken together, these facts demonstrate how p53 
mutations might have different functional consequences that are dependant on the type of 
activating stress. 
 
Gain of function 
 Despite debate over the importance of gain of function [GOF] mutations and their 
contribution to tumorigenesis, there is increasing evidence that mutant p53 proteins can 
also gain new abilities that promote tumorigenesis. Gain of function mutations typically 
work by stabilizing the mutant form of p53 (Natan et al. 2009). Although more work is 
needed to better understand how various mutations lead to a gain of function phenotype, 
some studies have demonstrated how p53 mutations can cause enhanced cell proliferation 
in culture (Zalcenstein et al. 2006), increased tumorgenicity in mice (Lang et al. 2004; 
Olive et al. 2004), and enhanced resistance to various anti-cancer drugs (Blandino et al. 
1999; Buganim et al. 2006).  
 
 One model explains that while mutations in p53 can reduce or abolish recognition 
of canonical response elements, certain mutations can give p53 the ability to recognize 
and regulate new target genes (O'Farrell et al. 2004). A growing number of reports 
provide evidence for this GOF model. For example, TGFβ1 [Transforming Growth 
Factor Beta 1] has a critical role in preventing the initiation and progression of cancer by 
maintaining cellular homeostasis through regulation of proliferation, differentiation, and 
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migration (Croxtall et al. 1992; Massagué 2000; Massagué et al. 2000). Mutant p53 
proteins (R175H and R248W), but not wild-type p53, can down regulate TGFβRII 
expression, which decreases TGFβ1-regulated functions (Kalo et al. 2007). Likewise ID4 
[Inhibitor of DNA Binding 4], implicated in preventing cell proliferation, differentiation 
and tumorigenesis, has been identified as a transcriptional target of GOF p53 mutants 
R175H, R273H and R280K (Fontemaggi et al. 2009). Another group demonstrated p53 
gain of function properties indirectly by showing that the inhibition of GOF p53 mutants 
R175H or R273H, via inducible short-hairpin RNA, leads to a delay in tumor formation 
and a reduction in tumor vascularization in tumor xenografts (Bossi et al. 2006). 
 
 Another GOF model suggests that mutant p53 can acquire new binding properties 
and sequester other proteins involved in cell cycle arrest or apoptosis. There is a growing 
pool of evidence supporting this sequestration model. In a study testing various p53 
mutants (Y220C, R249S, C277Y, R283H, R175H), three mutant p53 proteins (Y220C, 
R249S, R283H) can interact directly with close homologs p63 and p73 and inhibit their 
transcriptional activity. Furthermore there is a correlation between the efficiency of p53 
interactions with p63 and p73, and the ability to down regulate p63 or p73 transcriptional 
activity (Gaiddon et al. 2001). Indeed it is interesting to note that p53, once classified as 
an oncogene then properly characterized as a tumor-suppressor, can once again be 
viewed as an oncogene in certain circumstances. 
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p53 mode of action 
 The fate of the cell in the presence of genotoxic stress depends heavily on the 
DNA-binding activity of p53; mutant versions of p53 that loose this tight control can 
cause cell cycle deregulation and transformation. Almost all of the p53 functions, 
previously discussed, occur as a result of sequence-specific DNA binding and 
transactivation, making DNA-binding the critical function in p53-dependent tumor 
suppression. Approximately ten years after its discovery, when the biological significance 
of DNA-binding was not yet realized, over one thousand mutations in p53 from human 
cancers were already identified (Nigro et al. 1989; Hollstein et al. 1991; Wang et al. 
1993). Although small in comparison to the current count of 24,785 mutations (tp53 
Database Nov 2008), there was enough information to show that most mutations were 
targeted to four conserved domains (Fig. 1.2). Additionally, these conserved regions were 
located in the core portion (residues 102-292) already shown to contain the DNA binding 
activity of p53 (Pavletich et al. 1993; Wang et al. 1993; Halazonetis et al. 1993). 
 
Sequence-specific DNA binding 
 Although the DNA-binding and transcriptional activation functions of p53 were 
realized soon after its discovery, no specific DNA response element had yet been 
identified. In a gene activation study, co-transfections of wild-type p53 with a muscle-
specific creatine kinase [MCK]– chloramphenicol acetyltransferase [CAT] reporter gene 
into CV1 cells induced a 40-fold CAT activity over negative controls (Weintraub et al. 
1991). Through 5’ deletion mapping, the p53 response element was reduced to a region 
between positions -3,300 and -2,800 within the 3,300-bp enhancer situated upstream of 
the MCK gene in a variety of tissue culture cell types. 
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 Additional binding specificity experiments refined the wild-type p53 response 
element to a 50-bp region (Zambetti et al. 1992). The same study also reported that 
binding and gene activation did not depend on RE orientation. The boundaries of the p53 
RE region were subsequently reduced to a 33 bp sequence (Kern et al. 1991). The 
consensus p53 RE was then found to be composed of a tandem 10-base pair sequence 
motif separated by 0-13 base pairs (El-Diery et al. 1992). Concurrent with p53 binding is 
the transcriptional activation of those genes containing p53 binding sites (Raycroft et al. 
1990; Bargonetti, et al. 1991; Kern et al. 1992; Farmer et al. 1992), and in these same 
studies it was shown that mutant forms of p53 had compromised DNA binding abilities. 
The combination of these results defined DNA-binding as a critical activity of p53 in its 
tumor suppressing abilities. 
 
p53 response element 
 The transcriptional activities of p53 come primarily from binding to DNA 
response elements located in promoters or first introns of effector genes (Wei et al. 
2006). The p53 response element [ |◊ |] is composed of two 10-base pair half-
sites [ |] with each half-site separated [◊] by 0 to 13 base pairs. Each half-site 
contains two inverted pentameric sequences [] and []. The consensus sequence for 
each 10 bp half-site, 5’-RRRCW|WGYYY-3’, highlights the importance of the cytosine 
(C) at position 4 and guanine (G) at position 7 (invariable), and the limited variability of 
the other positions requiring either adenine or thymine (W), purines (R) or pyrimidines 
(Y) as indicated (Fig 3.9d; El-Diery et al. 1992).  
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Response element sequence affects p53 binding affinity 
 The definition of the p53 response element consensus motif has been further 
modified as a result of continued investigations of p53 DNA-binding properties on a 
larger scale. Recent chromatin immuno-precipitation [ChIP] and microarray analyses 
have identified 542 high confidence p53 binding sites that gave more insight into the 
specific sequence composition of the consensus p53 RE motif (Wei et al. 2006). Another 
recent study measured the effects of every possible single base-pair substitution in the RE 
on the affinity of full-length p53 for DNA (Veprintsev et al. 2008). The data generated 
made it possible to quantify the effect of response element sequence variation on p53 
binding affinity, allowing the prediction of p53 affinity for any potential RE sequence, 
thus adding even more information to the p53 RE definition. However, until recently, the 
subtle variations of nucleotide distribution within the RE were not yet linked to the 
functional outcome of p53 binding (e.g. activation or repression). 
 
Response element sequence affects p53 functional outcome 
 Recent evidence suggests that certain positions within the response element 
sequence can determine the functional outcome of p53 binding. Nearly 18 years after the 
initial descriptions of the p53 RE, current data suggest there are potentially two major 
types of p53 response elements; described as activator REs and repressor REs. A recent 
multi-disciplinary study found distinct patterns of nucleotide frequency distributions 
when p53 REs were analyzed in the context of activating or repressing activities. The 
results suggest that the p53 RE might actually exist as two functionally distinct types.  
While the definition of the canonical activator RE remains the same (half site 5’- 
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RRRCW|WGYYY-3’), the consensus repressor RE contains a slightly different 
sequence composition such as 5’-RRXCXXGXYX-3’ (Wang et al. 2009). 
 
Structures of p53-DNA complexes 
 Until now, no X-ray crystal structure of a p53 multimer containing both DNA-
binding and oligomerization domains, either unbound or bound to DNA, has been 
reported. The flexibility of the 30-residue linker connecting the DBD and oligomerization 
domains, coupled with the intrinsic marginal stability of the N- and C-terminal domains, 
has impeded crystallographic study for the past three decades. In order to address the 
questions of how p53 binds DNA, various groups have used the compactly folding DBD 
and various strategies to obtain crystals of the DBD bound to DNA. An overview of 
current p53-DNA structures is presented in figure 1.4. Therefore, before discussing the 
structure of a multi-domain p53 tetramer bound to DNA, the previously determined p53-
DNA structures warrant brief review. 
 
Initial structure of p53 DBDs bound to DNA 
 The hypothesis that DNA binding is critical for the biological activity of p53 was 
further supported by the first crystal structure of human p53 bound to DNA (Fig. 1.4a; 
Cho et al. 1994). This study was motivated by a need to better understand the growing 
list of mutations and how and why they inactivate p53. The structure revealed for the first 
time the protein fold topology of the p53 core DNA-binding domain. Proteolytic 
digestions of the human p53 protein showed that residues 102-292 constitute an 
independently folded, compact structural domain that exists as a monomer in solution 
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(Pavletich et al. 1993). The core domain is composed of a sandwich of two antiparallel β-
sheets, with each sheet composed of either four or five β-strands (Fig. 1.5). The β-
sandwich serves as a scaffold, while a loop-sheet-helix motif interacts with the DNA 
(loop L1 and helix H2). Two additional loops (L2 & L3), stemming from the β-sandwich, 
are stabilized by a tetrahedrally coordinated zinc atom (Fig. 1.5). 
 
 The major and minor grooves and the phosphate backbone of DNA are contacted 
by the DNA-binding motifs of p53. The structure revealed that the regions of the core 
domain that contact the DNA are highly conserved and also contain the majority of 
cancer related mutation hotspot residues, with 30% targeting loop L3, 25% of the 
mutations in the loop-sheet-helix motif (L1-sheet-H2), and 17% of mutations found in the 
L2 loop (Levine et al. 1994). 
 
 This structural work established the initial understanding of how p53 mutations 
observed in tumors could affect sequence-specific DNA binding functions. The atomic-
level description of the DNA binding surfaces of p53 showed how inactivating mutations 
in cancer are targeted to this conserved area. Analysis of mutation hotspot residues 
provided an understanding for both mutations that could abolish DNA-binding, and also 
those that lead to a destabilized DBD core, thus leading to structural defects affecting 
wild-type function. 
 
 Fifteen years after the discovery of p53, this structural study provided the first 
insight into the atomic details of the p53–DNA interaction. However there are many 
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aspects that were not completely resolved in this study that have continued to motivate 
structural research of p53 and p53-DNA interactions. 
 
 Most notable is that although it was already established that p53 binds the RE as a 
tetramer in vivo and in vitro, the structure shows only three monomers bound to DNA, 
and furthermore only one of the three monomers makes DNA base-specific contacts. As a 
transcription factor, interaction with specific DNA nucleotides is critical for recognition 
of the sequence contained within the corresponding response element. Most transcription 
factors make more than three nucleotide specific contacts, whereas this structure has one 
monomer making three nucleotide specific contacts.  
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Figure 1.4 
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 Of the three residues making base-specific interactions with the DNA, the 
significance of one of these contacts, K120 of loop L1, remains questionable. This lysine 
is not a mutation hotspot residue (although there are a few reported cases of mutations at 
this position), yet it is expected that a residue involved in making base-specific contacts 
is critical for the DNA binding activities. Therefore although this structure serves as the 
groundwork for understanding how p53 binds DNA, many open questions remain. 
Among the questions; If K120 is not frequently targeted for mutations, is it involved in 
RE recognition? Given that modeling the DBD tetramer leads to steric clashes, do the 
protein-DNA interactions presented in this structure reflect the physiological complex? 
Furthermore, the authors conclude that DNA binding by p53 did not result in any 
significant structural changes to either the core DBD or the DNA. Yet at that time, 
biochemical studies using conformation-specific antibodies demonstrated that p53 
changes conformation upon DNA binding (Halazonetis et al. 1993).  
 
Structure of a p53 dimer bound to DNA 
 This study performed by Ho et al. in 2006 employs a crosslinking strategy to 
covalently trap the mouse core DNA-binding domain on a response element half-site 
(two pentamer repeats). The resulting dimeric structure highlights some of the molecular 
details of cooperative DNA binding in a dimeric form (Fig. 1.4c). The surface regions 
involved in the dimeric protein-protein (anti-parallel) interface contain some of the 
hotspot mutations found in cancer, thus illustrating the functional importance of p53 
dimerization during DNA-binding. 
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Figure 1.5 
 
From: Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a 
  p53 tumor suppressor-DNA complex: understanding tumorigenic  
  mutations. Science. (1994) 265:346-55. 
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 The structure shows how the two subunits form an anti-parallel interface 
positioned over the DNA minor groove, and that this interface involves loops L2 and L3 
that coordinate a zinc atom. When compared to the original trimeric p53-DNA structure 
(Fig. 1.4a; Cho et al.1994), many structural similarities are observed. In particular, as in 
this first published p53-DNA structure (Cho et al.1994), within loop L2, R277 (residue 
R281 of human p53) of helix H2 makes base specific contacts with guanosine 7 in the 
DNA major groove and residues A276, R277, and R280 (residues A280, R281, and R283 
of human p53) make analogous DNA backbone contacts. In addition, residues S238 and 
R245 (residues S241 and R248 of human p53) from the L3 loop make interactions with 
the DNA minor groove. 
 
 The authors observe that the DNA is bent approximately 20 degrees just below 
the p53 dimer interface, arguing that p53 cooperative binding induces DNA bending. 
Extrapolation of this observation suggests that DNA binding by a full tetramer, two p53 
dimers, could induce the 40 degree bend in DNA observed in solution studies 
(Balagurumoorthy et al. 1995 & 2002; Nagaich et al. 1997). However in another 
structure released by the same group, a dimer of mouse DBD dimers crosslinked to DNA, 
shows no significant bending of the DNA (Fig. 1.4d; Malecka et al. 2009). 
 
 While providing more insight into the detail of the anti-parallel interactions, the 
structures presented in 2006 and 2009 provide limited detail of parallel tetrameric 
interactions. In both structures, the p53 DBD is covalently linked to DNA. Although this 
strategy has been used to obtain crystals of other protein-nucleic acid complexes (Huang 
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et al. 1998 & 2000), the presence of the crosslink could affect DNA recognition and bias 
protein-protein interfaces. The authors claim that because the linker is not visible in the 
electron density map of this structure that the chemical tether (a sulfur-bearing three-
carbon linker connecting C274 to N4 atom of a cytosine base in the RE) remains flexible, 
and accommodates native protein-DNA interactions. However the tether could bias, or 
even prevent, intermolecular interactions by fixing p53 into a potentially incorrect 
dimeric or tetrameric orientation. The potential effects of this tether on the parallel 
interface are discussed later in chapter three. Furthermore, p53-DNA binding is dynamic, 
and it is possible that this crosslink trapped the protein in a position “mid-binding” which 
may not representative of DNA-bound p53 in vivo. 
 
 Furthermore, loop L1 (mouse DBD residues 114-118), shown to make base-
specific contact with K120 (mouse K117) is found to be unordered in the 2006 structure. 
Conformational variations of loop L1 exist, ranging from and extended loop making base 
specific contacts with K120 (Cho et al. 1994), to a retracted helical form in the C. 
elegans structure in the absence of DNA (Huyen et al. 2004). The authors conclude that 
loop L1 does not make a significant contribution to DNA binding. In the 2009 structure 
reporting a dimer of p53 dimers bound to DNA, mouse K117 (human K120) is displaced 
from the DNA and positioned at the parallel interface between dimers.  
 
Structure of p53 DBDs bound to different response elements 
 Many open questions remained after the initial p53–DNA structure was elucidated 
in 1994 concerning the specificity, affinity and cooperativity of DNA binding by p53, 
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especially concerning the p53 tetramer. At the time, there was no structural information 
of a tetramer bound to DNA, nor any structural insight for different DNA response 
element targets. To address these topics, four different DNA oligonucleotides containing 
a p53 RE half-site were crystallized with the p53 core DBD. Within the structures, two 
human p53 dimers bound to DNA assemble in tandem via protein-protein and DNA base 
stacking interactions within the crystal, providing the first details of the p53 tetramer 
(Fig. 1.4b; Kitayner et al. 2006). 
 
 The ability of p53 DBDs to assemble as a tetramer on p53 REs had been 
established (Weinberg et al. 2005), providing support for cooperative binding through 
protein-protein interactions within the p53 core domain. This structure, released at the 
same time as another tetrameric structure with p53 DBDs crosslinked to DNA (Fig. 1.4c 
& d; Ho et al. 2006) describes these tetrameric parallel protein-protein interactions. The 
symmetric interactions of each dimer bound to DNA are similar to those previously 
described by NMR (Dehner et al. 2005; Klein et al. 2001) and mutagenesis studies of the 
core domain (Dehner et al. 2005) and full-length p53 (Veprintsev et al. 2006), 
strengthening the validity of the observed anti-parallel dimer interface across the DNA. 
However, there is more variability observed across the parallel interface made from a 
dimer of dimers along two non-continuous p53 half sites (Fig. 3.6a). 
 
 In order to gain insight into the differential binding affinities of p53 to the REs, 
the authors analyzed four structures containing different RE sequences. Four residues, 
R280, K120, A276, and C277 make direct DNA base contacts in each structure. As 
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predicted, the specific interactions of K120, A276, and C277 change in each of the 
structures when the central base pair of the pentameric quarter site is changed from G/C 
to A/T. Quantitative gel mobility shift assays demonstrate differences in affinities of the 
p53 DBDs for the various REs in the range of 14 to 50 nM, supporting in vivo DNA 
binding behavior. Higher affinity RE sequences correlate with those related to cell cycle 
arrest whereas sequences with lower affinity are related to cell apoptosis, as demonstrated 
by transcriptional activation studies (Weinberg et al. 2005). 
 
 While providing insight into the mechanisms of DNA RE recognition by p53, the 
strategies used to obtain p53-DNA crystals introduce a level of uncertainty in the results 
presented. The crystals were created by mixing p53 DBDs with RE half-sites, 12-basepair 
DNA oligonucleotides, with each dsDNA able to accommodate two p53 DBDs. Although 
the crystal packing arranged the p53 dimers in a tetrameric form, the DNA axis is shifted 
between dimers and one dimer is rotated about the DNA approximately 45° relative to the 
other (Fig 3.6a).  
 
 The rotational offset of one DBD to the other, in turn, reduces the protein-protein 
interface between dimers. These parallel interfaces are not symmetric, with one parallel 
interface burying 118 Å2 of surface area, and the other burying 282 Å2. The interfaces are 
the smallest of the p53-DNA structures, compared to the symmetric parallel interfaces of 
the tetrameric structure reported here, which involve approximately 550 Å2 each (Fig. 
3.8). Furthermore, molecular dynamics simulations of this structure show that this 
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parallel interface is quickly lost, showing that the energy minimized state has a parallel 
interface angle close to 0° (Pan et al. 2009). 
Structure of a multi-domain p53 tetramer bound to a response element 
 While various p53-DNA structures have been reported over the years, each 
contributing to an increased understanding of the atomic details of DNA-binding, there 
are still unanswered questions regarding many aspects of the DNA-binding functions of 
this tumor suppressor. The marginal stability of p53 makes crystallographic investigation 
challenging, requiring the use of short DNA half-sites or crosslinking the protein to the 
DNA in order to determine the DNA-bound structure.  
 
In the following chapters, we present the first stabilized p53 variant containing 
both DBD and the oligomerization domains, show that the variant is functional in vitro 
and in vivo, and solve the X-ray crystal structure of both an unbound p53 dimer and a 
DNA-bound p53 tetramer. We demonstrate for the first time how p53 oligomers bind to a 
full-length response element and form robust parallel protein-protein interfaces involving 
conserved residues. We describe conformational changes in the DBD that accommodate 
binding to invariable bases within the RE, and show how loop L1 can serve as a wedge to 
facilitate cooperative binding by creating a shift in the response element DNA. 
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Structure of a multidomain p53 oligomer bound to DNA† 
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Abstract 
The p53 tumor suppressor is the most frequently inactivated gene in human 
cancer. It encodes a transcription factor that contains two independently folding domains, 
a core sequence-specific DNA binding domain and a homo-tetramerization domain (1). 
Here we describe the structure of a p53 polypeptide containing both these domains on its 
own and in complex with DNA. The structure of the complex shows four DNA binding 
domains interacting with one another and with DNA. Both the DNA binding domains of 
p53 and the DNA undergo conformational changes upon DNA binding. These 
conformational changes are asymmetric, even though the p53 DNA binding site is made 
of four identical consensus repeats. The DNA corresponding to the center two repeats is 
distorted such that its helical axis shifts by more than four angstroms. This results in 
widening of the major groove at the center of the p53 binding site, which can thus 
accommodate sequence-specific contacts by both loop L1 and helix H2. The geometry of 
the DNA corresponding to the outer two repeats resembles better B-form DNA; this 
results in loop L1 of one subunit adopting a recessed conformation, in which Lys120 no 
†Submitted to the journal NATURE 
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longer makes sequence-specific contacts, but rather interacts with the phosphate 
backbone. The structure resolves the controversies of whether p53 and its target DNA 
change conformation upon binding, the unusual feature of p53 that it uses both a loop and 
a helix to contact the major groove of DNA, and why loop L1 is not targeted by cancer-
associated mutations. 
Introduction 
The first determined three-dimensional structure of a core p53 DNA binding 
domain in complex with DNA elegantly showed that most of the mutations in cancer 
target residues that contact DNA (2). However, this structure also left some unanswered 
questions. First, even though p53 physiologically binds DNA as a homotetramer, a model 
of four p53 DNA binding domains in complex with B-form DNA leads to steric clashes 
between the p53 subunits (3). Second, the structure showed that p53 uses an α-helix (H2) 
and a loop (L1) to make sequence-specific contacts with the major groove of the DNA. 
However, some experimental evidence argues against loop L1 making sequence-specific 
contacts: amino acid substitutions targeting loop L1 generally do not compromise DNA 
binding (4) and the structure of the DNA binding domain of C. elegans p53, which has 
been determined only in the absence of DNA, shows loop L1 in a conformation 
compatible only with non-specific contacts (5). 
 
Since p53 functions as a homotetramer, the questions raised above could perhaps 
be addressed by determining the structures of p53 oligomers in complex with DNA. 
Towards this goal two groups have determined structures of 2 or 4 core p53 DNA 
binding domains bound to DNA. The tetramer structure reported by the first group shows 
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2 DNA binding domains bound to a 12-mer DNA site; there are 2 such complexes in the 
asymmetric unit, creating a larger complex of 4 core domains bound to 2 semi-continuous 
DNA molecules (6). In this structure, loop L1 binds DNA as reported in the original p53 
monomer-DNA structure (2). The structures reported by the other group relied on a 
sulfur-bearing three-carbon linker to attach 2 or 4 core p53 DNA binding domains to 16-
mer or 23-mer oligonucleotides, respectively. In the dimer structure, loop L1 is 
disordered, while in the tetramer structure, loop L1 s displaced from the DNA, probably 
by the chemical crosslinker (7, 8). Thus, none of the p53 oligomer structures determined 
so far have demonstrated how four p53 DNA binding domains with well-defined DNA 
binding elements - including loop L1 - contact physiological DNA sites.  
Experimental procedures 
To determine the three-dimensional structure of a p53 oligomer bound to DNA, 
we expressed a p53 polypeptide that included not only the core DNA binding domain, but 
also the oligomerization domain. This required the introduction of stabilizing amino acid 
substitutions in the DNA binding domain, which otherwise has a very low melting 
temperature (9). The designed substitutions targeted non-conserved residues far away 
from the DNA binding surface and sampled residues from the repertoire of amino acids 
present at that position in p53 proteins from other species with the goal of maximizing 
the hydrophobic effect. A similar strategy has been employed by others (10, 11) and we 
incorporated some of the substitutions identified by them in our designed p53 proteins. 
After several rounds of mutagenesis and functional testing we obtained a human p53 
protein (stabilized 6, ST6) with 12 amino acid substitutions, of which 4 were previously 
identified by others (10, 11). p53-ST6, whose melting temperature was about 15o C 
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higher than the melting temperature of native p53, had wild-type DNA binding and tumor 
suppressor activities and could be expressed as a soluble protein in E. coli, but aggregated 
when mixed with p53 target DNA and did not prove useful for obtaining crystals of p53-
DNA complexes (Figs. 2.1a & c, and 2.2). 
Computational protein design: R209P substitution 
We reasoned that the p53-DNA aggregation was due to non-specific DNA 
binding mediated by basic residues of the p53 core domain located far away from the 
sequence-specific DNA binding surface and used an algorithm to identify energetically 
favorable amino acid substitutions that replaced such basic residues with non-charged 
residues (12). Substitution of Arg209 with Pro fit these criteria and was introduced in the 
stabilized p53-ST6 protein (Fig. 2.1b) to generate p53-ST7 (Fig. 2.2), a protein whose 
melting temperature exceeded 70o C and which did not aggregate when mixed with DNA 
(Fig. 2.1c). p53-ST7, hereafter referred to as p53-ST, had DNA binding and tumor 
suppressor activities that were indistinguishable from those of wild-type p53 (Figs. 2.3 & 
2.5b). 
Multi-domain p53 variants 
 We generated a multitude of p53-ST proteins for crystallization screens. All 
spanned residues 94-358 of human p53, but had deletions of different length between the 
DNA binding and oligomerization domains. In addition, they either contained a wild-type 
tetramerization domain or a mutant p53 oligomerization domain that can assemble as a 
dimer, but not as a dimer of dimers (13). All p53-ST proteins were incubated with DNA, 
22-28 nucleotides long, containing a high affinity p53 DNA binding site consisting of 
four contiguous pentamer repeats (Fig. 2.5a) or without DNA. The only two proteins that 
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yielded crystals are referred to as p53CR1 and p53CR2. p53CR1 crystallized only in the 
absence of DNA, whereas p53CR2 crystallized only in the presence of a 26 nucleotide-
long DNA (Fig. 2.5a). Both p53CR1 and p53CR2 have the mutant p53 oligomerization 
domain (13), but differ in the length of the deletion between the DNA binding and 
oligomerization domains; this deletion spans residues 292-321 and 292-320 of full-length 
human p53 in p53CR1 and p53CR2, respectively (Fig. 2.4). 
Results 
p53 Dimer 
 The three-dimensional structure of p53CR1 in the absence of DNA was 
determined at a resolution of 2.0 Angstroms [Å] (Table 2.1). As predicted, the protein 
crystallized as a dimer (Fig. 2.5c). The ST DNA binding domains adopted the same 
conformation as the wild-type DNA binding domain (2). The dimerization domain also 
adopted the same conformation as the half wild-type tetramerization domain (13, 14). 
The two DNA binding domains of the dimer did not interact with one another. Instead, 
their orientation relative to one another was dictated by crystal packing interactions.  
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Figure 2.1 
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Figure 2.2 
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p53 tetramer bound to DNA 
 The three-dimensional structure of two p53CR2 dimers bound to DNA was 
determined at a resolution of 2.3 Å (Table 2.1). We labeled the DNA pentamer repeats a, 
b, c and d, reflecting their 5-prime to 3-prime order in the DNA sequence (Fig. 2.5a). 
Repeats b and c are at the center of the p53 DNA binding site and will also be referred to 
as the "inner" repeats, whereas repeats a and d will be referred to as the "outer" repeats. 
The p53 protein subunits are labeled A, B, C and D, matching the label of the pentamer 
repeat, whose major groove they contact (Fig. 2.5d). According to this terminology, one 
p53 dimer is formed by subunits AC, while the other by subunits BD. With some 
exceptions listed below, the p53 subunits adopt very similar three-dimensional structures 
to those observed in the absence of DNA. However, while in p53CR1 there were no 
contacts between the DNA binding domains, in the structure of p53CR2 bound to DNA, 
there were extensive contacts between the 4 DNA binding domains (Fig. 2.5d & e). In 
what follows, we first describe how the DNA bound by p53 deviates from B-form 
conformation and then the p53-DNA contacts and p53-p53 intersubunit contacts that are 
responsible for this deviation. 
DNA is shifted upon p53 binding 
 To visualize changes in the conformation of DNA upon p53 binding, we plotted 
in the three-dimensional space for each base pair its C1'-C1' vector and its helical axis 
(Fig. 2.6). The same was done for B-form DNA. As indicated by the orientation of the 
C1'-C1' vectors, there is no significant bending of the DNA, except at the edges of the 
p53 binding site (base pairs a4, a5, d4 and d5). Instead, there is significant shifting of the 
helical axes, especially between base pairs b5 and c5 at the center of the p53 binding site 
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(Fig. 2.6a, compare to B-form DNA), but also between base pairs b1-b4 and c1-c4 and to 
a lesser extent between base pairs a1-a4 and d1-d4 (Fig. 2.6b, related by a 90o rotation to 
the view shown in Fig. 2.6a). (Note that we do not distinguish between shifting and 
sliding of the DNA helical axis (15) and, for simplicity, we refer to both as shifting). As a 
result, the helical axis of the DNA shifts from repeat a to repeat d by about 4.8 Å (Fig. 
2.6c), of which 3.0 Å are due to the shift at the center of the p53-binding site (Fig. 2.6d). 
Interestingly, the shift in the DNA axis is not associated with significant deviations in the 
values of base pair twist angles from those present in B-form DNA (Fig. 2.6e). 
 
 
Figure 2.3 
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Figure 2.4 
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Figure 2.5 
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DNA binding detail 
 Inspection of the p53-DNA contacts provides a first level of understanding of how 
the four p53 DNA binding domains induce the 4.8 Angstrom shift in the DNA helical 
axis. The sequence-specific contacts involve predominantly base pairs 2 and 3 of each 
pentamer repeat and are similar for all p53 subunits. Using p53 subunit B as an example, 
one observes the previously-described hydrogen bonds between the NH1 and NH2 atoms 
of Arg280 and the O6 and N7 atoms, respectively, of the guanine base at position 2 of 
repeat b (Fig. 2.7a; refs. 2, 6-8). In addition, we observe sequence-specific hydrogen 
bonds involving atoms N2 and N3 of the same guanine base and the NH1 atom of 
Arg248 from p53 subunit A. One network of these minor groove hydrogen bonds is 
mediated by a water molecule and is observed in all four p53 subunits. In addition, a 
novel direct hydrogen bond between the N3 atom of the guanine base and Arg248 is 
observed between p53 subunits A and D and the inner pentamer repeats, for which the 
distance between the interacting atoms is 3.7 Å; for subunits B and C and the guanine 
bases at position 2 of the outer repeats, the corresponding distance is 4.2 Å. In the 
previously-determined p53-DNA structures, Arg248, the most frequently mutated residue 
in human cancer (16), was shown to contact oxygen atoms in the sugar-phosphate DNA 
backbone (2, 6-8). The multitude of sequence-specific interactions involving the guanine 
base at position 2 of the pentamer repeat, explains why this nucleotide is invariant and the 
most critical determinant of p53 binding specificity (Fig. 2.5b). Base pair 3 of each 
pentamer repeat also makes sequence-specific contacts with p53 (2, 6-8). Again using 
p53 subunit B as an example, the SG atom of Cys277 makes a hydrogen bond with the 
N4 atom of the cytosine base at position 3 of repeat b (Fig. 2.7b). In repeats a and c the 
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corresponding base is a thymine, in which case the SG atom of Cys277 contacts the 
corresponding thymine O4 atom. In addition, in repeats a and c, the C5A atom of the 
thymine base is equidistant (about 3.7 Å) to the SG atom of Cys277, the CB atom of 
Ala276 and the CZ atom of Arg280 (Fig. 2.7b). Thus, the sequence-specific interactions 
of p53 with base pairs 2 and 3 dictate the relative position of these base pairs to each 
other. If one superimposes a B-form DNA to the p53-bound DNA using base pairs a2, a1, 
b1 and b2 for the superimposition (Fig. 2.5a), then one observes that base pair b3 is 
already shifted by 1.7 Å in the p53-bound DNA relative to B-form DNA (Fig. 2.7b). 
Differences between binding inner and outer DNA repeats 
 Unlike the contacts of p53 with base pairs 2 and 3, which are essentially similar in 
all four p53 subunits, the interactions with base pairs 4 and 5 vary depending on whether 
the p53 subunit contacts an inner (repeats b and c) or an outer (repeats a and d) repeat. 
Using p53 subunit B as an example of the contacts of subunits B and C to the inner 
repeats b and c, respectively, the NZ atom of Lys120 makes hydrogen bonds with atoms 
O6 and N7 of the guanine base at position 4' of repeat b (Fig. 2.7c). However, it is not 
clear how much these hydrogen bonds contribute to DNA binding specificity, because the 
side chain atoms of Lys120 had high B factor values. In contrast, the main chain of 
Lys120 and the remaining loop L1 residues had low B factors. The main chain N atom of 
Lys120 of p53 subunit B makes a hydrogen bond with the O2P atom of the phosphate 
backbone at position 5' of repeat b, whereas the main chain O atom of the same lysine 
and the OG atom of Ser121 make hydrogen bonds with oxygen atoms of the sugar-
phosphate backbone at position 5 of repeat c (Fig. 2.7c). All these interactions are 
possible thanks - and probably contribute - to the shift in the DNA helical axis.  
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Table 2.1  
Data collection and refinement statistics for the hp53 dimer and hp53 tetramer / 
DNA complex datasets*. 
 
 
    hp53 Dimer   hp53 Tetramer / DNA 
Data Collection                                                                              . 
X-ray Wavelength  0.87260 Å   0.87260 Å 
Space Group             P212121    P21212 
Cell Dimensions (Å)         a=69.68, b=73.82, c=106.69  a=163.30, b=169.76, c=55.66  
Resolution (Å)           60.86-2.00 (2.11-2.00)  58.62-2.30 (2.42-2.30) 
Observations            290,077 (41,979)   301,262 (40,665) 
Unique reflections         38,096 (5,459)   67,333 (9,800) 
Data coverage (%)         100.0 (100.0)   97.9 (98.6) 
<I/σ(Ι)>    11.7 (5.1)   9.4 (1.7) 
Rsym (%)               16.3 (36.0)   12.2 (61.7) 
 
Refinement statistics                                                                                . 
Resolution range (Å)        20-2.0    30-2.3 
Reflections used (>0 sigF)    37,833    67,333 
Protein atoms            3,704    7,452 
DNA atoms              0    1,060 
Water molecules           135    351 
R factor (%)            24.7    23.3 
Rfree (%)               26.9    27.0 
R.m.s. deviations 
 Bonds (Å)             0.005    0.006 
 Angles (o)              1.26    1.18 
Ramachandran plot 
 Most favored (%)          92.5    85.6 
 Allowed (%)             7.5    13.0 
 Generously Allowed (%)  0.0    1.2 
 Disallowed (%)   0.0    0.1 
 
Values in parentheses refer to the highest resolution shell. 
 
Rsym = ΣhΣi|Ih,i - Ih| / ΣhΣiIh,i for the intensity (I) of i observations of reflection h. 
 
R factor = Σ|Fobs - Fcalc| / Σ|Fobs|, where Fobs and Fcalc are the observed and calculated structure factors, 
respectively. 
 
Rfree = R factor calculated using 5% of the reflection data chosen randomly and omitted from the start of 
refinement. 
 
R.m.s. deviations for bonds and angles are the respective root-mean-square deviations from ideal values. 
 
*Software used for analyzing the X-ray diffraction data sets and for refinement of the 
structure described in references 29, 30 & 31
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Figure 2.6 
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Figure 2.7 
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 As mentioned above, the DNA helical axis shifts by 3 Å between base pair 5 of 
repeat b and base pair 5 of repeat c (Fig. 2.6a & d). In addition, in the axis perpendicular 
to the one shown in Fig. 2.6a, the helical axis of base pairs b5 and c5 can be seen to have 
moved away from the p53 DNA binding domains by 3 Å relative to the helical axis of 
base pairs b2 and c2 (Fig. 2.6b). Without these shifts, residues 119-121 of loop L1 would 
sterically overlap with the DNA backbone (Fig. 2.7d). In the previously determined p53 
monomer-DNA structure (2), loop L1 adopts a conformation that allows it to barely 
squeeze past the B-form DNA, Ser121 does not contact DNA and its CA atom has moved 
4.2 Å away compared to its position in subunit B of the structure reported here (Fig. 
2.7d). 
Differences in loop L1 position per DNA repeat 
The shift in the DNA helical axis is much smaller within the outer repeats than 
within and especially between the 2 inner repeats. Accordingly, in subunits A and D loop 
L1 cannot adopt the same conformation as in subunits B and C. In fact, the conformation 
of loop L1 and its contacts with DNA differed in subunits A and D. In subunit A, loop L1 
adopted a recessed conformation relative to the one observed in the absence of DNA or in 
subunits B and C of the DNA-bound structure (Fig. 2.7e). The side chain of Ser121 faced 
away from and did not contact DNA; the side chain of Lys120 did not make any 
sequence-specific contacts, but rather interacted with the phosphate backbone of the 
guanine located one position 5 prime of repeat a; while the main chain O atom of the 
same residue interacted with the phosphate backbone of the thymine located two 
positions 5 prime of repeat a (Fig. 2.7e). The CA atoms of Lys120 and Ser121 have 
moved 3.9 and 5.5 Å away, respectively, compared to their position in subunit B (Fig. 
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2.7f). The recessed conformation of loop L1 is reminiscent, although different, from the 
recessed conformation of loop L1 in C. elegans p53 (5) and allows subunit A to contact 
DNA that adopts regular B-form conformation (Fig. 2.7f). In subunit D, loop L1 adopted 
a conformation similar to that observed in the monomer p53-DNA structure (2); the side 
chain of Lys120 made a sequence-specific contact with the N7 atom of the guanine base 
at position 5 of repeat d; and the phosphate-sugar backbone of the DNA corresponding to 
repeat d had a conformation in between the conformations of repeat a and repeats b and c 
(Fig. 2.8). 
Protein-protein interfaces within the p53 tetramer 
The four p53 DNA binding domains contact each other in the DNA-bound 
structure (Fig. 2.5d). Two different p53-p53 interfaces are evident: an anti-parallel 
interface between subunits A and B and between subunits C and D and a parallel 
interface between subunits A and C and between subunits B and D, reflecting the 
orientation of the interacting DNA binding domains to one another. The anti-parallel 
interface buries 310 Å2 per two interacting subunits and is essentially as described in the 
previously determined structures of p53 oligomer core domains bound to DNA with only 
minor differences in the conformations of a few amino acid side chains (6-8). In contrast, 
the parallel interface is completely different from any of the previously observed such 
interfaces. Compared to the parallel interface observed in the structure of the four core 
DNA binding domains crosslinked to DNA (8), to which it is more similar, the p53 
subunits have shifted at the interface by between 3-7 Å; the buried surface area is almost 
twice as large, at 552 Å2 per two interacting subunits; and the interaction is mediated by 
evolutionarily conserved residues. Two main areas of interaction are evident at the 
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parallel interface. One area is dominated by hydrogen bonds involving the side chains of 
Thr123, Thr140 and Glu198 and the main chain O atom of Thr140 from one subunit and 
the side chains of Ser166, Gln167 and Thr170 from the other subunit (Fig. 2.9a). The 
second area shows hydrophobic interactions between Val225 from one subunit and 
Tyr103 and Leu264 from the other subunit, as well as electrostatic interactions and 
hydrogen bonds between Glu224, Ser227 and Asp228 from one subunit and Ser99, 
Lys101 and Arg267 from the other subunit (Fig. 2.9b). Residues Ser166, Gln167 and 
Arg267 are targeted by mutations in human cancer with the same frequency as residues 
Pro177, His178 and Arg181, which form the anti-parallel interface (16). In terms on their 
effect on DNA binding, the anti-parallel interface helps determine the position of Arg248 
from one subunit relative to Arg280 from the other subunit and, thus, facilitates the 
recognition of the guanine base at position 2 of the pentamer repeat (Fig. 2.7a). On the 
other hand, the parallel interface helps determine the relative position of subunits AB to 
CD to stabilize the 4.8 Angstrom shift in the DNA helical axis observed between repeats 
a and d (Figs. 2.5d & 2.6c). 
Discussion 
Cooperativity in p53 DNA binding 
The vast majority of the known p53 binding sites in the human genome, about 
90%, consist of four contiguous pentamer repeats with no gaps in between them, similar 
to the DNA site present in the p53CR2-DNA structure reported here, while the remaining 
10% of the sites have only a spacer of one nucleotide between repeats b and c (17). The 
presence of four contiguous pentamer repeats allows the establishment of moderately-
sized interfaces between the DNA binding subunits. The buried surface areas of these 
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interfaces are not sufficiently large, on their own, to mediate oligomerization of the DNA 
binding domains in the absence of DNA, but help explain the observed cooperativity in 
p53 DNA binding (18). As expected, this cooperativity is greater for p53 binding sites 
that contain four contiguous pentamer repeats; when a spacer of even one nucleotide is 
introduced between the inner pentamer repeats, then DNA binding cooperativity is 
significantly reduced (19), as would be expected, since then the interactions observed 
here at the parallel interface would not be maintained. 
Shifted DNA accommodates p53 tetramer 
The structure reported here also resolves the question of steric clashes when four 
p53 DNA binding domains bind DNA (3). Instead of p53 tetramers bending DNA, as 
previously contemplated (3, 20), the helical axis of DNA is shifted by 4.8 Å (Appendix II, 
Table a2.2). This allows the p53 subunits that bind to the inner pentamer repeats to 
recognize the major groove of DNA using both an α-helix and a loop, which is highly 
unusual among DNA binding proteins (2, 21). Without the shift in DNA helical axis, only 
the α-helix would be able to fit in the major groove of DNA, as is, indeed, observed for 
subunit A. The high B factors of the side chain atoms of Lys120 further suggest that the 
main role of loop L1 may not be to contribute to DNA binding specificity, but rather to 
facilitate the shift in the DNA helical axis. Substitution of Lys120 with Ala has little 
effect on the DNA binding and tumor suppressor properties of wild-type p53 (4), whereas 
substitution of Thr123 with Ala, which may stabilize the conformation of loop L1 
observed in subunits B and C, enhances both DNA binding and apoptotic activities (4, 
22). 
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The most unusual feature of the multidomain p53 oligomer structure bound to 
DNA is the shift in DNA helical axis. The biological significance of this shift remains 
unclear. However, one hypothesis is that the shift is necessary for p53 to activate 
transcription. Indeed, some transcription factors simply bind B-form DNA and then 
recruit enzymes that modify histones post-translationally (23). But other transcription 
factors, notably, TATA-binding protein [TBP], induce large architectural changes in the 
DNA that result in histone eviction (24). While p53 induces a much more modest change, 
binding of p53 to DNA may also lead to eviction or displacement of histones.  
 
The structure reported here suggests that the sequence-specific recognition of the 
base pairs at positions 2 and 3 of the pentamer repeats facilitates the shift in DNA helical 
axis. Interestingly, p53 can both activate and repress transcription, depending on the 
specific site in the genome to which it binds (25). The target sites that mediate activation 
of transcription match well the p53 consensus sequence at positions 2 and 3; whereas the 
target sites that mediate repression of transcription do not match the p53 consensus 
sequence at position 3 (26), raising the possibility that binding of p53 tetramers to 
repressor DNA sites does not induce a major shift in the DNA helical axis. 
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Figure 2.8 
 
 
 
 
 
 
 
Figure 2.9 
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Methods 
Protein sample preparation and crystallization.  
p53 polypeptides were expressed in E. coli. The cells were lysed in buffer 
consisting of 25 mM bis-tris propane (BTP) [pH 6.8], 250 mM NaCl, 5 mM DTT and 
protease inhibitors, and the polypeptides were purified by cation exchange (Sepharose SP 
column; Pharmacia Biotech, Uppsala, Sweden) and gel filtration (Superdex 200 column; 
Pharmacia Biotech). After purification the p53 protein was concentrated to 8 mg/ml in 25 
mM bis-tris propane [pH 6.8], 150 mM NaCl, 5 mM DTT buffer and was crystallized 
under standard hanging drop vapor diffusion conditions in 48-well plates (Hampton 
Research, Aliso Viejo, CA, USA) or in a novel microfluidics system (27) at 4o C in the 
absence of DNA or in the presence of DNA at a 1:1.1 protein:DNA molar ratio. The 
precipitant solutions used for crystallization were 0.2 M ammonium acetate, 0.1 M 
HEPES [pH 7.5], 45% v/v 2-Methyl-2,4-pentanediol for p53CR1 in the absence of DNA 
and 0.15 M DL-Malic Acid [pH 7.0], 20% Polyethylene Glycol 3350 for the p53CR2-
DNA complex (Appendix II, Fig. a2.5). 
 
Data collection and structure refinement.  
All X-ray diffraction data sets were collected at the ID23-2 microfocus beam line 
of the European Synchrotron Radiation Facility (Grenoble, France). Reflection data were 
indexed, integrated and scaled using the CCP4 software package. Initial solutions were 
determined by molecular replacement and refined using non-crystallographic symmetry 
restraints using the programs CNS and O. Base pair origins and origin vectors were 
determined using the program 3DNA (28). 
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Electrophoretic mobility gel shift assay.  
[35S]-methionine-labeled full-length human wild-type p53 and the equivalent p53 
protein containing the stabilizing amino acid substitutions (ST7, Fig. 2.2) were expressed 
by in vitro translation in rabbit reticulocyte lysate (Promega Corporation, Madison, WI, 
USA). The radiolabeled proteins were then incubated at ambient temperature with 
oligonucleotides containing consensus or variant p53 DNA binding site and analyzed for 
DNA binding by electrophoresis on non-denaturing tris-glycine gels as previously 
described (5). 
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CHAPTER 3 
Discussion: p53 DNA-binding 
 Key questions concerning how p53 binds DNA as a tetramer were answered by 
the results presented here;  
 Do p53 and its target DNA change conformation upon binding?  
 How does p53 use loop L1 and helix H2 to contact the major groove of DNA?  
 Why is loop L1 not targeted by cancer-associated mutations?  
 
As previously discussed, the current p53-DNA structures leave ambiguities in describing 
how p53 binds DNA, arising mainly from the strategies employed in order to crystallize 
p53 with DNA. The initial structure reported in 1994, while defining the architecture of 
the DBD (Fig. 1.5) and providing valuable insight into how cancer mutations affect DNA 
binding, consisted of three DBDs bound to DNA, with only one of the DBDs making 
base-specific contacts. A decade later three more p53-DNA structures were released that 
described DBD multimers bound to DNA, yet the DBDs were either crosslinked to the 
DNA or incubated with RE half-sites, failing to provide a structure of the p53 tetramer 
bound to a full-length response element. The structures reported here describe stable p53 
variants that contain both DBD and oligomerization domains, dimerize in the absence of 
DNA, tetramerize in the presence of DNA, and form substantial protein-protein interfaces 
by inducing a shift in the DNA response element upon binding. Furthermore, these stable 
variants retain wild-type DNA binding specificity in vitro and reflect wild-type 
transactivation functions in vivo.   
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Structure: multidomain p53 tetramer bound to a full-length RE 
Oligomerization domain 
 The p53 protein functions most efficiently as a tetramer, reflected by the high 
affinity for binding DNA REs in a tetrameric state (Kern et al. 1991; Tokino et al. 1994, 
Weinberg et al. 2005). Tetramerization of p53 monomers occurs through interactions 
within the oligomerization domain formed by residues 325-356 (Jeffrey et al. 1995). 
Each oligomerization domain consists of a short β-strand and α-helix connected by a 
sharp hairpin. Four monomeric oligomerization domains can self-assemble via helix 
packing and intermolecular β-sheet formation. Yet although all four monomer domains 
interact within the tetramer, the A-B (and C-D) interface is more extensive than those of 
A-C or A-D, implying that the tetramer can be regarded as a dimer formed through 
association of AB and CD dimers (Jeffrey et al. 1995). Indeed, dimeric forms of p53 
exhibit comparable DNA-binding and transactivation functions in vivo (Pietenpol et al. 
1994) 
 
 Therefore in order to reduce the complexity of the p53-DNA system and to 
increase chances of obtaining p53-DNA crystals, the oligomerization domain was altered 
so that dimers, but not dimers of dimers, can form (Davison et al. 2001). The two residue 
substitutions introduced, M340Q and L344R, affected neither the structure of the 
oligomerization domain (Fig. 3.1), nor the DNA binding capabilities of p53 both in vitro 
(Fig. 2.5b) and in vivo (Fig. 2.3). The oligomerization domains of the stable p53 variant 
structures reported here, both in the DNA-free dimer and DNA bound tetramer, are 
structurally similar to previously reported structures of this domain (backbone atom root 
mean square deviation [RMSD] of 0.35 Å to structure PDB code: 1C26) (Fig. 3.2).  
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Figure 3.1 
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Figure 3.2 
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DNA-binding domain  
 The DNA-binding domains of the stable p53 variant structures presented here 
exhibit the same compact domain architecture as other p53 DBD structures. Overall, the 
DBDs of both the DNA-bound tetramer and DNA-free dimers align to the DBD of Cho et 
al. with a 0.5 Å RMSD between backbone atoms (Fig. 3.3). Alignment to human DBDs 
from other structures generate similar results with RMSD values of 0.416 Å and 0.334 Å 
for a DBD dimer bound to DNA (Kitayner et al. 2006; PDB code: 2ACO) or a stable 
DBD monomer (Joerger et al. 2005; PDB code: 2BIM), respectively. The similarity 
among the various DBD structures reflects the high level of conservation found among 
species (Appendix II, Fig, a2.4) and highlights the importance of the three-dimensional 
domain architecture required to form protein-protein and protein-DNA contacts critical 
for p53 DNA-binding and subsequent transactivation functions.  
 
Domain rearrangement upon DNA binding 
 As described in chapter two, the structures of the stable multi-domain p53 both 
unbound and bound to DNA reveal conformational changes among domains, reinforcing 
the idea of cooperativity upon DNA binding. The binding event causes the DBDs of each 
monomer to rotate relative to the oligomerization domains to form a robust anti-parallel 
interface involving conserved residues (Fig. 3.4). Furthermore, both parallel and anti-
parallel interfaces within the tetramer situate the DNA-binding residues in coordinated 
positions to make backbone and base-specific contacts inducing a shift among bases 
within the 26-bp p53 response element (Fig. 2.6). Compared to other p53-DNA structures 
(Fig. 1.4), the shift increases binding by maximizing both backbone and base specific 
contacts, with the invariable guanines at position 7 and 17 within the RE helping to 
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anchor the p53 tetramer (Fig. 3.9d), which in turn aligns the four p53 monomers, 
increasing the protein-protein interfaces and stabilizing the complex. 
 
 
 
Figure 3.3 
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Figure 3.4 
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Cooperative interactions upon DNA binding 
Anti-parallel interface 
 Our tetrameric structure, compared to the human DBD dimer of dimers (Kitayner 
et al. 2006), and the mouse DBD crosslinked to DNA (Ho et al. 2006; Malecka et al. 
2009), has similar residues implicated in the anti-parallel interface (Fig. 3.5). This is in 
agreement with in vivo data demonstrating p53 first dimerizes and then binds REs as a 
dimer of dimers (McLure KG & Lee PW 1998).  
 
 DNA binding involves four p53 monomers forming a tetramer on DNA whose 
sequence contains four repeats, with each repeat interacting with each monomer. As the 
p53 subunits come together, a total of four protein-protein interfaces are formed. Two 
anti-parallel interfaces form between chains AB and CD crossing the DNA axis. The anti-
parallel interfaces from the tetrameric structure reporter here are similar to the anti-
parallel interfaces of previously determined p53-DNA structures (Fig. 3.5). The anti-
parallel interface involves the zinc-coordinating loop L2, helix H1 and loop L3 (Fig. 1.5). 
The regions involved in coordination of the zinc atom are highly conserved, and these 
same areas have a high frequency of cancer-related mutations (Fig. 1.2).  
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Figure 3.5 
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Parallel interface 
 Our tetrameric structure, compared to the human DBD dimer of dimers (Kitayner 
et al. 2006), and the mouse DBD crosslinked to DNA (Ho et al. 2006; Malecka et al. 
2009), has a more robust and consistent parallel interface (Fig. 3.6). The parallel 
interfaces are created on each side of the DNA, between chains AC and BD. Our p53 
tetramer structure demonstrates that the same interface residues are used in parallel 
interfaces I and II. Furthermore, our structure has 16 residues at the parallel interface that 
are the same within each dimer, whereas the structure from Malecka et al. has 10 residues 
in common, and the structure of Kitayner et al. has 4 residues in common (Fig. 3.6). The 
significance of these novel parallel interactions is reinforced by the observation that there 
are twice as many residues involved at the parallel interface, the same residues are used 
by both dimers on each side of the DNA, that the majority of residues are conserved (Fig. 
3.7), and that the buried surface area per two interacting subunits is almost twice as large 
as other tetramer structures (Fig. 3.8). 
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Figure 3.6 
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Figure 3.7 
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Figure 3.8 
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Characterization: DNA binding properties 
 DNA-binding gel shift assays with 15 different p53 RE variations (Fig, 2.5b) 
reveal that the ST p53 variants used for crystallography retain the same binding 
properties as wild-type p53 in vitro. DNA binding studies were carried out as described 
in the methods section. For creating p53-DNA complexes used in crystallographic 
experiments, ST p53 was also assayed for binding to oligonucleotides of length 21 to 27-
bp using size exclusion chromatography (Methods: Table m.1, Figs. m.3 & m.4).  
 
 The results show that ST p53 binds to dsDNA oligonucleotides of length 24-bp 
and greater. No stable complexes were observed for dsDNA of length 23-bp or shorter. 
However, other groups have crystallized human or mouse p53 DBDs with DNA as short 
as 12-bp. This seemingly contradictory observation can be explained by the fact that the 
p53 variants used in this study have a shortened linker, which positions the 
oligomerization domain much closer to the DBD compared to wild-type p53. Although 
these p53 variants retain wild-type DNA-binding and functionality in vitro and in vivo, 
the p53 dimer does not straddle the DNA (via the anti-parallel interface) as shown in 
other structures. Rather, the ST p53 dimer binds to DNA in a parallel manner along the 
DNA axis, contrary to the other structures in which p53 dimers bind across the DNA in 
an anti-parallel orientation. Regardless of binding orientation, similar DBD anti-parallel 
interfaces are created in the tetrameric complex (Fig. 3.5). A double-stranded DNA 
oligonucleotide of 24 base-pairs accommodates the two DBDs of each dimer binding to 
each long edge of the DNA. DNA that is 23-base pairs or shorter is not long enough to 
accommodate two complete DBDs of each dimer in a parallel interface in our system, 
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and thus could destabilize the complex by removing protein-DNA interfaces that in turn 
can reduce protein-protein contacts. 
 
 Cooperativity in DNA-binding is demonstrated by the structures reported here in 
conjunction with the results obtained from size exclusion chromatography. As described, 
the ST p53 dimer does not stably bind to dsDNA shorter than 24-bp, and the DBDs do 
not associate with each other in the absence of DNA. The DNA-bound structure reveals 
that the dimer forms on each side of the DNA and makes robust parallel interfaces (Figs. 
3.6 & 3.8). However if the parallel interface between p53 DBDs forms a stable protein-
protein interaction, then it could be expected that the tetramer would form on shorter 
dsDNA containing only one half-site. These observations therefore provide more 
evidence that the response element acts as a template, helping to orient the p53 DBDs 
relative to each other in order to form both the anti-parallel and parallel interfaces. 
 
 The vast majority (99%) of known p53 response elements have no spacer 
nucleotide between half-sites (such as the RE in our structure), and the majority of the 
remaining 1% have only one nucleotide spacer (Wang et al. 2009). Response element 
half-sites separated by 2 or more nucleotides would reduce or abolish the anti-parallel 
interface by separating the p53 dimers. While it is easy to see how a large spacer can 
prevent the parallel DBD interface by separating each p53 dimer, it is not as evident why 
a single or double nucleotide spacer could affect binding. However, at about 10.5 base-
pairs per complete 360° helical turn of B-form DNA, each nucleotide contributes 
approximately 34° of rotation about the central DNA axis. Therefore with even a two-
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nucleotide spacer between response element half sites, one DNA-bound p53 dimer could 
be rotated 68° in relation to the other. Even if the distance between p53 dimers on the 
DNA is close enough to accommodate parallel protein-protein interactions, the rotation 
would most likely prevent alignment of the surfaces used in the parallel interface.  
 
New DNA contacts 
 In addition to previously described p53-DNA contacts, we observe novel contacts, 
some of which are different from subunit to subunit. The structure reported here shows a 
sequence-specific contact made by Arg248 to the invariable guanine base of the response 
element through the minor groove. We also observe that helix H1, which contacts DNA, 
can move like a piston by 0.9 Å from subunit to subunit; and that this movement allows 
the helix to adapt to the induced DNA distortions.  
 
Interaction of tetramer with DNA: K248 & K280 
 In the p53-DNA structure reported here, we observe a new sequence-specific 
contact made by Arg248, the most frequently mutated residue of p53 in cancer (Fig. 1.2). 
In previously reported p53-DNA structures, this residue makes occasional non-specific 
contacts with the DNA backbone (Cho et al. 1994; Kitayner et al. 2006; Malecka et al. 
2009). However, the extensive protein-protein interactions at both the parallel and anti-
parallel interface in the tetramer reported here serve to position residues Arg248 and 
Arg280 of each monomer to interact with the conserved guanine nucleotide in the 
consensus p53 RE. Furthermore, the C4 and G7 within the consensus p53 response 
element half site are invariable (Fig. 3.9d; Wang et al. 2009). Our p53 tetrameric 
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structure demonstrates a striking link between residues Arg248 and Arg280 and the 
conserved C4 and G7 of the p53 RE.  
 
 We observe not only the previously reported nucleotide-specific contacts of 
Arg280, but also Arg248, to each invariant guanine base within the p53 RE. Upon 
binding DNA, opposing p53 DBDs make nucleotide specific contacts to the same 
guanine using these two arginines across the anti-parallel interface (Fig. 5.9a, b & c). For 
example, Arg280 of monomer A and Arg248 of monomer B both contact the same 
guanine at position 7 in the RE. Arg248 binds G7 through the minor groove while 
Arg280 binds through the major groove. This pattern is repeated 4 times within the 
tetrameric complex, each time involving the invariable guanines at positions 7 and 17 of 
the RE sense-strand, with a similar pattern on the anti-sense strand (Fig. 5.9d).  
 
 The significance of this interaction is two-fold. First, as demonstrated by the 
sequence composition of the p53 RE, the guanines at these four positions within the full-
length RE could act as anchor points used for guiding p53 DBDs to the RE. Once p53 
recognizes and binds the response element, each monomer is aligned relative to the next 
by interacting with two guanines. In other words, each guanine interacts with two DBDs, 
and each DBD interacts with two different guanines. Second, the reciprocality created 
through the coordination of a “shared” DNA base can in turn help align each DBD 
relative to the next, in order to guide formation of the anti-parallel and parallel interfaces 
observed in the tetramer complex.  
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 Evidence supporting the significance of the Arg248-[G]-Arg280 interaction 
comes from the fact that repressor REs, response elements that lead to down-regulation of 
associated genes upon p53 DNA binding, have a slightly different composition than 
activating REs. The repressor response elements contain guanines at neighboring 
positions relative to the invariable guanine. One model suggests that these neighboring 
guanines might compete with invariable guanines for Arg248 and Arg280 interactions. 
This can be likened to noise in a signal, with the ‘signal’ representing the activating RE 
invariable guanines, and the ‘noise’ representing the neighboring guanines. If either 
Arg248 or Arg280 were to interact with different guanines within the RE, then the 
relative positions of each DBD on the surface of the DNA could be altered, in turn 
potentially weakening the anti-parallel or parallel interfaces, leading to either different 
conformations or lowered binding affinities that could affect downstream transactivation 
functions.  
 
DNA conformational changes upon p53 binding 
 The 26-nucleotide long dsDNA containing the complete p53 consensus response 
element sequence, when bound by a p53 tetramer, is different than a structure of B-form 
DNA with the same sequence. As described in this chapter (and previously in chapter 2), 
although there is no significant bending of the DNA, p53 binding induces a shift among 
the base pairs in the response element that accommodates extensive protein-protein 
interfaces among the four p53 monomers.  The details of these shifting (and sliding) 
effects are presented in appendix II (Figs. a2.7 & a2.8). The largest effect occurs at the 
junction between the two p53 RE half sites with a slide of approximately 3 Å and is 
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situated at the parallel p53 protein interface (Fig. 3.8 & Table a2.2). Furthermore, a shift 
of approximately 1 Å is observed between each of the symmetric response element 
quarter-sites, located at the anti-parallel interfaces.  This shifting and sliding of the DNA 
base pairs within the RE helps to establish protein-DNA contacts as well as facilitate 
protein-protein interactions (presented in chapters 2 and 3).  
 
Model of full-length p53 bound to DNA 
 Our structure is in agreement with the size and shape of electron density of full-
length p53 bound to DNA. Recent SAXS and NMR experiments have revealed the three-
dimensional shape of full-length p53 bound to a p53 RE (Tidow et al. 2007). Although 
the 25-30 Å resolution is not detailed enough to outline individual domains, the overall 
shape of the electron density fits well with our crystallographic p53 tetramer-DNA 
structure.  
 
 By overlaying the tetrameric structure onto the cryo-EM density, the DNA and 
the DBDs of the tetramer fit well into the lower portion (Fig. 3.10). The DBDs do not fill 
the density completely; however the ~100 N-terminal residues making up the 
transactivation domain and the proline-rich region in full-length p53 could fit into the 
lower void of the density not occupied by the DBDs. The oligomerization domains 
protrude from the cryo-EM density (Fig. 3.10d, e & f), which can be explained by the 
shortened linker used in the ST p53 variants. In the context of a ~30 residue full length 
linker (Fig. 3.10g, h & i), the oligomerization domain would fit into the EM density 
located 40 Å from the DBDs (a 30-amino acid peptide could span 100 Å if fully 
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extended). In sum, our tetrameric p53-DNA structure agrees with the full-length p53-
DNA complex. 
 
Outlook 
Energetics of p53 binding 
Nucleotide variations are common in the p53 response elements located within 
the promoters of a diverse array of genes under the control of p53 (Wang et al. 2009). 
These sequence variations may be an important determinant of the p53 response element 
DNA plasticity. This variation in conformational flexibility could, in turn, dictate the 
affinity of p53-DNA interactions central to gene transcription and regulation.   
 
In future studies, the p53-DNA interactions could be further characterized at 
higher resolution using isothermal titration calorimetry (ITC). This technique makes use 
of a syringe containing a particular ligand that is titrated into a chamber containing a 
protein solution. As the two elements interact, heat is released or absorbed in direct 
proportion to the amount of binding. Measurement of this heat allows for accurate 
determination of binding constants (Kb), reaction stoichiometry (n), as well as 
thermodynamic properties such as observed molar calorimetric enthalpy (∆Hobs), entropy 
(∆Sobs), heat capacity of binding (∆Cp,obs) and change in free energy (∆G) (Liang 2008; 
Seldeen et al. 2009).  
 
For example, ITC was recently used to investigate the effect of single nucleotide 
variants of the Jun-Fos transcription factor response element. This study showed how 
 
 
 
 
- 95 - 
small sequence variations in the response element dictate the energetics of Jun-Fos 
heterodimer binding. In addition to the wealth of protein-DNA binding information that 
was obtained, thermodynamic dependencies on the position of nucleotide substitution 
within the response element could also be calculated (Seldeen et al. 2009). The ITC 
analysis thus provides a novel approach to dissecting interacting forces that may 
determine the overall binding affinity of protein-DNA interactions. 
 
One important observation was that conformational plasticity, such as the ability 
of the Jun-Fos response element to bend and wrap around Jun and Fos to attain a close 
molecular fit, is critical for high-affinity binding. Even though DNA bending is not 
observed in the crystal structure of the Jun-Fos heterodimer bound to the response 
element (Glover & Harrison 1995), several solution studies support the intrinsic 
flexibility of DNA as being a key factor in its ability to bind to Jun-Fos heterodimer with 
high affinity (Kerppola & Curran 1993; Leonard et al. 1997). Potentially, the subtle 
effects of response element nucleotide variation on p53-DNA binding may not appear in 
crystal structures, and would be better characterized with ITC analysis of p53 and p53 
response element variants. 
 
Structural characterization of p53 response elements 
High-affinity binding of p53 to the p53 response element requires the conserved 
C[A/T][A/T]G motif in each RE half site, however nucleotide polymorphisms at other 
locations within the 20 base pair motif can affect the transcriptional behavior of p53 (Inga 
et al. 2002; Osada et al. 2005; Jordan et al. 2008; Wang et al. 2009). In this study we 
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show that the response element, composed of the consensus sequence, shifts base pairs to 
accommodate novel protein-DNA contacts. Although we compare the shifted RE to the 
same sequence modeled as B-form DNA (Table a2.2), it is possible the consensus 
sequence does not have such an ideal B-form conformation in vivo in an unbound state.  
 
The wide variety of nucleotide substitutions found within confirmed p53 response 
elements in humans suggests DNA conformation plays a role in p53 recognition and 
binding (Wang et al. 2009). Therefore, the generation of additional high-resolution 
structures of both p53-bound and p53-free response element variants could provide more 
insight into p53 response element recognition, and what influence the DNA sequence and 
structures have on p53 binding. With the enhanced thermostability of the multi-domain 
p53 variant presented in chapter 2, and given that the binding and crystallization 
protocols have already been established, obtaining novel multi-domain p53-DNA 
structures should be relatively straightforward. 
 
 
 
 
 
 
 
- 97 - 
 
Figure 3.9 
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Functional consequences of p53-RE binding 
The selective mutagenesis and probabilistic protein design strategies that are 
described in chapter 5 and applied to human p53 have made it possible to substantially 
increase p53 stability without compromising response element recognition and binding, 
generating the means to determine the first multi-domain structure of p53 bound to a full-
length response element. While the structures presented in chapter 2 provide greater 
detail of the p53-DNA binding mechanisms, other p53-DNA structures could 
substantially contribute to the understanding of p53 function. 
  
While the research presented here focuses on p53 binding to a consensus response 
element, recent evidence points to the existence of RE sequences that lead to p53-
mediated down regulation of genes as well (Wang et al. 2009). These repressor REs 
differ in sequence to the canonical RE which might, in turn, propagate conformational 
differences in p53 upon binding. As described in the previous section, continued 
crystallographic studies probing p53 bound to a variety of response elements, including 
those with suppressor sequences, could provide more insight into the mechanisms of RE 
recognition, binding and transactivation. 
 
 There is, however, evidence that mutant p53 can bind a variety of other DNA 
structures such as those formed by matrix attachment regions and Holliday junctions. 
Likewise, the observed gain of function activity for certain p53 mutants might be a result 
of binding to DNA secondary structures of non-canonical effector genes (Fig. a2.6; Will 
et al. 1998; Göhler et al. 2002 & 2005). New, computationally re-designed stable p53 
 
 
 
 
- 99 - 
variants containing these mutations could provide the means to determine high-resolution 
structures of p53 bound to different conformations of DNA, thus providing more insight 
into the diverse modes of p53 binding, and possibly explaining why and how certain p53 
mutations result in oncogenic function. 
Atomic detail of full-length p53 complexes 
 The newly acquired DNA-binding functions of p53 reported in various 
investigations could involve different binding orientations of the DBDs relative to the 
DNA that simply have yet to be characterized. A full-length linker connecting the DNA-
binding and oligomerization domains of p53 could thus serve to probe these potential 
complex structure variants. Computational probabilistic protein design strategies have 
already been used to solubilize trans-membrane proteins and re-engineer enzyme 
substrate specificity (see chapter 5). Therefore protein re-design strategies have 
demonstrated the potential to stabilize the linkers, in turn facilitating crystallographic 
study. Through linker residue sequence analysis, ensembles of mutations could be 
sampled, potentially highlighting substitutions that would increase linker stability and 
facilitate experimental investigation of p53 variants containing full-length linkers. The 
ability to study p53 dimers or tetramers with more relative freedom of movement among 
DNA binding domains could provide insight as to how the DNA-binding domains adopt 
various conformations on different DNA structures. In addition to focusing on p53-DNA 
complexes, stabilized multi-domain p53 variants could be complexed with regulatory 
factors such as Mdm2 and MdmX, or with other interacting proteins involved in DNA 
metabolism and cell cycle control, in order to uncover more structural detail of the p53 
complexes leading to activation or suppression of target genes. 
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Figure 3.10 
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Structures of p53, p53 isoforms, p63, and/or p73 complexes 
 More multi-component structural studies on p53 and its various isoforms, or 
homologs p63 and p73, could provide information on how specific functions are 
enhanced through different, if any, domain arrangements. This might explain how 
different modes of oligomerization occur among the various p53 isoforms and family 
members. Additionally, solving structures of the p53 ancestral proteins p63 and p73 will 
help to further define their architectures and to analyze the evolutionary changes that 
have shaped such a universal effector molecule as p53. While p63 and 73 structural data 
is currently unavailable, comparative modeling using p53 as a guide structure, coupled 
with various protein design strategies, could aid in stabilizing these proteins for 
crystallographic analysis.  
 
Benefits to computational research 
 A growing number of computational studies probing the p53 regulatory network 
(and other biochemical and cell-related pathways) contribute to the understanding of how 
p53 functions in a wide range of cellular processes (Lev Bar-Or et al. 2000; Ma et al. 
2005; Yip et al. 2006). Many of these computational approaches use structural 
information as a basis for defining various parameters used in the calculations. High-
resolution X-ray crystal structures of proteins, and protein complexes, can therefore serve 
to further increase the accuracy and predictive powers of the computational models 
created to help decipher complex biological networks and processes. 
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Cyclic olefin homopolymer-based microfluidics for protein 
crystallization and in situ X-ray diffraction 
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Background 
 In this chapter we present a novel microfluidics platform that we have adapted for 
protein crystallization, in a format that is automated and has high throughput capacity. 
The unique combinatorial fluid multiplexing capabilities of the SpinX lab makes it well 
suited to serve as a high-throughput screening platform for protein crystallography. The 
microfluidic gCards each contain over 500 reaction chambers, all within a space smaller 
than a compact disc, that are connected together during each experiment at precise 
locations and times to dilute, mix and incubate assay components. Each chamber holds 
200 nanoliters of liquid and contains enough space to grow crystals to sizes beyond 300 
micrometers in size (Fig. 4.1). Furthermore, diffraction patterns can be obtained from the 
crystals without removing them from the screening card, thus drastically reducing hit-to-
lead optimization time (Fig. 4.2). Additionally, the programmability and precision of the 
fluid mixing in the cards offers a high-level of customization that can be applied to many 
 
 
 
 
- 103 - 
protocols such as optimization of conditions with additives, crystal cryo-preservation and 
even ligand or small molecule mixing for co-crystal experiments. 
 
 
 
Figure 4.1 
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Figure 4.2 
 
 
 
Abstract 
Microfluidics is a promising technology for the rapid identification of protein 
crystallization conditions. However, most of the existing systems utilize silicone 
elastomers as the chip material which, despite its many benefits, is highly permeable to 
water vapor. This limits the time available for protein crystallization to less than a week. 
Here, the use of a cyclic olefin homopolymer-based microfluidics system for protein 
crystallization and in situ X-ray diffraction is described. Liquid handling in this system is 
performed in 2 mm thin transparent cards that contain 500 chambers, each with a volume 
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of 320 nl. Microbatch, vapor-diffusion and free-interface diffusion protocols for protein 
crystallization were implemented and crystals were obtained of a number of proteins, 
including chicken lysozyme, bovine trypsin, a human p53 protein containing both the 
DNA-binding and oligomerization domains bound to DNA, and a functionally important 
domain of Arabidopsis Morpheus’ molecule 1 [MOM1]. The latter two polypeptides have 
not been crystallized previously. For X-ray diffraction analysis, either the cards were 
opened to allow mounting of the crystals on loops or the crystals were exposed to X-rays 
in situ. For lysozyme, an entire X-ray diffraction data set at 1.5 Å resolution was 
collected without removing the crystal from the card. Thus, cyclic olefin homopolymer-
based microfluidics systems have the potential to further automate protein crystallization 
and structural genomics efforts. 
 
Introduction 
Crystallization of proteins and determination of their three-dimensional structure 
provides biological information that is often critical to understanding their function. 
Indeed, it has been proposed that the three-dimensional structures of all proteins should 
be solved and the term ‘structural genomics’ has been used for these efforts. So far, these 
efforts have met with mixed success (Service 2002; Chandonia & Brenner 2006), in part 
because protein crystallization is a tedious and time-consuming process that is not easily 
amenable to automation. Nevertheless, progress towards automation has been made and 
currently many crystallographers rely on some level of automation for their daily 
experiments. 
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Perhaps the most widely used systems for automating protein crystallization are 
pipetting/robotic systems that simply recapitulate the steps performed by humans (Hui & 
Edwards 2003). One set of pipetting systems prepares crystallization reactions by mixing 
a precipitant solution with the protein to be crystallized in very small drops (about 200 nl 
in volume). These drops are placed in chambers containing a much larger volume of 
precipitant solution. Through vapor diffusion, the volume of the protein drop slowly 
decreases, leading to protein crystallization. This type of pipetting system has gained 
acceptance because vapor diffusion is a well established method of protein crystallization 
(Hui & Edwards 2003; Chayen & Saridakis 2008) and because it utilizes about ten times 
less protein than would be required if the same reactions were set up manually. However, 
a disadvantage of pipetting systems is that the small volume of the protein-precipitant 
drops leads to significant water evaporation before the chambers are sealed. The degree 
of evaporation can vary from drop to drop, creating heterogeneity in the experiment, and 
even occurs when the reactions are prepared in a humidified environment. Robotic 
systems have also been developed to identify crystals in protein-precipitant drops; these 
systems consist of a cabinet, in which crystallization plates are stored, a robotic arm and a 
microscope (Hui & Edwards 2003). Several images are acquired from each drop (at 
various focal planes, since the drops are not flat) and these images are then processed by 
software that attempts to identify protein crystals, which is a difficult task because the 
drop geometry leads to poor images. Finally, a robotic system has also been developed to 
position crystallization trays in the path of a synchrotron X-ray beam (Jacquamet et al. 
2004). This system can screen crystals for their ability to diffract X-rays and allows some 
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crystal parameters, such as space group and unit-cell size, to be determined without 
manual handling of the crystals. 
 
As an alternative to the systems described above, efforts have been made to use 
microfluidics for protein crystallization. Several such systems have been developed, most 
of them employing chips made of elastic silicone (Hansen & Quake 2003). In one system, 
the chips contain wells that are connected by a channel; the elastomeric nature of the 
chips permits the channel to be sealed by applying mechanical pressure to the chip 
(Hansen et al. 2002, 2004 & 2006). In its most simple form, two wells are filled with 
protein and precipitant solution, respectively; the pressure on the channel connecting 
these two wells is then released, allowing the contents of the wells to mix by a process 
called free-interface diffusion. Depending on the viscosity of the liquids, equilibration of 
the contents of the two connected chambers is achieved in as little as 1 hour. Crystal 
growth is followed over a period of a few days, but generally for less than a week. The 
observation time is limited by evaporation of water through the silicone, which is 
intrinsic to the nature of these microfluidic chips because the silicone elastomer is 
permeable to water vapor. On the other hand, water evaporation also offers the advantage 
that it results in higher protein-precipitant concentrations, which may favor 
crystallization. 
 
Another microfluidics system mixes protein and precipitant in nanoliter-volume 
droplets that are formed within water-immiscible fluids flowing inside capillary channels 
(Zheng et al. 2003, 2004; Li et al. 2006). The droplets initially form in silicone elastomer 
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channels, but are eventually guided into glass or Teflon capillary tubes, which are then 
sealed to prevent evaporation. Depending on the nature of the fluid separating the 
droplets, this system crystallizes proteins by microbatch or vapor-diffusion methods. 
When the oil separating the droplets is impermeable to water, the proteins crystallize by 
the microbatch method. For vapor diffusion, protein-precipitant droplets alternate with 
droplets containing high concentrations of salt and are separated by a water-permeable 
oil; this allows the slow transfer of water from the protein-precipitant droplets to the 
high-salt droplets, resulting in a vapor-diffusion effect. 
 
The use of silicone elastomer is prevalent in microfluidics systems and offers 
certain advantages, as described above. However, the water-vapor permeability of 
silicone limits its use in cases where protein crystallization requires incubation with 
precipitant for more than a few days. Thus, microfluidics systems that utilize vapor-
impermeable chips could provide an alternative to silicone elastomer-based systems. 
Here, we describe our experience with a microfluidics system that uses cyclic olefin 
homopolymer (COP) as the chip material. We demonstrate the crystallization of several 
proteins at 277 K and at room temperature using microbatch, vapor-diffusion and free-
interface diffusion protocols. 
 
Experimental procedures 
Protein-sample preparation 
Chicken egg-white lysozyme (gene accession code NM_205281) and bovine 
pancreatic trypsin (gene accession code NM_001113727) were purchased as lyophilized 
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powders from Sigma-Aldrich (St Louis, Missouri, USA) and AppliChem (Darmstadt, 
Germany), respectively. Lysozyme (140 mg/ml) was resuspended in 50 mM sodium 
acetate pH 4.5, whereas trypsin (80 mg/ml) was resuspended in 25 mM HEPES pH 7.0, 
10 mM calcium chloride, 10 mg/ml benzamidine hydrochloride. A polypeptide consisting 
of residues 94-291 of human p53 (gene accession code NM_000546) fused to residues 
322-356 was expressed in Escherichia coli. The cells were lysed in a buffer consisting of 
25 mM bis-tris propane (BTP) pH 6.8, 250 mM NaCl, 5 mM DTT and protease inhibitors 
and the polypeptide was purified by cation exchange (Sepharose SP column; Pharmacia 
Biotech, Uppsala, Sweden) and gel filtration (Superdex 200 column; Pharmacia Biotech). 
After purification, the p53 protein was concentrated to 8 mg/ml in 25 mM bis-tris 
propane pH 6.8, 50 mM NaCl, 5 mM DTT buffer. A polypeptide corresponding to amino 
acids 1699-1814 of Arabidopsis thaliana Morpheus’ molecule 1 (MOM1; gene accession 
code NM_179277) was also expressed in E. coli. The cells were lysed in buffer 
consisting of 25 mM MES pH 6.0, 200 mM NaCl, 5 mM DTT and protease inhibitors; the 
polypeptide was then purified by cation exchange (Sepharose SP column; Pharmacia 
Biotech) and gel filtration (Superdex 200 column; Pharmacia Biotech) and concentrated 
to 6 mg/ml in 25 mM MES pH 6.0, 150 mM NaCl, 5 mM DTT . 
 
Protein crystallization 
Proteins were crystallized either under standard hanging-drop vapor-diffusion 
conditions in 48-well plates (Hampton Research, Aliso Viejo, California, USA) or in 
COP cards using a dedicated microfluidics instrument (SpinX Technologies, Meyrin, 
Switzerland). Lysozyme and trypsin were crystallized at room temperature and the 
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MOM1 fragment was crystallized at 277 K; human p53 was crystallized in the presence 
of double-stranded DNA containing a high-affinity p53 DNA-binding site at 277 K at a 
1:1.1 protein:DNA molar ratio. The double-stranded DNA was prepared by annealing the 
following two oligonucleotides: 5’-AGAC GGG CATG TCT GGG CATG TCT CA-3’ 
and 5’-CTTG AGA CATG CCC AGA CATG CCC GT-3’. The precipitant solutions 
used for crystallization were as follows: 4-30%(w/v) PME 5000, 1 M sodium chloride, 50 
mM sodium acetate pH 4.5 for lysozyme; 30%(w/v) PEG 8000, 0.2 M ammonium 
sulfate, 0.1 M sodium cacodylate pH 6.5 for trypsin; Index Screen No. 87 [20%(w/v) 
PEG 3350, 0.2 M sodium malonate pH 7.0], Index Screen No. 89 [15%(w/v) PEG 3350, 
0.1 M succinic acid pH 7.0] and Index Screen No. 90 [20%(w/v) PEG 3350, 0.2 M 
sodium formate pH 7.0] (Hampton Research, CA, USA) for p53-DNA complexes and 
0.2-0.4 M magnesium formate, 0.1 M Tris pH 8.5 for MOM1. 
 
Data collection and processing 
All data sets were collected on the FIP-BM30A beam line of the ESRF (Grenoble, 
France; Roth et al. 2002). For in situ data collection, COP cards containing lysozyme 
crystals were positioned in the path of the X-ray beam using a robotic arm, as described 
previously (Jacquamet et al. 2004). Reflection data were indexed, integrated and scaled 
using the program XDS (Kabsch 1993). The crystals formed in space group P43212, with 
unit-cell parameters a = 77.1, b = 77.1, c = 37.2 Å, and contained one molecule in the 
asymmetric unit. The coordinates of lysozyme (PDB code: 1iee) were used as input for 
refinement, which was performed with the program CNS (Brünger et al. 1998). The 
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electron-density maps and the protein atoms were visualized using the program O (Jones 
et al. 1991). 
 
Figure 4.3 
 
Establishment of protein crystallization protocols in COP microfluidics cards. (a) Image of a 
microfluidics card. Samples are loaded at the top and then move through the card by centrifugal force. (b) 
Diagram of a cross section of a COP card illustrating how defined volumes of liquid are ‘pipetted’. Liquid 
is contained within a chamber by the thin membrane separating the chambers from the vertical channels 
(1), holes are opened in the thin membrane by a laser (yellow arrowheads; 2) and the liquid above the hole 
moves through the vertical channel to a chamber ‘below’ (3). The volume transferred is determined by the 
vertical position of the hole in the thin membrane. (c) Vapor-diffusion protocol. Equal volumes of protein 
and precipitant were dispensed into one chamber and precipitant only was dispensed into an adjacent 
chamber. Holes were then opened in the thin membrane above the liquid level to establish connections 
between the chambers, according to the paths shown by the red lines. (d) Changes in liquid volume 
consistent with vapor diffusion after 6 days of incubation of the COP card at room temperature. The level 
of liquid at day 0 is indicated by the red lines. The level of liquid in the ‘precipitant’ chamber increases, 
while the level of liquid in the ‘protein-precipitant’ chamber decreases. In this example, the protein was 
lysozyme and the black arrow indicates a crystal that formed within 6 days. (e) Free-interface diffusion 
protocol. Protein and precipitant were dispensed into two adjacent chambers. Holes were then opened in the 
thin membrane below the liquid level to establish connections between the chambers, according to the 
paths shown by the red lines. All images of individual chambers were acquired using the camera built into 
the microfluidics instrument. Images showing multiple chambers were assembled from images acquired 
using an inverted microscope and a low-magnification lens (Zeiss, Gottingen, Germany). 
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Results 
Principle of operation of a cyclic olefin homopolymer-based microfluidics device 
Most microfluidics devices use either silicone elastomers or rigid COPs as the 
chip material. The vapor-permeability of COPs is several orders of magnitude lower than 
that of silicone (Mair et al. 2006), which in theory should make COPs better suited for 
traditional methods of protein crystallization, where no vapor exchange of the 
crystallization chamber with the outside environment is desirable (Chayen & Saridakis 
2008). To explore the potential of COPs in protein crystallization, we used a 
microfluidics instrument in which the movement and mixing of liquids in COP chips is 
controlled by centrifugal forces (SpinX Technologies, Meyrin, Switzerland). In this 
particular system, the microfluidics chip takes the form of a card made of two COP 
pieces bonded together via a thin COP membrane (Figs. 4.3a & 4.3b). One side of the 
COP card has chambers arranged in rows and horizontal channels. The chambers have 
dimensions of 2 x 0.7 x 0.25 mm, corresponding to a volume of about 320 nl. The other 
side of the COP card contains vertical channels. Connections between chambers and 
vertical channels, and between vertical and horizontal channels are made by a laser that 
opens holes in the thin membrane that separates the two sides of the card. Depending on 
where the openings are made, specified volumes of liquid can be directed from a chamber 
in one row to a chamber in the row ‘below’ (Fig. 4.3b). The movement of the liquids is 
driven by the centrifugal force generated as the cards are spinning in the instrument. 
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Establishment of microbatch, vapor-diffusion and free-interface diffusion 
crystallization protocols. 
 
The COP cards used in this study permit the establishment of several protocols for 
protein crystallization. In the traditional microbatch protocol, protein and precipitant 
solutions are mixed and the resulting aqueous solution is overlaid with low-density 
paraffin oil, which is impermeable to water vapor (Chayen & Saridakis 2008). This 
protocol can easily be established in the COP cards simply by directing appropriate 
volumes of protein and precipitant solutions to the same chamber. Even though the holes 
that are opened to direct the liquids in the chambers are never sealed, the very small 
cross-sectional area of the channels results in very small evaporation rates; even after 
several months the volume of liquid in the chambers does not change appreciably (data 
not shown). 
 
The second protocol that we established in the COP cards was vapor diffusion 
(Chayen & Saridakis 2008). Protein and precipitant solutions were mixed in one 
chamber, while an adjacent chamber was filled with precipitant solution only. 
Connections were then established between these two chambers by opening holes above 
the liquid level (Fig. 4.3c). When the COP cards were incubated at room temperature, 
changes in the volumes of the liquids in the two chambers consistent with vapor diffusion 
were observed within 6 days (Fig. 4.3d). However, at 277 K vapor diffusion proceeded 
more slowly, as would be expected. 
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The third protocol established in the COP cards was free-interface diffusion 
(Chayen & Saridakis 2008). One chamber was filled with protein solution, while an 
adjacent chamber was filled with precipitant solution. Connections between these two 
chambers were again established, but in this case by opening holes below the liquid level 
(Fig. 4.3e). For both the vapor-diffusion and free-interface diffusion protocols, the rate of 
diffusion can be controlled by opening a larger or smaller number of connections 
between the chambers (between one and five for vapor diffusion and between one and 
three for free-interface diffusion). 
 
Protein crystallization in COP cards 
The suitability of new protein crystallization platforms is usually documented in 
the literature using proteins that crystallize readily. Following this tradition, we used the 
microbatch method to monitor the crystallization of chicken egg-white lysozyme and 
bovine pancreatic trypsin in the COP cards. For both proteins crystallization was 
performed in final volumes of 200 nl at room temperature. For lysozyme we implemented 
a grid of final protein concentrations ranging from 20 to 60 mg/ml and PME 5,000 
concentrations ranging from 4 to 30%. Crystals formed at protein concentrations of 
between 22 and 30 mg/ml and at PME concentrations of between 18 and 30% (Fig. 4.4a). 
For trypsin, the final protein concentrations ranged from 15 to 40 mg/ml and PEG 8,000 
was used at a concentration of 30%. Crystals formed at protein concentrations of between 
25 and 30 mg/ml (Fig. 4.4a). Lysozyme and trypsin also crystallized in the COP cards 
using the vapor-diffusion and free-interface diffusion protocols (Fig. 4.3d and data not 
shown). 
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Figure 4.4 
 
 
Protein crystallization in COP cards. (a) Lysozyme and trypsin crystals formed in COP cards using the 
microbatch protocol. (b) Crystallization of human p53-DNA complexes in COP cards using the microbatch 
and vapor-diffusion protocols and three precipitant solutions (Index Screen Nos. 87, 89 and 90). Each 
condition was performed in triplicate or quadriplicate (numbered 1-3 and 1-4, respectively) and the results 
are color-coded as follows: protein precipitate, grey; protein crystals, purple; clear solution, white. 
Examples of the crystals that were formed using each protocol are shown. (c) Crystallization of A. thaliana 
MOM1 in COP cards using the microbatch, vapor-diffusion and free-interface diffusion protocols. Each 
condition was performed in quadriplicate (numbered 1-4) using magnesium formate as the precipitant at the 
indicated concentrations. The results are color-coded as described for the p53-DNA complexes in (b). For 
the free-interface diffusion protocol, both the protein (left half) and the precipitant (right half) chambers 
were scored, since over time both chambers will contain both protein and precipitant. Examples of the 
crystals formed using each protocol are shown. All images were acquired using the camera built into the 
microfluidics instrument. The width of the chambers is 750 µm. The detailed compositions of the 
precipitant solutions are described in the experimental procedures section. 
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Because lysozyme and trypsin crystallize readily, we then studied other proteins 
that might be more difficult to crystallize. We first focused on the human p53 tumor-
suppressor protein. The gene encoding p53 is the most frequently mutated gene in human 
cancer (Hollstein et al. 1991). The p53 protein contains a transactivation domain, a 
sequence-specific DNA-binding domain (residues 94-289) and a homotetramerization 
domain (residues 325-356). The latter two domains are independently folding domains 
and their three-dimensional structures have been determined (Cho et al. 1994; Jeffrey et 
al. 1995); however, no structure is available of a p53 polypeptide containing both of these 
domains. Polypeptides containing more than one independently folding domain are 
generally not easy to crystallize, as the linker between the domains imparts 
conformational flexibility, which inhibits crystallization. We engineered a p53 
polypeptide containing residues 94-291 of human p53 fused to residues 322-356. Based 
on the boundaries of the crystallized DNA-binding and tetramerization domains, this 
polypeptide has a flexible interdomain linker that is five amino acids long. Two amino-
acid substitutions were introduced in the tetramerization domain of this polypeptide to 
convert it into a dimerization domain (Davison et al. 2001). In addition, 13 amino-acid 
substitutions were introduced in the DNA-binding domain in order to increase its melting 
temperature and solubility (TJP and TDH, chapters 1-3). The resulting polypeptide 
retained its sequence-specific DNA-binding activity. We therefore examined its ability to 
crystallize in complex with an oligonucleotide containing a p53 DNA-binding site using 
the microbatch and vapor-diffusion protocols and three different crystallization buffers. 
Crystals formed with both protocols after 6 days of incubation at 277 K in the COP cards. 
Tabulating the results shows that vapor diffusion yielded p53-DNA crystals with all three 
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crystallization buffers, whereas with the microbatch method p53-DNA crystals were only 
obtained with two of the three crystallization buffers (Fig. 4.4b). The p53 polypeptide-
DNA complex also crystallized using the hanging-drop vapor-diffusion method in 48-
well plates under the same crystallization conditions (TJP and TDH, chapters 1-3). 
 
As a second protein that had not been previously crystallized, we focused on A. 
thaliana Morpheus’ molecule 1 (MOM1), a protein that regulates chromatin structure and 
gene expression without affecting DNA and histone methylation (Amedeo et al. 2000; 
Habu et al. 2006). An evolutionarily and functionally conserved domain of MOM1 maps 
to a region approximately between amino acids 1734 and 1815 (Caikovski et al. 2008). 
We expressed various MOM1 fragments in E. coli and found by systematic deletion 
analysis that a MOM1 polypeptide corresponding to residues 1699-1814 of the full-
length protein is soluble. This polypeptide was purified to homogeneity and examined for 
crystallization at 277 K by the microbatch, vapor-diffusion and free-interface diffusion 
methods in COP cards, varying the concentration of the precipitant from 0.2 to 0.4 M. 
The best results were achieved using the vapor-diffusion protocol (Fig. 4.4c). This 
fragment of MOM1 also crystallized using the hanging-drop vapor-diffusion method in 
48-well plates under the same crystallization conditions (data not shown). 
 
Collection of X-ray diffraction data from crystals in COP cards 
The crystals that formed in the COP cards could easily be harvested after opening 
the cards; these crystals could then be cryopreserved, mounted on cryoloops and frozen, 
thus allowing complete X-ray diffraction data sets to be collected. When there is a need 
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to examine many crystals, the ability to collect X-ray diffraction data while the crystals 
are still in the COP card could allow significant savings in time and effort. A robotic arm 
that is able to position crystallization multi-well plates in front of an X-ray beam has 
already been described (Jacquamet et al. 2004). By comparison to multi-well plates, the 
geometry of the COP cards used in this study appears to be well suited for in situ X-ray 
diffraction analysis. 
 
To examine whether we could actually collect X-ray diffraction data, COP cards 
containing p53-DNA, MOM1 and lysozyme crystals were positioned by the robotic arm 
in the path of the X-ray beam. The robotic arm was programmed to rotate the card during 
data collection, allowing oscillation of the crystal over a 1° range. For all crystals, we 
could observe diffraction patterns that were of sufficient quality to allow indexing (Figs. 
3a and 3b and data not shown). The p53-DNA and MOM1 crystals exposed to X-rays in 
situ diffracted to a somewhat lower resolution level than crystals that had been harvested 
from the cards, cryopreserved, mounted on loops and frozen. For example, cryopreserved 
p53-DNA crystals diffracted to 3 Å resolution, whereas the same crystals in COP cards 
diffracted to about 4.5 Å. We attribute this difference to the temperature shift that 
occurred during data collection, since the p53-DNA and MOM1 crystals formed at 277 
K, whereas the in situ data collection was performed at room temperature. In contrast, the 
lysozyme crystals, which were formed at room temperature, diffracted to a resolution of 
1.5 Å when exposed to X-rays through the COP cards (Fig. 4.5b). 
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Figure 4.5 
 
Collection of X-ray diffraction data sets from crystals in COP cards. (a) X-ray diffraction 
pattern of a p53-DNA crystal exposed to the X-ray beam while still in the COP card. The 
oscillation range was 1°. (b) X-ray diffraction patterns of a lysozyme crystal exposed to the X-ray 
beam while still in the COP card. Two regions of the diffraction image are shown, one 
encompassing a resolution range lower then 3.5 Å (left) and the other a region from 1.9 to 1.6 Å 
resolution (right). The oscillation range was 1°. Note that COP absorbs X-rays in the resolution 
range between 5.4 and 5.1 Å. (c) Part of the lysozyme electron-density map contoured at 1.9σ for 
the 2Fo-Fc map (olive green) and at 3σ for the Fo-Fc map (dark blue, positive values; orange, 
negative value). The map shows residues Trp46, Val47 and Ile116 and part of the side chain of 
Trp126. 
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To evaluate the quality of the data collected from crystals in COP cards, we 
obtained 45 consecutive X-ray diffraction images, each over an oscillation range of 1°, 
from a lysozyme crystal. The COP absorbed X-rays, but only over a narrow resolution 
range from 5.4 to 5.1 Å (Fig. 4.5b). In lower and higher resolution ranges the COP did 
not compromise data collection, as evidenced both by observing the X-ray diffraction 
images (Fig. 4.5b) and also from the statistics describing the integration of the X-ray 
reflection intensities over the 45 frames of collected data (Table 4.1). Data in the 
resolution range 40-1.5 Å were used for refinement using a previously determined 
lysozyme structure as input (Sauter et al. 2001). The refined structure had excellent 
statistics (Table 4.1) and well resolved electron-density maps (Fig. 4.5c), especially 
considering that data from only 45 frames were used for refinement. 
Discussion 
The need to optimize the efficiency with which X-ray diffraction-quality protein 
crystals are produced has led to the development of methods for automating the setup of 
protein crystallization reactions and for reducing the amount of protein required (Chayen 
& Saridakis 2008). Most microfluidics systems utilize silicone elastomers as the chip 
material and have achieved exceptional economies in the amount of protein consumed: in 
one system, 10 nl protein solution is required per crystallization condition. However, 
silicone elastomers are also highly permeable to water vapor and this limits their utility to 
proteins that crystallize within a few days (Hansen & Quake 2003). Materials that are 
impermeable to water vapor have also been explored in protein crystallography at a 
miniaturized scale, but in general these systems require significant human intervention or 
are compatible with only one method of protein crystallization, usually free-interface 
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diffusion (Ng et al. 2003 & 2008). This is because materials that are impermeable to 
water vapor, such as COPs, are rigid. Unlike chips made of silicone elastomers, in which 
liquids can be moved by deforming the chip itself, the movement of nanoliter volumes of 
liquid in rigid chips is not a trivial task. The system we used here solves the ‘pipetting’ 
problem by opening holes at defined positions to control the volume of liquid to be 
dispensed and by spinning the cards to move the liquids by centrifugal force. Once the 
problem of pipetting had been addressed, COP-based microfluidic chips could easily be 
adapted for protein crystallization using several well established protocols, as 
demonstrated here. 
 
COP cards may overcome some of the limitations inherent in microfluidics chips 
made of silicon elastomers. The first is the issue of water-vapor permeability. In COP 
cards there is very little water evaporation even after months of incubation at room 
temperature. A second limitation of silicone elastomer chips is that crystals cannot 
readily be isolated for X-ray diffraction analysis. This means that new protein crystals 
have to be obtained using traditional protein crystallization methods. In some cases, it is 
not straightforward to translate the conditions under which proteins crystallize by free-
interface diffusion in the microfluidics chip to conditions under which they will 
crystallize by the traditional hanging-drop vapor-diffusion method in multi-well plates. 
COP cards overcome this limitation, because the volume of the chambers (320 nl) allows 
even relatively large protein crystals to form; these crystals can then be easily harvested 
from the COP cards for the collection of X-ray diffraction data sets. Alternatively, limited 
diffraction data can also be collected from the crystals in situ, because COPs absorb X-
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rays only within a defined resolution range of about 5.4-5.1 Å (Fig. 4.5a; Ng et al. 2008). 
In exceptional cases, as illustrated here with the example of lysozyme, entire X-ray 
diffraction data sets can be collected. However, this was possible with lysozyme because 
sufficient data could be collected from just 45 images and because the lysozyme crystals 
did not suffer extensive radiation damage, even though the COP card was at room 
temperature during data collection. In the case of the MOM1 and p53-DNA crystals only 
about ten images could be collected per crystal. 
 
COP-based microfluidics systems compare favorably with automated pipetting 
systems that set up crystallization reactions in multi-well plates (Chayen & Saridakis 
2008). In the latter systems all pipetting steps are performed in an open environment, 
which allows water to evaporate while the drops are being set up, especially when the 
volume of these drops is in the nanoliter range. In contrast, in microfluidics systems all 
pipetting steps are performed in a closed environment, thus eliminating the problem of 
water evaporation during setup. Further, the COP cards described here can be stacked in 
holders, so that their inlets adopt the same geometry as the wells of 384-well plates. Thus, 
the initial loading of protein samples and precipitant solutions in the COP cards can be 
performed with standard pipetting robots. A final advantage of the COP cards is the 
geometry of their chambers, which allows easy visualization of their contents. Thus, 
protein crystals can be easily identified, a task that is much harder to accomplish with 
crystals formed in round hanging or sitting drops. Based on our experience, we anticipate 
that COP-based microfluidics will play an important role in protein crystallization efforts 
in the near future. 
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Table 4.1  
Data collection and refinement statistics for a lysozyme data set, comprised of 45 
consecutive frames, each having an oscillation range of 1º.  Values in parenthesis are for 
the highest resolution shell.  
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Introduction  
Protein design algorithms identify protein sequences consistent with a particular 
fold, and often simultaneously quantify the many subtle, non-covalent interactions that 
govern protein folding, stability and function. Efforts in protein design stand to advance 
our knowledge of protein folding and function and also can identify new proteins with 
applications to biotechnology, catalysis, and materials research. Here, recent 
developments in protein design are discussed with a focus on features common to many 
of the computational design methods. A sampling of studies is presented in which 
computationally designed proteins have been experimentally realized; exemplifying what 
may be learned and accomplished with protein design.  
 
Advances in protein design inform our understanding of the molecular basis of 
life processes and provide tools for new applications in biotechnology. Proteins are 
molecular workhorses, and they play central roles in cellular functions such as 
cytoskeleton assembly, transport, signaling, bioenergetics, metabolism and gene 
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regulation. Structural proteins (e.g. actin, microtubules, collagen) are vital for 
maintaining the morphological properties of organelles, cells, and tissues. Enzymes 
catalyze reactions selectively and efficiently, and protein-based hormones and receptors 
are critical for inter- and intracellular communication. Thus proteins exhibit a multitude 
of functions, and this versatility can potentially be leveraged. Polypeptide synthesis and 
protein overexpression are often straightforward, facilitating the realization of natural and 
non-natural sequences. Designed proteins obtained using such methods provide systems 
for critically testing our present understanding of the molecular features most relevant to 
protein folding, stability, and function. In addition, novel proteins can provide new 
biotechnological applications, such as selective catalysts and sensors.  
 
Protein folding enables function to be encoded in sequence. Most polymers can 
take on a large number of conformations in dilute solution. Folding, however, implies 
that a protein has a well-defined three-dimensional structure under physiological 
conditions, a structure that is usually requisite for the protein’s function. Anfinsen (1) 
showed that ribonuclease could be denatured and refolded without loss of enzymatic 
activity. This led to the general acceptance of the ‘‘thermodynamic hypothesis,’’ which 
states that ‘‘the three-dimensional structure of a native protein in its normal physiological 
milieu . . . is the one in which the Gibbs free energy of the whole system is lowest; that is, 
that the native conformation is determined by the totality of inter-atomic interactions and 
hence by the amino acid sequence, in a given environment.’’ (1) While there are certainly 
exceptions to this rule, the three-dimensional structures of most proteins are encoded in 
their amino acid sequences. Due to the complexity of proteins and the many possible 
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compact structures to which they can fold, protein structure prediction from amino acid 
sequence remains one of the fundamental open problems of molecular science, but much 
progress has been made in recent years (2). In addition, protein folding dynamics remains 
an active area of research. Such studies are motivated in part by Levinthal’s paradox (3): 
how is it that proteins having exponentially large numbers of conformations are able to 
fold on timescales of minutes or less? There has been much recent development of 
mechanisms and models that quantitatively describe folding kinetics (4–9), including the 
energy landscape theory of protein folding (10–20).  
 
Proteins are involved in an increasing number of industrial applications such as 
chemical production, pharmaceuticals and fine chemicals, pulp and paper, food, textiles, 
and energy (21–23). Exploiting the structural and functional features of proteins stands 
also to give rise to new biomaterials. Peptides may respond structurally and functionally 
to environmental changes in pH, temperature, pressure, salt concentration, UV or visible 
light exposure. Such ‘‘smart-material’’ peptides may be used as building blocks for 
filaments and fibrils, scaffolds, hydrogels, and surfactants (24). These protein and 
peptide-based systems have applications in tissue and surface engineering, as drug or cell 
carriers, for patterning of targeted cell growth, as miniaturized solar cells or in optical and 
electronic devices (25–31). Commercial biocatalysts have been obtained from natural 
enzymes or via the directed mutagenesis of such enzymes (22). Advances in genomics, 
directed evolution, and bioinformatics (21) have led to the development of recombinant 
enzymes and biomolecular pathways (32–36). For example, a recently developed 
industrial process uses a re-engineered and extended E. coli pathway to convert D-
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glucose into the polymer precursor 1,3-propanediol within a single organism (36); such 
efforts illustrate the ‘‘green chemistry’’ (37) possible with biomolecular systems. Protein 
design efforts have also led to the discovery of new sensors and enzymes (38–42). 
Therapeutic proteins may affect intercellular communication and the physiology of the 
human immune system, and there remains enormous potential for the development of 
therapeutic agents for autoimmune diseases, cancer, infections, and inflammatory 
diseases (43–45). Thus, the ability to reliably design structure and function into proteins 
stands to inform our basic understanding of biomolecular function and can lead to a wide 
variety of biotechnological and biomedical applications.  
 
Although realizing a particular protein sequence may be straightforward 
(problems with protein synthesis or expression notwithstanding), protein design is non-
trivial. Proteins are large macromolecules that range in length from tens to tens of 
thousands of amino acid residues. The number of possible sequences is exponentially 
large. For a protein with 100 variable residues, there are 20100 possible sequences. In 
addition, many amino acids have multiple possible side-chain conformations, further 
increasing the complexity of the search for sequences consistent with a desired structure. 
Non-covalent interactions such as van der Waals forces, hydrogen bonding, salt bridges, 
and solvation effects stabilize the protein structure. Many of these interactions are 
coupled and interdependent in protein structures, and their parameterization in the form 
of a molecular energy function is necessarily approximate. As a result, accurate 
determination of the stabilities of proteins using molecular simulations is often 
impractical and remains computationally intensive (46, 47). The difficulties of protein 
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structure prediction suggest that the mapping from sequence to structure is subtle (2, 48). 
Ultimately, the best assessment of the quality of a particular protein design effort is to 
create and study the resulting sequences. This validation of design is typically more 
experimentally intensive than structure prediction, where thousands of structures already 
in the protein structural database may serve as test cases.  
Empirical approaches to protein design 
Hierarchical protein design 
Early work in protein design, also referred to as the inverse folding problem (49), 
applied knowledge gleaned from biochemical experiments and structural databases to the 
construction of small proteins. Often a hierarchical approach was used, where sequences 
likely to form particular substructures or secondary structures were assembled with a 
particular tertiary structure in mind (50, 51). Principles guiding the design process 
included the trend to have largely hydrophobic amino acids within the interior of the 
folded protein (52, 53), and the propensities of individual amino acids to appear in 
particular secondary structures such as α-helices or β-sheets (54–56). Early design efforts 
often focused on α-helical proteins and did not necessarily use all 20 amino acids (57–
61). Electrostatic interactions were found to play a smaller role in determining topology 
than the relative positioning of interior hydrophobic residues (62). Via such qualitative 
protein design, it was found that two proteins having 50% or greater sequence identity 
could have different folds (63, 64).  
 
Helical proteins have been targets of many design efforts. Designed, α-helical 
peptides have been constructed to solubilize membrane proteins (65) and to retard the 
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HIV-1 infection of human T cells (66). Rational, structure-informed de novo design based 
on α-helical bundles has been used to design proteins that bind metal ions such as zinc 
(67–70), iron (71,72), copper (73), cadmium (74), mercury (75), and calcium (68), as well 
as proteins that bind metal-containing cofactors such as heme (76–78). The B1 domain of 
Streptococcal IgG-binding protein G was also used as a template for designing a zinc 
binding protein (79). A four-helix peptide (maquette) was shown to efficiently 
incorporate an iron-sulfur cluster as a tetramer and exhibit properties typical of natural 
ferredoxins (80). While successfully realizing some of the targeted functionality and 
structure, often these designed proteins did not have well-defined tertiary structures. 
These proteins exhibited more mobility in the interior than native proteins, and in many 
cases had the features of a molten-globule-like state (50,51,81). The approaches used 
often consider the secondary structure propensities of the amino acids and the appropriate 
patterning of hydrophobic residues for a particular tertiary structure. These methods do 
not typically consider, however, the complementarities of steric and other inter-atomic 
interactions (e.g. hydrogen bonding) observed in the structures of natural proteins. As a 
result, such designed proteins may be compact and have a large degree of the appropriate 
secondary structure but may not form well-defined tertiary structures.  
Combinatorial methods  
Generating and screening combinatorial protein libraries for variants with new or 
improved function or stability has become an established method for protein engineering 
(82). Diverse, partially random libraries are experimentally obtained by using degenerate 
oligonucleotides during gene assembly (83), by performing the polymerase chain reaction 
under mutagenic conditions (84), or by using DNA shuffling (85,86). In directed 
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evolution protocols, these methods are used as part of an iterative mutation-selection-
enrichment cycle. The use of such protocols has been spurred by the development of 
high-throughput assays and the availability of various library platforms for expressing 
and displaying proteins. Phage display libraries are popular tools in directed evolution 
(87), but bacterial (88), yeast (89), and ribosomal (90) display systems are also widely 
used.  
 
Combinatorial libraries have been used to examine protein folding and stability 
(91–94). Proper patterning of hydrophobicity was found to be a key determinant of 
whether variants of λ repressor are compatible with the wild-type fold (91), and multiple 
substitutions in the helix-turn-helix region of λ repressor are largely additive with regard 
to their impact on folded state stability of the protein (92). Combinatorial libraries have 
been constructed to investigate the utility of binary patterning of hydrophobic and 
hydrophilic amino acids in a manner consistent with predetermined secondary and 
tertiary structures. Such efforts have identified native-like protein structures that fold into 
well-ordered four-helix bundles and beta proteins (95–102).  
Directed evolution  
Directed evolution and related methods have identified proteins with a variety of 
functionally important properties. Partial randomization of sequence followed by 
selection is a powerful, evolutionarily inspired, tool for introducing new function into 
proteins. Through directed evolution, protein function can be engineered if a suitable 
selection assay is available. Applications include the ability to maintain binding affinity 
when removing segments non-essential for a protein (103), improve binding affinity 
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(104), evolve RNA polymerase from DNA polymerase (105), endow an antibody with 
catalytic activity (106–109), and accelerate the maturation of a red fluorescent protein 
(110). Retroviruses have been reengineered to greatly enhance their spreading efficiency 
through human fibrosarcoma cells for possible use in gene therapy (111). New 
biosynthetic pathways have been engineered in E. coli for the production of non-native 
carotenoids (33), and a new genetic circuit has been evolved (112). These studies show 
that directed evolution methods have a broad reach into exploring and tailoring the 
functions of proteins. Complex functional properties may be engineered without 
requiring a detailed molecular understanding as to how these are achieved. The 
development of a selection method yielding proteins with the desired properties is one of 
the key features of such methods. The particular selection strategy usually is dependent 
on the desired function. Affinity columns with immobilized ligands are useful for 
selecting tight binding proteins. For more subtle and complex functions, such as catalysis, 
more sophisticated selections must be used and often are tied to cell (or phage) viability. 
In addition, the targeted functions must be accessible via evolution methods where 
usually only a few mutations are accumulated per generation.  
Intrinsic limitations  
Despite some of the striking successes of hierarchical protein design, 
combinatorial, and directed evolution methods, these techniques are not without 
shortcomings. Optimizing the many interactions within a particular folded state structure 
can be difficult by inspection alone and, as mentioned, many designed proteins do not 
have well-defined tertiary or oligomeric structures (50). While combinatorial methods 
can address large numbers of sequences, 103 to 106 for high-throughput screening and 
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1012 for display methods, these numbers are far smaller than the number of possible 
sequences. Thus, such approaches may miss proteins with the desired properties and 
structures. Directed evolution methods often require a well-folded protein as a starting 
point for evolving new structures and functions (82,113), and as a result these methods 
are usually limited to the redesign of natural proteins. DNA shuffling protocols often 
require high degrees of sequence homology (60%) for appreciable rates of recombination 
(114). Several approaches have been developed to overcome this limitation (115,116), 
but functional hybrids often become more sparse.  
 
It is of interest to explore sequence and structure more extensively and to arrive at 
proteins having novel structures that differ from natural proteins. The development of 
methods that allow simultaneous consideration of the myriad of interactions and levels of 
structure present in proteins quantitatively permit detailed predictions about structure, 
stability, and sequence variability that may be rigorously tested. Such studies can further 
our physical chemical understanding of the stability, folding, functions, and dynamics of 
proteins.  
Computational approaches to structured-based design  
Computational protein design involves the search for sequences compatible with a 
given fold with the aid of computer modeling methods to address and quantify protein 
structure and amino acid variability. The template fold is often represented in atomistic 
detail and, as opposed to more qualitative design methods, inter-atomic interactions 
involving variable residues are explicitly quantified and evaluated. Computational design 
involves simultaneous consideration of multiple interacting residues. A complete 
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enumeration of all possible sequences, however, is only possible when only a few 
residues are varied. As a result, powerful methods for sampling or characterizing 
sequences consistent with a particular fold must be employed when large numbers of 
residues are varied. Such methods may be used to design particular sequences or to guide 
the construction of combinatorial libraries and directed evolution experiments.  
 
Although there are different approaches to computational protein design, most 
make use of similar methods for specifying the properties of the target protein and for 
quantifying the physical and chemical interactions that stabilize structure and confer 
functionality. A target polypeptide backbone structure serves as a template to guide the 
selection of sequences. At each variable position, residue degrees of freedom include the 
allowed amino acids and their side-chain conformations, which are usually treated as a 
discrete set of rotamer states. The interactions between all residues are quantified through 
energy or scoring functions, which often contain terms representing such effects as 
hydrogen bonding, van der Waals interactions, electrostatic interactions, and solvation. 
Energy functions are often used to arrive at foldability criteria, which take unfolded states 
into account and quantify the degree to which a particular sequence is likely to fold into 
the target structure. There have been several studies that examine protein design and 
variability through the use of sequence alignment methods (117,118), but herein we focus 
on the design of structure and sequence based upon the physico-chemical properties of 
the amino acids.  
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Backbone structure and sequence constraints  
A backbone structure specifies the coordinates of the main chain atoms, the 
bonded series of carbon, nitrogen, and oxygen atoms associated with each amino acid 
residue in a protein. This structure serves as the target for computational protein design. 
The backbone coordinates may be obtained from a known structure (119) or from 
modeling novel structures (120–123). Naturally occurring protein structures are often 
used, as many such structures support a wide variety of biological functions, e.g. the TIM 
barrel superfamily (124). This specification of the template structure partially defines the 
design problem, reduces the number of degrees of freedom, and avoids some of the 
difficulties of structure prediction. The fixed-backbone approximation has been 
successfully used in computational protein design, but flexibility of the main chain may 
be included to accommodate backbone readjustments that result from changes in 
sequence (125,126). While flexible-backbone protein design is more computationally 
intensive than fixed-backbone design, recent studies have shown that such methods can 
yield well-structured proteins (121,127).  
Residue degrees of freedom  
Since the backbone structure is largely predetermined, the degrees of freedom in 
protein design mainly involve the distinguishable states of the amino acid residues. These 
residue degrees of freedom include both the allowed amino acids at each variable 
position as well as the side-chain conformations of these amino acids. The naturally 
occurring 20 amino acids are most often used, but this number may be reduced, as in the 
patterning of residue properties (95,128), or expanded with the inclusion of non-natural 
amino acids. Most amino acids may assume multiple, distinguishable side-chain 
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conformations (rotamers) (129–131). Libraries of allowed rotamer states reduce the 
complexity of the side-chain states to a discrete set of side-chain conformations. Such 
rotamer states have been statistically deduced from protein structure databases, and 
usually are consistent with bond and torsion angles corresponding to local energy minima 
(131). Depending on the size and topology of an amino acid, the number of possible 
rotamers can range from one (glycine and alanine) to as many as 80–100 (or more) for 
larger side chains. Rotamer libraries have been developed that are backbone-independent 
or are sensitive to the local backbone and secondary structure (129,132–143). Atomistic 
representations of side chains and their conformations enable the design of well-packed 
protein interiors. Rotamer libraries may also be developed for non-biological amino acids 
by identifying local torsional minima using a molecular mechanics force field (144,145).  
 
In order to make the design of larger proteins more tractable, approaches have 
been introduced that reduce the residue degrees of freedom. Such methods include 
reducing the number of allowed amino acids, often in a patterned or site specific manner 
(95,128), or simplifying the representation of the amino acid side chains. Studies with 
limited numbers of amino acids can suggest the minimal set of amino acids necessary for 
certain structures. For example, a 108-residue, four-helix bundle structure has been 
constructed using only 7 of the 20 possible amino acids (146). Similarly, only five amino 
acids have been used to reconstruct large portions of an SH3 domain structure (147). 
Simplified models of side chains have been successfully used in the design of proteins, 
using an energy landscape approach (148).  
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Energy function  
Quantification of intra- and intermolecular interactions is critical to computational 
protein design. The energy functions used in protein design are often similar to those 
used in molecular modeling and simulation (149), such as the atom-based molecular 
mechanics force fields Amber (150), CHARMm (151), and Gromos (152). Energy 
functions like these may comprise contributions arising from deformation of bond 
lengths, bond angles, and dihedral angles, as well as non-bonding interactions arising 
from van der Waals, electrostatic, and hydrogen bonding interactions. In protein design, 
the non-bonding interaction terms often dominate, since the approximation of discrete 
rotamer states and the rigid backbone largely fixes bond lengths and bond angles. So as 
not to overestimate the repulsive energies of van der Waals interactions, which may often 
be readily alleviated by slight backbone adjustments, the van der Waals radii are often 
uniformly diminished using ad hoc scaling factors (153,154).  
 
In addition to atom-based physico-chemical energy functions, effective energies 
quantifying the structural propensities of the amino acids can be included using scoring 
functions. Statistical analysis of protein structure databases reveals that the relative 
frequencies of amino acids may depend on the local structural environment, and 
experimental studies have quantified the degree to which different amino acids 
destabilize secondary structures (55,56,149,155–157). Such experimental or database 
studies can yield effective scoring functions. The individual terms in the energy function 
may be weighted in order to combine molecular mechanics potentials and empirical 
scoring functions. This weighting may be subtle, and is often accomplished by 
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comparison with known sequences and structures (158), or with training sets of 
randomized sequences (159).  
Solvation  
Solvation and hydrophobic effects play critical roles in protein folding (160). 
Hydrophobic residues tend to be sequestered in the interior of the protein, while 
hydrophilic residues are found more frequently on the exterior. In protein design, 
evaluating free energies of solvation through explicit modeling of solvent is 
computationally prohibitive. Solvation effects, and indirectly the hydrophobic effect, are 
often approximated using energies expressed in terms of the solvent accessible area of 
each atom. The corresponding free energy cost per unit area exposed is often 
parameterized using a structural protein database, or known free energies of transfer 
between water and either a vacuum or organic phase (161–164). Although much simpler 
than the explicit modeling of solvent, calculating such surface areas may still be 
computationally expensive (165), particularly since these areas are sequence dependent. 
As an alternative method, a statistical potential may be introduced that quantifies the 
propensities of the amino acids to reside in buried and exposed local environments (166).  
Foldability criteria and negative design  
A designed protein should fold into a unique three-dimensional structure defined 
as the ‘‘native’’ state. Non-target conformations of the protein should not be appreciably 
populated. In order to achieve this, the conformational energy landscape should have 
‘‘funnel’’ shape, with the folded state at the free-energy minimum (11–13,167). Including 
information about stabilization with respect to misfolded structures is often referred to as 
‘‘negative design’’ (60). In order to achieve structural specificity, the target structure 
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should correspond to an energetic ground state that has an energy gap separating the 
target from other competing structures (13,168,169).  
 
Many approaches to computational protein design focus on energy minimization 
(through variation of sequence) as the foldability criterion. However, the notion that 
decreasing energy is correlated with improved foldability can be problematic, particularly 
for models involving reduced representations of the amino acids (170). The absence of 
explicit negative design may result in proteins that populate multiple topologies (171). 
For simple models of proteins, other foldability criteria that more accurately approximate 
the free energy of folding and/or address unfolded structures explicitly may be used. Such 
criteria can act as objective functions in sequence design (169,172–174). Such quantities 
include Δ/Γ, where Δ is the energy gap between the target structure and the average 
energy of other competing, unfolded structures and Γ2 is the variance of the energy 
averaged over this same ensemble of unfolded structures (169,172–175).  
 
For atomistic representations of proteins, however, energy minimization appears 
to be a viable strategy. This is not unreasonable, given that most design algorithms yield 
structures that are sterically and energetically self-consistent, in keeping with what is 
observed in natural structures. For proteins comprising a single chain, such tightly packed 
sequences are specific to the target backbone structure, and it is unlikely that the same 
interior packing could be observed in alternative backbone conformations. Viewed in 
another way, the use of explicit side-chain conformations in protein design increases the 
effective number of monomer types by associating a set of rotamers with each amino 
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acid, and tailoring a sequence for a particular tertiary structure becomes more 
straightforward with the expanded monomer set (13,176,177). Elements of negative 
design may also already be involved in the design process in an indirect manner, via the 
use of effective energies of the residues in unfolded structures (i.e. reference energies) 
(120,178), by imposition of composition constraints on the numbers of each amino acid 
(179,180), or by application of hydrophobic and hydrophilic patterning (128). Explicit 
negative design can become crucial in cases where degenerate or low-energy competing 
structures are likely to compete with the target structure, such as may be the case in low-
resolution protein models (coarse-grained or simplified representations of amino acids) 
(148) or in cases involving protein–protein interfaces, which may have smooth energy 
landscapes supporting multiple possible orientations of the associating proteins (181). 
 
Implementations of negative design have yielded well-folded proteins. Qualitative 
use of negative design based on the patterning of hydrophobic and hydrophilic amino 
acids enabled the conversion of a designed amyloid-forming protein into a monomeric β-
sheet protein (102). In the redesign of a three-helix bundle topology, an ensemble of 
denatured structures from folding simulations was used as a set of competing unfolded 
structures (148). Optimal sequences were selected using a modified Δ/Γ score, and one 
such sequence appeared native-like upon experimental characterization. Explicit negative 
design has also been implemented in an algorithm for designing coiled-coil interfaces 
(181), where sequence specificity was selected by comparing energies of the target 
structure with non-target, misfolded, homodimeric and heterodimeric states.  
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Search and characterization of sequence ensembles  
Protein design involves identifying viable sequences subject to imposed 
constraints on structure, sequence, and function. Various algorithms can be utilized for 
the identification of sequences consistent with the target structure and target protein 
properties. These approaches may be grouped into two categories: directed or search-
based methods that seek to identify sequences optimizing a particular scoring or energy 
function; and probabilistic approaches that seek to characterize the properties of the 
ensemble sequences likely to fold to the desired structure.  
 
In an optimization approach, the goal is identification of a high-scoring (low-
energy) sequence for the target using energy or other scoring functions. Since exhaustive 
enumeration of sequences and rotamer positioning are only tractable for cases involving 
just a few variable residues, approaches such as genetic algorithms (125), simulated 
annealing (158,182), and Monte Carlo methods (183) are used. Alternatively, elimination 
and pruning methods identify global optima by successively removing residue states that 
cannot be a part of the optimal solution (153,184–186).  
 
A statistical approach estimates the site-specific probabilities of the amino acids 
among sequences consistent with the targeted structure and other desired properties 
(166,174). Such a probabilistic approach is motivated by several considerations. Nature 
often provides multiple sequences that fold to the same structure, so there are usually 
multiple possible solutions in protein design. Probabilistic information regarding the 
likelihoods of the amino acids is a natural input into combinatorial studies of proteins. 
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Many aspects involved in design, such as parameterized energy functions, discrete side-
chain conformations, fixing backbone atoms, and effective solvation energies, involve 
approximations. The sequences identified by optimization-based approaches are likely to 
be sensitive to the details of the energy function used and to the nature of these 
approximations, whereas statistical features may be more robust. Site-specific amino acid 
probabilities can highlight the allowed mutations at each location, and provide a broad 
characterization of the ensemble of sequences. Such methods are implemented in two 
complementary approaches: maximization of an effective entropy to determine the most 
likely set of site-specific amino acid probabilities (120,166), and sampling of sequences 
using Monte Carlo methods (183,187). These probabilities may then be used to determine 
specific protein sequences or to specify the composition in a combinatorial library. This 
approach has been termed a statistical, computationally assisted design strategy (SCADS) 
(120,188).  
Recent successes in protein design  
De novo designed proteins have appeared within recent years that make use of 
advances in computational design methods. We discuss only a few here, but other 
noteworthy design achievements include biocatalysts (42,189,190), sensors (191), and 
protein–protein interactions (192). Several recent reviews have also appeared that detail 
further exploration of this field (126,127,169,176,177,193–195).  
 
Verification of a designed protein sequence is best accomplished by experimental 
realization and characterization. Empirical structure determination efforts, via X-ray 
crystallography or NMR structure determination, provide demanding but time-intensive 
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assessments of design. Often stringent biophysical and functional assays are used. The 
examples discussed here involve the computational design of proteins that have been 
characterized experimentally, affirming the theoretical methodology employed.  
Designing structure and sequence  
Protein design can suggest not only variants of naturally occurring proteins but 
also lead to de novo designed proteins as well, where structure, sequence, and even 
function are elements of the design process. A small protein based on a zinc finger 
topology has been successfully computationally designed (153). Novel sequences that 
fold into desired target structures have been identified by cycling between sequence 
design and backbone optimization (158,179,209–211). A computationally designed 97-
residue α/β protein, Top7, based upon a topology not found in isolation, has recently been 
realized (121,212). This design was achieved using backbone templates assembled from 
structural fragments with subsequent design of sequence (158). These findings suggest 
that additional protein folds not yet found in nature may be physically possible (Fig. 5.1).  
 
Probabilistic methods have also been successful in large-scale protein design. 
SCADS has been applied to the de novo design of DFsc, a 114-residue four-helix bundle 
containing a di-iron center (120). The backbone template was based on the crystal 
structure of a previously designed dimeric helix protein DF1 (213). The topology of DF1 
was re-engineered by altering the interhelical turns in an effort to arrive at a stable and 
monomeric (single-chain) protein. Residue identities and conformations were fixed at 26 
positions to confer metal binding, provide access to the active site, and initiate helix 
formation. SCADS was used to identify the remaining 88 residues. The structure of the 
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final sequence has been characterized using CD and NMR spectroscopy. DFsc is well 
structured and may be catalytically active (120).  
 
Computational methods have also been extended to the design of β-sheet 
metalloproteins (123). The rubredoxin protein family consists of simple iron sulfur beta 
proteins having a redox active Fe(II)/Fe(III) ion in an tetra-cysteine binding site (213). A 
novel backbone was obtained by simplifying the metal binding site of rubredoxin to a 
pair of pseudo-equivalent β-hairpins. The two-stranded sheet was extended into a three-
stranded structure, resulting in a dimer that was connected with a tryptophan zipper 
hairpin (214). The resulting structure contained only 40 residues, compared to the 54 in 
rubredoxin, and consisted of an entirely different overall topology. Some residues were 
fixed prior to computational design including the Trpzip linker, the four metal binding 
cysteines, two glycine residues that adopt an αL conformation, and an isoleucine to shield 
the active site from solvent. The remaining residues were chosen based on the highest 
probabilities from SCADS calculations, resulting in the protein RM1. Experimental 
studies confirmed that the metal ions bound in the proper geometry with the expected 
stoichiometry, and that RM1 is monomeric and properly folded with the expected β-sheet 
structure, both with and without metal ions. RM1 could be reversibly reduced and 
oxidized over 16 cycles under aerobic conditions, suggesting a protein that is 
significantly more robust electrochemically than previously designed 
metalloproteins.(71,215).  
 
 
 
 
- 146 - 
Outlook  
The design of a novel protein may appear to be a daunting process, given the 
many degrees of freedom and myriads of subtle interactions that guide folding. 
Computational methods have been successful, however, in overcoming these hurdles by 
leveraging some of the fundamental rules governing protein folding and by addressing 
many coupled degrees of (sequence) freedom simultaneously. Through the use of 
computational design methods it is now feasible to sample, search, and characterize 
sequences for a variety of target proteins. Several challenges still remain. It will be of 
interest to quantify sought-after properties in a manner consistent with protein design 
algorithms. Such properties include solubility, cellular toxicity, or lack thereof, high-
affinity ligand binding, selective protein–protein association, and specificity in enzyme 
catalysis. With continued efforts in protein design, a greater understanding of these 
properties will become available as well as an improved understanding of protein folding 
and assembly.  
 
Although the field of computational design is still under development, it has 
already proven successful in generating new proteins with a diverse range of structures 
and functions. Computational design methods may also be extended to proteins 
containing unnatural amino acids and non-biological folding systems or ‘‘foldamers’’ 
(231,232). Aided by computational methods, novel molecular ‘‘machinery’’ comprising 
proteins (or other polymers) may potentially be designed that can carry out desired 
functions with the same specificity and selectivity of natural proteins.  
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Figure 5.1 
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Abstract 
Endothelial lipase [EL] is a member of a subfamily of lipases that act on 
triglycerides and phospholipids in plasma lipoproteins, which also includes lipoprotein 
lipase and hepatic lipase. EL has a tropism for high density lipoprotein, and its level of 
phospholipase activity is similar to its level of triglyceride lipase activity. Inhibition or 
loss-of-function of EL in mice results in an increase in high density lipoprotein 
cholesterol, making it a potential therapeutic target. Although hepatic lipase and 
lipoprotein lipase have been shown to function as homodimers, the active form of EL is 
not known. In these studies, the size and conformation of the active form of EL were 
determined. Immunoprecipitation experiments suggest oligomerization, and ultra-
centrifugation experiments show that the active form of EL has a molecular weight 
higher than the molecular weight of a simple monomer, but less than a dimer. A construct 
encoding a covalent head-to-tail homodimer of EL [EL-EL] was expressed and had 
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similar lipolytic activity to EL. The functional molecular weights determined by radiation 
inactivation were similar for EL and the covalent homodimer EL-EL. We previously 
showed that EL could be cleaved by proprotein convertases, such as PC5, resulting in 
loss of activity. In cells overexpressing PC5, the covalent homodimeric EL-EL appeared 
to be more stable, with reduced cleavage and conserved lipolytic activity. A comparative 
model obtained using other lipase structures suggests a structure for the head-to-tail EL 
homodimer that is consistent with the experimental findings. These data confirm the 
hypothesis that EL is active as a homodimer in head-to-tail conformation. 
 
Three members of the triglyceride lipase family, lipoprotein lipase [LPL], hepatic 
lipase [HL], and endothelial lipase [EL], contribute to lipoprotein catabolism in the 
plasma compartment. They are all secreted proteins that bind to heparin sulfate 
proteoglycans on the luminal side of endothelial cells where they interact with their 
lipoprotein substrates. They have different specificities for lipoproteins, and all hydrolyze 
triglycerides and phosphatidylcholine at the sn-1 position, albeit with widely differing 
efficiencies (1). The preferred lipoprotein substrates for LPL are the triglyceride-rich 
lipoproteins, chylomicrons, and very low density lipoproteins; the triglyceride lipase 
activity of LPL is more than 100-fold greater than its phospholipase activity. The primary 
lipoprotein substrates for HL are chylomicron remnants, intermediate density 
lipoproteins, and large triglyceridase-enriched HDL; its triglyceride lipase activity is 
about 20-fold higher than its phospholipase activity. EL is much more active on HDL, 
and its phospholipase activity is quite similar to its triglyceride lipase activity. 
 
 
 
 
 
- 167 - 
These three lipolytic enzymes share a number of structural features. By analogy to 
the crystal structure of pancreatic lipase (2), another member of the triglyceride lipase 
family, each has a clearly defined N- and C-terminal structural domain, joined by a hinge 
region. They are all serine esterases with a catalytic triad of serine, aspartic acid, and 
histidine located in the N-terminal domain. The catalytic triad is covered by a lid domain 
that contributes to the preference for either triglyceride or phospholipid substrates (3-6). 
The C-terminal domain contributes to lipid binding and determines the preferences for 
binding to lipoproteins (7-12). The N-terminal portion of the EL molecule contains the 
active site of the enzyme. However, when this portion of the molecule is expressed 
without the C-terminal domain, it lacks enzymatic activity against phospholipid (13), 
triglyceride, and the more soluble micellar substrate tributyrin. Thus, the presence of the 
C-terminal domain is necessary for activity. All three enzymes are glycosylated to 
varying degrees, and two of the glycosylation sites (one each in the N- and C-terminal 
domains) are common to all three enzymes (14, 15). All three enzymes are also heparin-
binding proteins, and regions that contribute to heparin binding are found in both the N- 
and C-terminal domains (16-18). 
 
EL and, to a lesser extent, LPL are subject to proteolytic cleavage by proprotein 
convertases at a prototypical RXKR site in the hinge region, but HL lacks the site and is 
not cleaved (19, 20). The catalytically active forms of both LPL and HL have been shown 
to be homodimers (18, 21-27), and in the case of LPL, the orientation of the subunits of 
the dimer has been shown to be head-to-tail (28-30). The present study tested the 
hypothesis that EL also functions as a head-to-tail dimer. 
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Experimental Procedures 
Construction of a head-to-tail dimer of EL (EL-EL) 
We used PCR to engineer a head-to-tail dimer of two monomeric subunits of EL [EL-EL] 
in an approach similar to that of Wong et al. (28) for LPL using the same short hinge of 8 
amino acids (GSIEGRLE) to create the head-to-tail dimer of EL (Fig. 6.1). 
 
 
Figure 6.1 
 
Schematic diagram of EL-EL construct. Shown is a schematic diagram representing EL-EL, 
the homodimer of EL in a head-to-tail conformation. A short hinge (linker) of 8 amino acid 
residues (GSIEGRLE) joined the two monomeric subunits of EL using overlap extension PCR. 
EL-EL contained sequences coding for the signal peptide (SP) of EL, the mature EL protein, the 8 
amino acid-peptide linker containing a factor Xa site, and another mature EL protein. Each 
monomeric subunit of mature EL protein has an N-terminal domain (N) and a C-terminal domain 
(C). To allow comparison of the levels of expression of the dimeric construct (EL-EL) and wild-
type EL, we constructed C-terminal myc-His-tagged proteins. 
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Two cDNAs of human EL were amplified separately by PCR. Each cDNA 
contained engineered restriction sites to facilitate assembly and subcloning into the 
expression plasmid pcDNA3.1/myc-His(-)A (Invitrogen). The sense primer of the first 
cDNA of EL (5’-ACGTTCTAGAGGCAGGATGAGCAACTCCG-3’) contained an XbaI 
restriction site and the first 13 coding nucleotides of the EL cDNA.  
 
The antisense primer of the first cDNA of EL (5’-
CGCTCTCGAGACGACCTTCGATGGATCCGGGAAGCTCCACAGTGGGAC-3’) contained 
the last 20 coding nucleotides of the EL cDNA, a factor Xa site (coding for 8 amino 
acids, GSIEGRLE), and an XhoI restriction site. The sense primer of the second cDNA 
of EL (5’-GCGTCTCGAGAGCCCCGTACCTTTTGGTC-3’) contained an XhoI restriction 
site and the first 19 coding nucleotides of the mature EL protein. The antisense primer of 
the second cDNA of EL (5’-TGACAAGCTTTCAGGGAAGCTCCACAGTGGGAC-3’) 
contained the last 23 coding nucleotides of the EL cDNA and a HindIII restriction site. 
These two PCR products were purified, digested using XbaI, XhoI, and HindIII 
restriction enzymes, and then ligated using T4 ligase from a rapid ligation kit (Roche 
Applied Science). The final product contained sequences coding for the signal peptide of 
EL, the mature EL protein, an 8-amino acid-peptide linker containing a factor Xa site, 
and another mature EL protein (Fig. 6.1). To allow comparison of the levels of 
expression of the EL-EL dimeric construct and wild-type EL, we constructed C-terminal 
myc-His-tagged proteins by inserting the full-length cDNA into pcDNA3.1/myc-His(-)A 
plasmid expression vector (Invitrogen). The construct was sequenced to confirm 
accuracy. 
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Cell culture and transfections 
HEK293 cells and sub-lines stably expressing profurin or PC5a were maintained 
in Dulbecco's modified Eagle's medium, 10% fetal bovine serum, and 1X— 
antibiotic/antimycotic supplement (Invitrogen). The cells were transfected with EL 
constructs using LipofectamineTM reagent (Invitrogen). Twenty-four hours after 
transfection, the medium was replaced with Dulbecco's modified Eagle's medium 
containing 10 units/ml heparin (Sigma) and incubated for another 24 h. Thirty min prior 
to harvesting this conditioned medium, more heparin was added to the medium, bringing 
the final concentration of heparin to 20 units/ml. Conditioned media were collected, 
subjected to low speed centrifugation, and frozen in aliquots at -80°C. For some 
experiments where high enzyme activity was required (sucrose gradients and radiation 
inactivation), the conditioned medium was concentrated 5-fold using an Amicon 
ultracentrifugal filtration device (30,000 Mr cutoff; Millipore). 
 
Western blotting 
The levels of protein expression of wild-type EL and EL-EL were estimated by 
Western blot. For each experiment, we used conditioned medium from cells transfected 
to express green fluorescent protein (GFP) as a negative control. Ten µl of conditioned 
media were resolved on 10% BisTris or 7% Tris acetate SDS-PAGE (Invitrogen) and 
transferred to Hybond ECL nitrocellulose membrane (Amersham Biosciences). Proteins 
were detected using either a polyclonal rabbit anti-human EL primary antibody specific 
for a peptide in the N-terminal region or a monoclonal mouse anti-Myc primary antibody 
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(clone 9E10) and a horseradish peroxidase-conjugated secondary antibody (Jackson 
ImmunoResearch). 
 
Co-immunoprecipitation 
Conditioned media from HEK293 cells transfected with GFP and co-transfected 
with EL-myc-His and EL-FLAG or a 1:1 mixture of media from HEK293 cells, which 
had been transfected with EL-myc-His or EL-FLAG, were incubated with mouse (or 
rabbit) anti-Myc (Abcam) or mouse anti-FLAG IgG (Sigma) at 4°C in the presence of 
0.1% Triton X-100 (Fisher) for 2 h. Protein G magnetic beads (New England Biolabs) 
were added to each sample, and samples were incubated overnight at 4°C. Supernatant 
and pellet were separated after centrifuging for 10 min at 10,000 X g, 4°C. Pellets were 
washed three times with phosphate-buffered saline and eluted from the beads with 4X 
loading buffer and 10X— dithiothreitol (Invitrogen). Western blot analysis of samples 
was performed using a rabbit anti-EL antibody or a rabbit anti-Myc (Biovision) or a 
mouse anti-FLAG antibody (HRP conjugate, Sigma). 
 
Sucrose gradient ultracentrifugation 
Sucrose gradients were prepared as described (27). Briefly, 5-20% sucrose 
gradients containing 50 mM ammonium hydroxide, pH 8.1, were prepared. Glucose-6-
phosphate dehydrogenase (G6PDH) (110 kDa) was added to each sample to serve as an 
internal standard. Cytochrome c (12.5 kDa), ovalbumin (45 kDa), malate dehydrogenase 
(74 kDa), and catalase (240 kDa) were centrifuged in two separate tubes and served as 
external standards. After centrifugation (22 h at 200,000 X g at 4°C), 600-µl fractions 
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were collected and assayed for enzyme activity and protein concentration. The protein 
concentration was determined in each fraction of external standards using a commercially 
available kit (BCA protein assay kit, Pierce). 
 
Radiation inactivation 
Conditioned medium containing partially cleaved myc-His-tagged EL was 
prepared by transfection in HEK293 cells as described above. Media containing either 
uncleaved myc-His-tagged wild-type EL or uncleaved myc-His-tagged EL-EL dimer 
were prepared in a similar manner by transfection in HEK293 cells that stably express 
profurin. Apotransferrin (2 mg/ml, Sigma) and G6PDH (4 units/ml, Sigma) were added 
to the media. Samples of these media (0.55 ml) were placed in glass vials, quick frozen, 
sealed, and stored at -80°C. Vials were shipped and returned on dry ice. Irradiations were 
performed with a linear electron accelerator at the Armed Forces Radiobiology Research 
Institute, Bethesda, or at the National Institute of Standards and Technology, 
Gaithersburg, MD. Frozen samples were irradiated at -135°C with a beam of 13-MeV 
electrons as described (31). Two aliquots not irradiated served as the zero dose controls. 
Radiation dose was determined with thermoluminescent or alanine dosimeters. Irradiated 
frozen samples were stored at -80°C until assayed for triglyceride lipase activity. The 
activity (A) at each dose was divided by the activity at zero dose (A0) to determine the 
fractional residual activity at each dose. For each enzyme preparation, the natural 
logarithm of the fraction remaining was plotted as a function of radiation dose. The 
slopes of these lines were determined by linear regression (GraphPad Prizm) and were 
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used to calculate molecular mass as described previously (31). The slopes for the 
inactivation of G6PDH were identical in all sample sets. 
 
Triglyceride lipase and phospholipase assays 
Emulsions of triolein or dipalmitoylphosphatidylcholine were used to measure 
triglyceride lipase or phospholipase activity, respectively (1, 32, 33). For the triglyceride 
lipase assay, the emulsion contained triolein and egg phosphatidylcholine containing 
glycerol tri[9,10-3H]oleate stabilized with glycerol. For the phospholipase assay, a 
similar glycerol-stabilized emulsion was used that contained radiolabeled phospholipids 
([14C]dipalmitoylphosphatidylcholine) and cholesteryl oleate as the neutral lipid core. 
Samples were incubated for 15 min at 37°C. All enzyme activities are reported as 
nanomoles of free fatty acid liberated/h-ml conditioned medium as source of enzyme. All 
assays were done in triplicate. 
 
Other enzyme assays 
Malate dehydrogenase activity was measured by incubating 2 µl of sample with 
294 µl of substrate made of 367.4 µM oxaloacetate and 204 µM NADH in 40 mM Tris-
H2SO4, pH 7.4, at 25°C. The decrease in absorbance was monitored at 340 nm. G6PDH 
activity was measured by incubating 5 µl of sample in a final volume of 200 µl 
containing 50 mM Tris-HCl, pH 7.8, 3 mM MgCl2, 0.2 mM NADP, and 3.3 mM glucose 
6-phosphate for 15 min at 25°C and monitoring the increase in absorbance at 340 nm. 
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Comparative protein structure modeling methods 
The human EL models were generated using the molecular modeling suite 
MODELLER version 8v1 (Accelrys Discovery Studio, San Diego) and evaluated with 
MODELLER versions 8v1 and 9v1 (34-37). As input for the modeling algorithm, the 
human EL protein sequence, NCBI protein data base accession code NP_006024.1, was 
aligned to the following lipase structures obtained from the Protein Data Bank: Homo 
sapiens pancreatic lipase and Sus scrofa co-lipase complex (PDB accession code 1N8S), 
H. sapiens pancreatic lipase and S. scrofa co-lipase complex inhibited by undecane 
phosphonate methyl ester (PDB accession code 1LPB), and Equus caballus pancreatic 
lipase (PDB accession code 1HPL). Multiple sequence alignments with the human EL 
protein sequence and those of the aforementioned three protein structures were generated 
by ClustalW (EMBL-EBI) using default parameter settings (38). The human EL sequence 
has 27% identity to human pancreatic lipase and 25% identity to horse pancreatic lipase. 
These identical residues located throughout the crystal structures of the pancreatic lipases 
served as anchors to guide the modeling of human endothelial lipase. The EL sequence 
contains 37 residues at the C-terminus that were not used in the modeling process 
because there is no significant sequence homology to the other template lipase structures 
in this region. The human EL models were evaluated using the discrete optimized protein 
energy algorithms of MODELLER version 9v1 (39). To investigate the model structure 
in the context of a homodimer, the best scoring human endothelial lipase monomer 
models were structurally aligned to each monomer of the horse pancreatic lipase 
homodimer using MacPyMOL version 0.96. 
 
 
 
 
 
- 175 - 
Results 
EL is a dimer that forms intracellularly 
To understand the intermolecular interaction of EL, we used two EL constructs, 
one encoding a FLAG tag and the other a myc-His tag at the C-terminus. Neither tag had 
any effect on EL lipolytic activity (data not shown). Constructs encoding EL-myc-His 
and EL-FLAG were co-transfected in HEK293 cells. Conditioned medium was harvested 
and subjected to immunoprecipitation using an anti-Myc antibody to precipitate any 
Myc-containing proteins. The precipitated proteins were examined by Western blotting 
using an anti-FLAG antibody as well as an anti-EL antibody specific for a peptide in the 
N-terminal domain. No immunoreactive bands were detected in conditioned medium 
from cells transfected with a construct encoding GFP. As shown in Fig. 6.2, when 
constructs encoding EL-myc-His and EL-FLAG were co-transfected in HEK293 cells, 
the anti-FLAG antibody detected FLAG-tagged EL in the material that had been 
immunoprecipitated with anti-Myc antibody, indicating that there was interaction 
between EL-FLAG and EL-myc-His proteins, consistent with dimer formation. When 
conditioned medium containing EL-FLAG was mixed with conditioned medium 
containing EL-myc-His and subsequently immunoprecipitated, no interaction was 
detected, suggesting that the association between monomeric units occurs intracellularly 
and that the association between subunits is very strong. 
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Figure 6.2 
 
EL protein forms immunoprecipitable complex during secretion but not after secretion. 
HEK293 conditioned media were prepared as follows. Lanes 1 and 4 are from cells expressing 
GFP; lanes 2 and 5 are mixtures of media from cells separately transfected with either EL-myc-
His or EL-FLAG; lanes 3, 6, and 7 are media from cells co-transfected with EL-myc-His and EL-
FLAG. Western blots (WB) show supernatants (lanes 1-3) and pellets (lanes 4-6) after 
immunoprecipitation (IP) with mouse anti-Myc from samples as indicated. Lane 7 shows the 
pellet after immunoprecipitation with mouse anti-FLAG from conditioned media from HEK293 
cells co-transfected with EL-myc-His and EL-FLAG. These Western blots used either an 
antibody against an EL peptide, FLAG tag, or Myc tag for detection. F indicates the full-length 
monomer size of EL; N indicates the N-terminal domain of EL, and C indicates the C-terminal 
domain of EL. 
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Active EL is larger than a monomer and consistent with partially cleaved dimer 
Sucrose gradient centrifugation of conditioned medium from cells expressing 
wild-type EL was used to determine the size of the functional unit of EL. The major peak 
of the triglyceride lipase activity of EL appeared as a distinct species somewhat smaller 
than G6PDH (which has a molecular weight of 110,000) as shown in Fig. 6.3A. A linear 
relationship was observed when the molecular weights of standard proteins versus 
sucrose concentrations were plotted (Fig. 6.3B). The relative molecular weight of the EL 
functional unit was 94,500, considerably smaller than a dimer of full-length monomers 
(136 kDa) and larger than a monomer (68 kDa). This functional size is most consistent 
with partially cleaved forms where part of the cleaved monomer remains associated with 
an uncleaved monomer (Fig. 6.4A). 
 
A covalent head-to-tail EL dimer is highly active 
We engineered a construct encoding a covalent head-to-tail dimer of two 
monomeric subunits of EL [EL-EL] joined by a short hinge of eight amino acid residues 
(GSIEGRLE) using an approach similar to that of Wong et al. (28) for LPL. The final 
cDNA product contained sequences coding for the signal peptide of EL, the mature EL 
protein, the 8-amino acid peptide linker followed by another mature EL protein, and a C-
terminal myc-His tag (Fig. 6.1). The expression of the dimeric EL-EL construct was 
compared with wild-type EL, which was also myc-His-tagged. Western blots of 
conditioned media of transiently transfected HEK293 cells using an antibody against the 
myc tag as primary antibody (Fig. 6.4B) showed a band corresponding to a full-length 
monomer (68 kDa) in the case of wild-type EL and a dimer (136 kDa) in the case of EL-
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EL, as well as the cleavage products that are myc-His-tagged. Although dimeric forms 
are not always present in Western blots for wild-type EL, a dimeric form and partially 
cleaved dimer are also visible in the wild-type EL lane. In the Western blot of the same 
media using an antibody against EL as primary antibody (Fig. 6.4C), we observed the 
full-length monomer of wild-type EL (68 kDa) and the full-length dimer of EL-EL (136 
kDa), and as expected some cleavage products (20). Interestingly, in the case of EL-EL 
we detected cleavage products of intermediate size between a monomer and a dimer 
corresponding to a monomer plus the N-terminal domain (108 kDa) and a monomer plus 
the C-terminal domain (96 kDa). 
 
We compared the enzymatic activity of wild-type EL and EL-EL using lipid 
emulsions of triglyceride and phospholipid to measure triglyceride lipase and 
phospholipase activity, respectively. The EL-EL dimer showed both triglyceride lipase 
and phospholipase activities. For each transfection, we consistently measured more lipase 
activity (both triglyceride lipase and phospholipase) in EL-EL despite the protein band in 
the respective Western blot often appearing of similar or lesser intensity than the band of 
the full-length wild-type EL (Fig. 6.4B). The ratio of the triglyceride lipase activity to 
phospholipase activity (triglyceridase/phospholipase ratio) reflects the substrate 
specificity of the enzyme and was not significantly different for EL-EL (1.46 ± 0.57) than 
for EL (1.56 ± 0.24). Thus the EL protein in a dimeric head-to-tail conformation (EL-EL) 
was active both as a triglyceride lipase and phospholipase. These data are consistent with 
a model that EL is active as dimer in a head-to-tail conformation. 
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Figure 6.3 
 
A) Sucrose gradient centrifugation of wild-type EL. After 5-20% sucrose gradient 
ultracentrifugation, samples were collected. Each fraction was tested for TG lipase activity (♦) 
and G6PDH activity (■). The percentage of sucrose was also measured in each fraction collected. 
B) Molecular weight of wild-type EL determined by ultracentrifugation. The molecular 
standards used in this experiment were cytochrome c (12.5 kDa), ovalbumin (45 kDa), malate 
dehydrogenase (74 kDa), G6PDH (114 kDa), and catalase (240 kDa). After centrifugation (22 h 
at 200,000 x g at 4°C), fractions were collected and assayed for enzyme activity and protein 
concentration. There is a linear relationship between the molecular weights of standard proteins 
and the sucrose percentage. 
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Figure 6.4 
 
A) Cleavage products of EL monomer and EL dimer. A schematic diagram is shown of all the 
potential intermediate forms of EL monomer and EL dimer induced by the proteolytic cleavage of 
EL by proprotein convertases. All the possible forms varying from uncleaved to partially cleaved 
and fully cleaved in the case of EL monomer and EL dimer are represented. The relative 
molecular mass of each of these forms in kDa is shown.  
B) Western blot of EL and EL-EL detected by an antibody against Myc tag. Expression in 
HEK293 conditioned media of Myc-tagged EL and EL-EL was detected by Western blot using a 
mouse anti-Myc monoclonal antibody and HRP-conjugated secondary antibody. Schematic 
diagrams of the different forms of EL detected by the anti-Myc antibody are shown.  
C) Western blot of EL and EL-EL detected by an antibody against EL. Expression in 
HEK293 conditioned media of Myc-tagged EL and EL-EL was detected by Western blot using a 
rabbit anti-human EL polyclonal antibody and HRP-conjugated secondary antibody. Schematic 
diagrams of the different forms of EL as detected by the anti-EL antibody are shown. 
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Intermediate oligomeric forms of EL are enzymatically active 
EL is active as a dimer in a head-to-tail conformation, but other intermediate 
forms could potentially also be active provided that an intact active site is present and 
preserved. To test that hypothesis, we expressed wild-type EL and EL-EL in HEK293 
cells under conditions promoting different levels of cleavage. We used HEK293 cells 
stably expressing profurin, which has been reported to prevent EL cleavage, or 
expressing PC5a, which has been reported to fully cleave EL (20). Figure 6.5 shows that 
indeed more full-length EL and EL-EL dimer were present in the media of cells 
expressing profurin, whereas wild-type EL and EL-EL dimer were more heavily cleaved 
in the presence of PC5a expression. Interestingly, EL-EL appeared more resistant to 
cleavage in HEK293 cells and in the absence or presence of PC5a in comparison with 
wild-type EL. These data support the concept that the oligomeric state of EL is dimeric 
and that the linker hinge in the EL-EL protein stabilizes the enzyme, making it less prone 
to inactivating enzymatic cleavage by enzymes of the proprotein convertase family such 
as PC5a. The linker hinge also ensures that the N-terminal and C-terminal domains 
remain attached and presumably preserve an active site. 
 
We measured the triglyceride lipase and phospholipase activity of wild-type EL 
and EL-EL in these three experimental conditions (Table 6.1). In the case of EL, both the 
triglyceride lipase and phospholipase activity of wild-type EL decreased as the amount of 
cleavage increased (Fig. 6.5 & Table 6.1). Similar results were observed in the case of 
EL-EL, where both the triglyceride lipase and phospholipase activity of EL-EL decreased 
as the amount of cleavage increased (Fig. 6.5 & Table 6.1). EL-EL differed from wild-
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type EL only in the extent of the effect. Indeed, EL-EL only partially lost activity in the 
presence of PC5a, whereas wild-type EL was more drastically affected. Our activity data 
(triglyceride lipase and phospholipase) associated with the mass indicated that as less 
protein was cleaved in the case of EL-EL compared with wild-type EL, more lipolytic 
enzymatic activity remained (Fig. 6.5 & Table 6.1). These data indicated that not only is 
EL active as a homodimer but that the cleavage of EL results in a loss of activity and the 
partially or wholly cleaved forms of EL are less active or inactive. 
 
Comparison of the molecular mass of uncleaved wild-type EL and uncleaved 
dimeric EL 
The functional size of EL was examined using radiation inactivation. Conditioned 
medium was prepared from cells expressing myc-His-tagged wild-type EL that was 
partially cleaved. The same construct was transfected in cells expressing profurin to 
produce EL that was uncleaved, as was the myc-His-tagged head-to-tail construct EL-EL, 
to produce the covalently linked dimer, also uncleaved. As shown in Fig. 6.6, all three 
preparations gave single exponential decays as a function of radiation dose. Unlike the 
sucrose density analysis, radiation inactivation is not influenced by glycosylation. The 
inactivation is a function only of the protein component of the enzyme. The predicted 
protein mass of a dimer of wild-type EL is 109,201 Da and of the dimer with the covalent 
linker is 110,061 Da. Both of the uncleaved preparations gave highly similar decay 
functions, which indicated a functional molecular mass of protein of 103.3 kDa for the 
uncleaved wild-type EL and 108.5 kDa for the uncleaved dimer that contains the 
additional 8-amino acid linker. Thus we can conclude that EL functions as a head-to-tail 
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homodimer. The wild-type EL that had undergone cleavage also gave a single 
exponential decay as a function of radiation dose that was clearly different from the other 
two. The functional molecular mass of protein calculated for that preparation was 79 
kDa. The predicted molecular masses of the protein components of partially cleaved 
forms are 90,629 and 82,629 Da, respectively (these are the 108- and 96-kDa forms in 
Fig. 6.4A with carbohydrate). These data indicate that, after cleavage, one of the domains 
can dissociate from the intact monomer, whereas the other remains with the monomer 
and the molecule remains active. 
 
Structural modeling of EL 
Comparative models of EL were created computationally to assess the feasibility 
of head-to-tail homodimer formation with EL and the possible impact of such a 
configuration on activity. Presently, no high-resolution structures of EL have been 
determined, in part due to the marginal stability of the EL protein under laboratory 
conditions. Therefore, comparative modeling was employed to infer likely structures of 
the protein. Previously published structures of pancreatic lipases from human and horse 
were used as structural templates in conjunction with multiple sequence alignments of 
lipase sequences from several different species to generate three-dimensional models of 
human EL monomers. After model refinements using the MODELLER suite, the best 
scoring EL monomer models were aligned to the structure of the horse pancreatic lipase, 
which crystallized as a head-to-tail dimer (40). The EL dimer model (Fig. 6.7) aligns well 
to each monomer within the horse pancreatic lipase dimer, and the overall positions of 
the N-terminus, activation lid, hinge, and C-terminal domains are similar to those of 
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horse pancreatic lipase. The EL dimer model contains no steric clashes between 
monomers at the dimer interface. Within the EL dimer model, the N-terminal catalytic 
triad is in proximity (within 30 Å) to the C-terminal domain of the other monomer. 
 
Figure 6.5 
 
Western blot of EL and EL-EL under conditions promoting different levels of cleavage. The 
level of protein expression in HEK293 conditioned media was detected by Western blot using a 
mouse anti-Myc monoclonal antibody (Ab) and HRP-conjugated secondary antibody. GFP (as 
negative control), EL, and EL-EL were expressed in HEK293 cells under conditions promoting 
different levels of cleavage. HEK293 cells stably expressing profurin prevented EL cleavage, and 
HEK293 cells stably expressing PC5a promote the cleavage of EL. 
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Discussion 
LPL, HL, and EL are members of the triglyceride lipase gene subfamily involved 
in plasma lipoprotein metabolism. EL has a particular tropism for HDL and modulates 
HDL metabolism in mice and in humans (41,42). To date, only the three-dimensional 
structure pancreatic lipase has been resolved by X-ray crystallography (2). Based on the 
high amino acid homology and the conservation of the catalytic triad, LPL, HL, and EL 
are assumed to present three-dimensional structures similar to pancreatic lipase. Both HL 
and LPL have been shown to be active in a homodimeric form, using methods varying 
from ultracentrifugation, gel filtration, antibody inhibition, to radiation inactivation (18, 
21, 23, 24, 26-28, 43). Mutants of LPL engineered by molecular biology have shown that 
LPL is active as a homodimer in a head-to-tail conformation (28-30). 
 
The purpose of this work was to determine the active form of EL. Initial 
experiments of immunoprecipitation of media from co-transfection of constructs 
encoding EL-myc and EL-FLAG showed that proteins immunoprecipitated with anti-
Myc antibody contained both Myc-tagged EL and FLAG-tagged EL. Thus, there was an 
interaction between EL-FLAG and EL-myc proteins, consistent with an oligomerization 
of EL. However, when conditioned media from cells expressing either EL-myc or EL-
FLAG were incubated together prior to immunoprecipitation, no evidence of interaction 
was observed. This suggests that dimerization occurs intracellularly, before secretion, and 
that there is a high affinity, stable interaction between subunits. 
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Ultracentrifugation studies of other triglyceride lipase family members suggested 
that the plasma compartment lipases are dimers. Human HL was shown to have a 
molecular mass of 121 kDa (43), and similar studies of rat HL showed 113 kDa (26). 
Together, these data suggested that HL exists as a dimer. Analysis of the sedimentation 
coefficient of bovine LPL yielded a molecular weight of 96,900, whereas the molecular 
weight of the monomer was 48,300 (21). Thus the native LPL enzyme appears to be a 
dimer of presumably identical subunits. Similarly, the bovine LPL activity profiles from 
sedimentation equilibrium as well as from gel filtration indicated that activity was 
associated almost exclusively with the dimer fraction (24). Sucrose density gradient 
centrifugation was also used to determine that monomeric LPL refolded in the presence 
of calcium becomes dimeric (44). 
 
A complicating issue in determining the functional size of catalytically active EL 
relates to its susceptibility to proteolytic cleavage by proprotein convertases (19, 20). One 
can predict that, upon cleavage of a dimeric uncleaved EL, a number of possible forms 
might be obtained (Fig. 6.4A) and that some of these partially cleaved forms could 
potentially retain catalytic activity. The lack of enzymatic activity of the N-terminal 
portion of EL (14) indicates that an interaction with the C-terminal domain is essential to 
activity. Even if EL is active as a dimer in a head-to-tail conformation, other intermediate 
forms could potentially also be active as long as an intact active site is present and the 
contribution of the C-terminal domain is preserved. Using classic sucrose density 
ultracentrifugation methods, we compared the mobility of wild-type EL to that of several 
proteins of known molecular masses and calculated that the molecular mass of wild-type 
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EL was 94.5 kDa. As this preparation of EL was made in HEK293 cells, which also 
secrete proprotein convertases, EL in the preparation was at least partially cleaved. The 
estimated molecular mass is consistent with either of the partially cleaved forms (Fig. 
6.4A) where an intact N- or C-terminal domain remains associated with an intact 
monomer. These data suggest that one or both of these partially cleaved forms is active. 
 
We then prepared EL in a head-to-tail homodimer using methods similar to those 
used by Wong et al. (28), wherein we made a construct encoding such a dimer covalently 
linked by an 8-amino acid hinge region (Fig. 6.1). The construct also contained a myc-
His tag to allow estimation of expression. The dimer construct expressed nearly as well 
as the wild-type. However, the triglyceride and phospholipase activities of the dimer 
preparations were consistently higher that those of the wild-type. The ratios of 
triglyceride to phospholipase activities were essentially unchanged, indicating that the 
covalent linkage of the dimer had no effect on substrate specificity. To determine the 
effect of cleavage on activity, we compared activity from wild-type to that of the dimer in 
conditions of normal, high, or low activity of proprotein convertases. As shown in Table 
6.1, activity was highest in the absence of cleavage for both wild-type and dimeric EL 
and lowest for both in the presence of the highest degree of cleavage. Interestingly, the 
dimeric form appeared to be more resistant to loss of activity than the wild-type. This 
may be due to a resistance to cleavage by proprotein convertases or to the fact that the 
covalent hinge between the C-terminus of the original first EL monomer keeps the N-
terminus of the second EL monomer attached so that an active molecule is retained. Even 
with a high degree of cleavage (Fig. 6.5) of EL prepared in cells expressing PC5, robustly 
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detectable activity remains (Table 6.1), suggesting that fully cleaved N- and C-terminal 
fragments can remain together and maintain an active site. 
 
 
Table 6.1 
293 cells Lipases TG activity PL activity TG/PL ratio  
  nmol P/h/ml nmol P/h/ml (mean ± S.D.) 
PC5a EL 172.5 ± 8.4 92.7  ± 7.4 1.92 ± 0.12 
 EL-EL 425.5 ± 8.6 173.1 ± 10.6 1.56 ± 0.62 
 EL 265.9 ± 3.8 172.4 ± 1.1 1.56 ± 0.24 
 EL-EL 484.9 ± 20.2 226.0 ± 11.3 1.46 ± 0.57 
Profurin EL 445.2 ± 10.5 306.5 ± 79.1 1.72 ± 0.24 
 EL-EL 673.5 ± 22.1 313.1 ± 4.5 1.79 ± 0.58 
 
Triglyceride lipase and phospholipase activities of EL and EL-EL under conditions 
promoting different levels of cleavage 
Wild-type EL and EL-EL were expressed in HEK293 cells under control conditions and under 
conditions promoting different levels of cleavage. HEK293 cells stably expressing profurin 
prevent EL cleavage, and HEK293 cells stably expressing PC5a promote the cleavage of EL. The 
triglyceride lipase activity (TG activity) and phospholipase activity (PL activity) of each 
conditioned medium were expressed in nanomoles of free fatty acid product (P) formed/h-ml of 
conditioned media as source of lipase. The activity values reported in this table are the mean 
values and the standard deviations (mean ± S.D., n = 3). The ratio of the triglyceride lipase to 
phospholipase activity (TG/PL ratio) represent the substrate specificity of the enzyme. The last 
column represents the mean values and the mean ± S.D. of the triglyceride/phospholipase ratios 
across independent experiments (n = 5 for HEK 293 cell media and n = 4 each for cell media 
from HEK293 cells expressing profurin or PC5a). Statistical analysis was run using an unpaired t 
test to determine whether the mean of the triglyceride/phospholipase ratios were significantly 
different (p < 0.05). The triglyceride/phospholipase ratios of EL-EL and wild-type EL were not 
statistically different experimentally whatever the cell types used for the transfection. 
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The functional size of EL was also examined using radiation inactivation to 
determine the size of the active unit. The radiation inactivation method was developed to 
determine the size of enzymes (45) and has been previously used to determine the 
functional molecular mass of both LPL (23, 46) and HL (25, 44). For bovine milk LPL, 
the combined data of radiation inactivation under a number of different conditions 
yielded a functional size of 72 kDa for the unglycosylated protein, which is close to that 
expected for a dimer, 77 kDa (23). For rat LPL the functional molecular mass was 
calculated to be 127 kDa, again the unglycosylated size (46), consistent with a dimer. 
Thus the smallest unit required for enzyme function constitutes a dimer in the case of 
LPL. There is some discrepancy in the literature with regard to the functional unit of HL. 
When recombinant human HL was subjected to radiation inactivation, the size of 
functional HL was calculated to be 109 kDa (unglycosylated), the size of a homodimer 
(43). An examination of rat HL from liver, adrenal gland, and ovaries showed that the 
liver enzyme had a functional molecular mass of 63 kDa (monomeric), but the enzymes 
from the adrenals and ovaries both showed functional molecular masses of 117 kDa 
(dimeric) (26). Unlike the sucrose density analysis, radiation inactivation is not 
influenced by glycosylation and might therefore be a more accurate method in the case of 
glycosylated protein such as EL. Another advantage to the radiation inactivation is that it 
is a method for determining the functional size of a protein without the need of prior 
purification. Uncleaved preparations of wild-type EL and EL-EL gave similar functional 
molecular mass estimates, consistent with the concept that EL is active as a homodimer 
and are in agreement with the data previously generated for LPL (23, 46) and HL (25, 
43). Interestingly, cleavage of only one “side” of the homodimer results in an 
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intermediate size form (Fig. 6.4A) that is still active, although less so than the full 
homodimer. 
 
In an elegant model of LPL (47), a head-to-tail conformation was proposed where 
the monomers associate side-by-side. This conformation has enough space for the lid to 
move freely to enable a conformational change upon substrate binding (47). Based on 
this, we developed a similar model for EL (Fig. 6.7). Our EL dimer model contains no 
steric clashes between monomers at the dimer interface. Within this model, the N-
terminal catalytic triad of one-half of the dimer is in close proximity to the C-terminal 
domain of the other half. This model suggests how the C-terminal domain could affect 
substrate specificity by playing a role in positioning the substrate in proximity to the 
catalytic triad of the other half of the dimer across the dimer interface. In contrast, in a 
monomer model, the C-terminal domain is almost twice as far from the catalytic triad 
(~60 Å). Indeed in the EL dimer model, a hydrophobic collection of amino acids 
(Met351, Leu382, Pro383, Ile386, Val387, Phe398, Leu399, Val400, Pro437, Pro440, 
and Gly441) in the C-terminal domain is in proximity to the catalytic triad (under the 
activation lid) of the N-terminal domain of the other monomer (Fig. 6.7). Furthermore, 
there is ample volume for the activation lids of each monomer to open into the middle 
part of the dimer interface, and therefore head-to-tail packing could help stabilize the 
opening of the lid through ionic or hydrophobic interactions on the surface of the 
opposing monomer, similar to the observations of Kobayashi et al. (29) with their 
computational model of LPL. These observations, in conjunction with the biochemical 
activity data, suggest that head-to-tail dimerization of EL may help position the C-
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terminal domain, important for substrate specificity, in close proximity to the catalytic 
region of the enzyme while in turn stabilizing the movement of the activation lid. 
 
In conclusion, HL and LPL have been shown using a variety of methods to be 
active in a homodimeric form and, at least for LPL, in a head-to-tail conformation. We 
comprehensively studied EL functional size using a variety of similar methods, including 
ultracentrifugation, radiation inactivation, covalent EL homodimer, immunoprecipitation, 
and molecular modeling. Our data are wholly consistent with a model in which EL 
oligomerizes into a homodimer that is active in a head-to-tail conformation. Only the full 
length EL is present on the cell surface (data not shown), and it is conceivable that 
dimerization of EL confers optimal activity against and interaction with its substrates, 
HDL, on the endothelial surface. Furthermore, EL is proteolytically cleaved in the hinge 
region by proprotein convertases, resulting in partially cleaved dimeric forms of EL that 
retain some activity and could have particular physiologic roles. Because EL is a 
pharmacologic target for inhibition as a strategy to raise HDL cholesterol levels, detailed 
structural information regarding the active forms of EL could be important to the optimal 
design of EL inhibitors. 
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Figure 6.6 
 
Radiation inactivation of EL and EL-EL. The loss of triglyceride lipase activity of EL as a 
function of radiation dose (megarads) is shown. Three sources of EL were studied as follows: 
conditioned medium from cells expressing myc-His-tagged wild-type EL that was partially 
cleaved (◊, wt(cleaved)), conditioned medium from cells expressing profurin to produce EL that 
was uncleaved (∆, wt(uncleaved)), and conditioned medium from cells expressing profurin to 
produce EL-EL that was uncleaved ( +, dimer(uncleaved)). 
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Figure 6.7 
 
Molecular model of the EL dimer. Top view of the human endothelial lipase dimer model is 
shown. The N-terminal “head” domains are shaded in blue; the C-terminal “tail” domains are 
colored red and the activation lid is shaded green. The three catalytic residues, Ser169, Asp193, 
and His274 are rendered in a space-filling format and located under the activation lid. A 
collection of exposed hydrophobic residues, Met351, Leu382, Pro383, Ile386, Val387, Phe398, 
Leu-399, Val400, Pro437, Pro440, and Gly441, is highlighted in pink on monomer 1. Monomer 2 
is rendered so as to reveal the N- and C-terminal domains, hinge, and secondary structure. 
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The abbreviations used in chapter 6 are: 
BisTris 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol 
Da  Dalton 
EL  endothelial lipase 
G6PDH glucose-6-phosphate dehydrogenase 
GFP  green fluorescent protein 
HDL  high density lipoprotein 
HL  hepatic lipase 
HRP  horseradish peroxidase 
LPL  lipoprotein lipase 
PDB  Protein Data Bank. 
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Abstract 
Endothelial lipase [EL] is a plasma enzyme that previous reports have shown to 
be important in high-density lipoprotein [HDL] metabolism. A collection of EL 
comparative models was developed based on the crystal structure of pancreatic lipase. 
Based on this suite of models, four surface regions of basic charge were identified, 
14KLHKPK19, 292RKNR295, 304KKMRNKRNSK313 and 427RRIRVK432. Alanine scanning 
mutants were generated and studied for heparin-binding capacity and enzymatic activity 
using both radiolabeled emulsion substrates and isolated human HDL2 and VLDL. The 
mutant 14ALAAPA19 bound to heparin with a KD_apparent of 35.6 + 4.5 nM, compared to 
wild-type EL with a KD_apparent of 19.8 + 2 nM, but had only 50% activity toward isolated 
human HDL, suggesting that 14ALAAPA19 is important to HDL binding. The mutants 
292AANA295 and 304KKMRNAANSK313 had heparin-binding affinities of 3.2 + 0.6 nM 
and 5.0 + 0.8 nM, respectively, with less than 50% of the binding capacity and loss of 
>90% of their enzymatic activity, suggesting that these segments are important for both 
structure and heparin-binding. The mutant 427AAIAVA432 had normal heparin-binding 
but had nearly complete loss of enzymatic activity. Based on the molecular models, the 
†In preparation for submission to BIOCHEMISTRY in 2010 
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carboxyterminal region, 427RRIRVK432, is a potential site of substrate coordination and 
could also be implicated in dimer interaction. This interaction may be essential for EL 
enzymatic activity (discussed in chapter 6). 
 
Introduction 
 Endothelial lipase [EL] is a member of the triglyceride lipase family that is unique 
in its synthesis by endothelial cells. EL has significant sequence homology and 
remarkably similar domain structure to lipoprotein lipase and hepatic lipase (1). While 
the two latter enzymes have well-characterized substrate preferences for triglyceride 
emulsions and triglyceride-rich lipoproteins (2-4), EL has greater activity toward 
phospholipids and high density lipoprotein [HDL] particles (5).  
 
 EL is active within the plasma compartment and has been shown to be released by 
heparin sulfate (6). The nature of the interaction between EL and proteoglycans [PGs] is 
likely to be electrostatic, involving surface-exposed, basic amino acids (Fig. 7.1). EL 
contains several regions of basic amino acids that are positively charged at physiologic 
pH, a number of which are located in the carboxyterminus. We have previously reported 
that the carboxyterminal domain of EL is essential to its hydrolysis of HDL (7). The 
interaction(s) between EL and HDL may be electrostatic as well as hydrophobic, between 
the negatively charged HDL particle and positively charge regions of EL (8). The amino 
acids involved in these interactions have not been identified. 
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 We developed molecular models of EL, based on the crystal structures of 
pancreatic lipases from human and horse. These models were used to generate 
hypotheses about the regions of EL that might be involved in binding to PGs and to HDL 
as a substrate. In this report, we describe the details of these EL models and the results of 
studies showing that certain positively-charged regions of EL are important for heparin-
binding and activity while others are necessary for the enzymatic activity of EL. 
 
Figure 7.1 
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Results 
Molecular models of EL 
The Discrete Optimized Protein Energy (DOPE) profiles and scores for all models, 
in addition to the template structures, were calculated using MODELLER version 9v1 with 
a smoothing window of 15 residues. A single pancreatic lipase chain in each crystal 
structure was used in the calculations, disregarding co-lipases and in the case of the 
1HPL dimer structure, disregarding one of the monomers. The overall DOPE score of the 
endothelial lipase models is 87% of the score for 1HPL crystal structure, 88% that for 
1N8S, and 88% that for 1LPB. Thus the models adopt structures with scores comparable 
to those obtained for related structures that have been determined experimentally (See 
Appendix I for more detail).  
 
The human EL amino acid sequence shares many similarities to other lipase 
family members, including those of the pancreatic lipases used as guide structures in the 
modeling process. The aminoterminal domain, defined here as the first 320 residues of 
endothelial lipase, has 49% sequence similarity to lipoprotein lipase, 42% similarity to 
hepatic lipase, and 29% similarity to human and 28% similarity to horse pancreatic 
lipase. The C-terminal domain, defined by the remaining 123 residues, has 32% 
similarity to lipoprotein lipase, 31% similarity to hepatic lipase, 13% similarity to the 
human pancreatic lipase, and 14% similarity to horse pancreatic lipase (Fig. 7.2).
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Figure 7.2 
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The models provide viable representations of the EL structure. Although four 
surface exposed regions in the model (4-51, 268-315, 339-347, 427-440) exhibit slightly 
higher DOPE scores than those of the templates, the remaining regions of the models, 
especially those regions surrounding the conserved catalytic triad (S149, D173, H254) 
exhibit DOPE scores similar to those of the template structures. After structurally 
aligning the α-carbon backbones of the human EL models to the templates, the three 
catalytic residues were analyzed for variability among the models. Each of the three 
catalytic residues had residue RMSD values of less than 0.6 Å when comparing pairs of 
models considered in this study (Appendix I). This small positional variability of these 
functionally significant residues from model to model further supports the viability of 
these comparative models.  
 
 We then examined regions of the EL models that are enriched in basic residues: 
Four regions, 14KLHKPK19, 292RKNR295, 304KKMRNKRNSK313, 427RRIRVK432, are 
located on the surface of the models. From a structural standpoint, three of these regions 
(292-285, 304-313, 427-432) appear to be exposed across the same surface of the protein 
(Fig 7.3) opposite the lid. When the 427-432 region is examined in the context of a model 
dimer (Fig 7.4), it is involved in part of a hydrophobic surface 403WYNLW407 positioned 
within 4 angstroms of the dimer interface and approximately 25-30 angstroms from the 
lid of the opposite monomer. The 14KLHKPK19 region is positively charged and may be 
involved in binding to PGs on the endothelial surface. In lipoprotein lipase, a heparin 
binding region is located in the hinge region between the two domains, and this region is 
similar to 292RKNR295 and 304KKMRNKRNSK313 in EL, which are also located at the 
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hinge. The proximity of the 427RRIRVK432 region to the highly hydrophobic sequence 
403WYNLW407 suggests that it may be involved in lipid binding. The models, therefore, 
suggest the following hypotheses: 
• The 14KLHKPK19 aminoterminal region binds to PGs on the endothelial surface. 
• The 292RKNR295 and 304KKMRNKRNSK313 regions bind to PGs on the 
endothelial surface. 
• The 427RRIRVK432 region is part of a lipid substrate binding region. 
 
Recombinant expression of EL and EL mutants 
 The concentrations of wild-type and mutant EL were determined by ELISA. The 
average concentrations of wild-type and mutant EL in medium from 2 transfections are 
shown in Table 7.2. The concentrations were very similar between the two transfections. 
With the exception of the 292-295 and 304-313 mutants, protein expression levels were 
equal to or greater than wild-type. The low expression of the 292RKNR295 and 
304KKMRNKRNSK313 mutants suggests that mutation in these areas results in misfolded 
protein that is not secreted. This region, which forms a hinge between the aminoterminal 
and carboxyterminal domains, may be important in the formation of the proper 
conformation of the protein. An examination of the intracellular content of these mutants 
was not conducted, however. 
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Figure 7.3 
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Figure 7.4 
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Binding of EL and EL mutants to heparin 
 Previous studies of HL and LPL binding to heparin have used NaCl elution 
profiles from heparin sepharose columns to distinguish between the two proteins (23, 29). 
To determine differences in binding affinities between wild-type EL and protein with 
mutations in potential heparin binding sites, we employed equilibrium binding studies to 
estimate apparent KD values. EL binds to heparin with an affinity of 19.8 + 2 nM. (Fig. 
7.5). The mutant, 427AAIAVA432, was equal to wild-type in its affinity to heparin, 19.1+ 
2.3 nM but had a slight decrease in binding capacity, Bmax = 2.5 absorbance units. The EL 
mutant 14ALAAPA19 had an approximately 2-fold lower affinity, 35.6+ 4.5 nM, with a 
lower Bmax of 2.1 absorbance units, suggesting that it contains a high affinity, low 
capacity heparin-binding site. In contrast, the EL mutants, 292AANA295 and 
304KKMRNAANSK313, had heparin-binding affinities of 3.2+ 0.6 nM and 5.0 + 0.8 nM, 
respectively, and Bmax of 0.5 and 1.0 absorbance units, respectively, suggesting that they 
represent a high capacity heparin-binding site. 
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Figure 7.5 
 
 
 
Lipase activity using emulsion substrates 
 The triglyceridase and phospholipase activity of wild-type EL and each mutant 
are summarized in Figure 4.6a and b, respectively. Wild-type EL hydrolyzed the 
triglyceride substrate, generating 6.17 + 2.3 nmol FFA/hr/µg protein. There was an 
approximate 50% loss of activity in the 14ALAAPA19 mutant, 3.2 + 0.23 nmol FFA/hr/µg 
protein, and even greater loss of activity in the other mutants: 292AANA295, 2.5 + 0.19, 
304KKMRNAANSK313, 1.5 + 0.28 and 427AAIAVA432 , 0.66 + 0.39 nmol FFA/hr/µg 
protein, p<0.001 for all in comparison to wild-type EL.  
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 The results from the phospholipid substrate assay demonstrated some differences 
in the relative importance of these charged areas (Fig. 7.6b). Wild-type EL hydrolyzed 
the phospholipid substrate, generating 5.88 + 1.23 nmol FFA/hr/µg protein. The 
14ALAAPA19 mutant retained 85% of the activity of wild-type EL, 4.98 + 0.53 nmol 
FFA/hr/µg protein, while the 292AANA295 mutation lost 88% of its activity, 0.70 +0.33, 
the 304KKMRNAANSK313 lost 98% of its activity, 0.135 + 0.06 nmol FFA/hr/µg protein, 
and the 427AAIAVA432 mutant lost all activity.  
 
Figure 7.6 
 
Tributyrin assay 
 The loss of positive charge associated with alanine-scanning mutagenesis can 
result in marked changes in protein structure that could alter the function of the active 
site. To examine this possibility, we assessed the integrity of the active site conformation 
using tributyrin, a triglyceride with three 4-carbon fatty acids used as an active site-
specific substrate. The results of these assays are summarized in Table 7.3. With the 
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exception of the 427AAIAVA432 mutant, the specific activity of wild-type and the EL 
mutant constructs was nearly identical. This suggests that the 427AAIAVA432 mutant is 
essential for active conformation of the protein. In contrast, the other mutants appear to 
be important for substrate and surface-binding. 
Lipase activity using native lipoproteins 
 Although the use of emulsion substrates provides insight into the relative 
triglyceride versus phospholipid preference of EL and the influence of different regions 
of the protein in facilitating the activity of the enzyme, in vitro assays using native 
lipoproteins may be more useful in determining the effect of these regions on EL activity 
in vivo. We therefore examined the activity of EL and mutated EL constructs on the 
hydrolysis of the larger VLDL and smaller HDL lipoprotein particle. The results are 
summarized in Table 7.3.  
 
 Similar to the results of the emulsion substrate assays, the 14ALAAPA19 mutant 
lost ~50% of its ability to hydrolyze HDL2 particles and 86% of its activity toward 
VLDL. The 292AANA295 and 304KKMRNAANSK313 mutants lost ~95% of their ability to 
hydrolyze HDL2 and had no ability to hydrolyze VLDL. The 427AAIAVA432 mutant again 
lost all activity. Given that the specific activity of native EL in hydrolyzing VLDL was 
~50% of that of HDL2, the complete loss of VLDL hydrolysis by the mutated EL proteins 
may be due to activity that is below the detection level of the assay. 
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Discussion 
In this study, we combine computational and experimental approaches to 
investigate the functional and substrate-specific aspects of EL, the most recently 
identified member of the plasma lipases. Although other members, such as pancreatic and 
LPL are well characterized, the lack of a crystal structure complicates efforts to explore 
the particular functional aspects of EL. To this end, we developed a suite of molecular 
models of human EL to gain further insight into various functional subtleties. 
 
In an attempt to better understand the differentiating features of each lipase family 
member in the absence of crystal structures, modeling approaches have already been used 
to investigate human LPL (23) and HL (24). Here we have developed molecular models 
of human EL that provide an appropriate context to develop hypotheses concerning 
heparin binding, substrate-specificity, and lipase functionality.  
Endothelial lipase topology 
Human EL shares significant amino acid sequence homology to other family 
members such as lipoprotein and hepatic lipases, yet this enzyme has a uniquely high 
affinity for phospholipids within HDL particles. From amino acid sequence alignments 
alone, the conservation of the residues surrounding and including the catalytic triad 
suggests the presence of an α/β hydrolase fold characteristic of the esterase, lipase and 
thioesterase superfamily. Furthermore, conservation of cysteine pairs throughout the 
primary sequence is consistent with a two-domain structure of the enzyme stabilized by 
disulfide bridges. Indeed, the EL models are consistent with the crystallized structures of 
pancreatic lipase in that the catalytic triad is structurally similar, cysteines are positioned 
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to form disulfide bridges as occurs at similar locations of other lipases, and the overall 
topology comprises two domains separated by a hinge region (Fig. 7.1).  
 
The human endothelial lipase models have noticeably large differences in surface 
residue composition in the four basic regions analyzed in this study when compared to 
the crystal structures of the pancreatic lipases. Four out of six, approximately 67%, of the 
surface exposed residues in region 14-19 of endothelial lipase contain basic residues, 
whereas only 1 in 6 residues are charged in the corresponding regions of the horse and 
human pancreatic lipases, leading to a near 4-fold increase in basic residues in this same 
region. This increase in basic residue density is also evident elsewhere in the surface of 
EL, with the 292-296 region having a 3-fold increase and the 304-313 region having an 
approximately 2-fold increase in basic residues over the pancreatic lipases. The most 
extreme differences are found in the 427RRIRVK432 positively charged surface region of 
human endothelial lipase. In contrast to EL, the same surface regions in the pancreatic 
lipases are void of basic residues, and have only one or two acidic residues that would 
confer a negative charge at physiological pH. This dramatic difference in local charge 
between lipase types, in conjunction with the loss of enzymatic activity observed from in 
vitro experiments, further supports the idea that region 427-432 could be implicated in 
substrate coordination as well as dimer stabilization particular to endothelial lipase. 
 
These region-specific surface residue composition comparisons between the EL 
models and PL structures are dependant upon the sequence alignments. However, often 
there is not one ‘best’ multiple sequence alignment. Although the conserved residues 
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positioned throughout the EL sequence served as useful anchors to guide the construction 
of the models, the first N-terminal 30 residues were subject to slight variations in 
alignments since this region has only 15% sequence similarity and multiple insertions. 
This small variation in alignment position could alter the spatial positions of 14-19 in the 
generated models of EL.  
 
In addition to the differences found in the four basic regions of human EL and the 
horse and human pancreatic lipases, the activation lid of EL is also different in both 
residue composition and structure. Amino acid variation between the lid residues of the 
various lipases has been implicated as a reason for their substrate specificity. Indeed, the 
residues Gly233, Tyr243, Val250 and Lys251 located in the lid region are conserved in 
the endothelial lipases from species to species (Appendix I), yet differ within the lipase 
family. From a structural standpoint, the pancreatic lipases have larger lids that contain a 
small alpha-helical turn in the middle of the lid.  
Substrate recognition and specificity 
Of particular interest in this study are four basic regions implicated in heparin 
binding and/or substrate recognition and specificity. Region 14KLHKPK19 exhibits a two-
fold lower affinity for heparin and a decrease in binding capacity when these lysines are 
mutated to alanines. This distal aminoterminal region shows little sequence similarity to 
the other lipase family members, and it seems that EL alone possesses a lysine-rich 
cluster at this location. LPL and HL have two tandem arginines in this area but lack 
additional basic residues. Region 14KLHKPK19 also has ~ 50% loss of activity toward 
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triglyceride substrate and HDL with an 86% loss of ability to hydrolyze VLDL. This 
finding suggests that this region contributes to substrate binding. 
 
Mutation of basic amino acids in the regions 292RKNR295 and 
304KKMRNKRNSK313 yielded a significant decrease in heparin-binding affinity and 
capacity as well as on enzymatic activity. The solvent-exposed 292RKNR295 cluster, 
located opposite the catalytic center, is directly flanked by two conserved cysteines 
capable of forming a disulfide bridge in the models (Figs. 7.1 & 7.2); a similar bridge is 
also present in the crystal structures of pancreatic lipase (11). These four residues are 
conserved in LPL, and mutational studies with LPL demonstrated that these basic 
residues constitute a high-affinity, heparin binding site (25). This sequence has also been 
shown to be a proprotein convertase cleavage site (26, 27). HL has a similar sequence in 
that region, KKGR, but it has not been shown to be involved in heparin-binding.  
 
In the models, adjacent to the four residues, 292RKNR295, lies another basic cluster 
304KKMRNKRNSK313. Together, the 292-295 and 304-313 clusters may form a 
positively charged surface at physiological pH opposite the catalytic core of the enzyme. 
Similar to the residues located in the 292-295 cluster, many of the basic residues from 
304-313 are conserved in LPL and HL. In HL, this region was shown to be a heparin-
binding site (28). Similarly, in the comparative models of EL, this likely heparin binding 
site is positioned on the opposite face from the catalytic triad. 
 
 
 
 
 
- 215 - 
The decrease in secretion of protein with loss of positive charge in these areas, as 
well as the decrease in heparin-binding capacity and loss of enzymatic activity suggest 
that this region of EL is essential for proper folding. These findings also suggest that 
binding to a negatively charged surface is important for enzymatic activity, in particular 
phospholipase activity.  
Active form of endothelial lipase 
We previously reported that the carboxyterminal region of EL mediates its greater 
ability to hydrolyze HDL (7). This suggested that there must be a specific area in the 
carboxyterminal region that binds to HDL. EL is not, however, lacking in ability to 
hydrolyze VLDL and LDL (5). A more accurate view of the role of the EL 
carboxyterminus may be to mediate lipid binding. Boren et al. found that the interaction 
between LPL and LDL occurred through binding to the triglyceride in the lipoprotein, not 
through interactions with apolipoprotein B (29). The nearly complete loss in enzymatic 
activity, when basic residues in the region 427RRIRVK432 were changed to alanine, 
suggests that this region may be important for lipid binding. A homologous region in 
LPL, 403KIRVK407, was examined as a potential heparin-binding site (30). Similar to our 
findings, when the basic residues in this region were changed to asparagines, there was a 
loss of enzymatic activity. In contrast to our finding that the heparin-binding affinity of 
the 427RRIRVK432 mutant is equivalent to wild-type EL, two previous reports (30,31) 
found that the 403KIRVK407 LPL mutant eluted with a lower NaCl concentration from a 
heparin sepharose column. When this region was examined within the context of a model 
of the LPL dimer, however, it was found that the amino acids coordinate with a putative 
heparin-binding site in the aminoterminus (32). In the EL dimer models, this region exists 
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as a short β-strand that is part of a hydrophobic region near the catalytic pocket of the 
opposite monomer. These results suggest that the active enzyme requires the head-to-tail 
association of the two monomers. The loss of activity toward the short chain tributyrin 
substrate also suggests that there are complex interactions between the two monomers 
required for hydrolysis of any substrate. 
 
The EL dimer models are consistent with having the distal regions 14KLHKPK19 
and 427RRIRVK432 in close proximity [within 25 angstroms] to each other. The resulting 
positively charged surface could potentially coordinate the alignment of EL with 
substrate at the lipid/water interface. In the context of an active monomer, the catalytic 
serine (Ser149) is approximately 60 angstroms from the 427RRIRVK432 cluster. However, 
as a head to tail homo-dimer, Ser149 is about half this distance, 30 angstroms, from 
427RRIRVK432 thus suggesting why mutations in this region may affect substrate 
recognition.  
 
The role of EL in lipoprotein metabolism and in the development of 
atherosclerosis continues to be an important area of study. Based on its ability to 
hydrolyze HDL and its reported association with coronary artery disease (17), EL is a 
potential therapeutic target. Understanding key structural, substrate and surface binding 
domains can contribute to the efforts to regulate EL pharmacologically. The findings of 
this report add specifically to this effort, demonstrating that the 292-313 region of EL is 
important to overall protein structure and is an important heparin-binding site, and that 
the carboxyterminal region, 427RRIRVK432, is key to active conformation of the protein. 
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Methods 
Comparative protein structure modeling 
All human EL models were generated using the molecular modeling suite 
MODELLER version 8v1 (9-12) and evaluated with MODELLER versions 8v1 and 9v1. 
As input for the modeling algorithm, the human EL protein sequence, NCBI protein 
database accession code NP_006024.1, was aligned to the following lipases, whose 
structures were obtained from the protein structure database (http://www.rscb.org/pdb/): 
Homo sapiens pancreatic lipase and Sus scrofa colipase complex (Protein Data Bank 
accession code 1N8S) (9), Homo sapiens pancreatic lipase and Sus scrofa colipase 
complex inhibited by undecane phosphonate methyl ester (Protein Data Bank accession 
code 1LPB) (10), and Equus caballus pancreatic lipase (Protein Data Bank accession 
code 1HPL) (11). The presence of undecane phosphonate methyl ester in the human 
pancreatic lipase crystal induced a conformational change in the lid region of 1LPB 
relative to the other lipase structures. To avoid skewing the modeling by the inactive 
human endothelial lipase monomer, the lid region from residues Pro235 to Ala260 of 
1LPB was not used as a template. Multiple sequence alignments with the human EL 
protein sequence and those of the aforementioned three protein structures were generated 
by CLUSTALW (EMBL-EBI) (12) using default parameter settings (Fig. 7.2). The first 
20 aminoterminal residues of human EL were not used for modeling, given that they are 
cleaved in the active form. Additionally, the carboxyterminal sequence of EL, 
 TEDPENTSISPGRELWFRKCRDGWRMKNETSPTVELP,  
has no significant homology to the other lipase structures used as templates. These 
terminal 37 residues were not used in the modeling process.  
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Model evaluation 
The human EL models were evaluated using the Discrete Optimized Protein 
Energy (DOPE) (13) algorithms of MODELLER version 9v1. Of approximately 300 
models generated, the ten best human EL models exhibiting DOPE energy scores similar 
to that of the crystallized pancreatic lipases were selected for further investigation. Using 
MacPyMOL version 0.96 (14), the α-carbons of these EL models were structurally 
aligned to those of the three template pancreatic lipase structures. The root mean square 
deviation (RMSD) of each of the three conserved catalytic residues of human endothelial 
lipase, Ser149, Asp73, His254, was then calculated to confirm similar acceptable 
positions of these residues relative to the catalytic pocket. 
Site-directed mutagenesis  
Single and multiple amino acid substitutions in the EL sequence were introduced 
using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The 
sequences of primers used are displayed in Table 7.1. Mutated EL in pcDNA3.1 in XL-1 
Blue super-competent cells was selected on LB-ampicillin agar plates and expanded in 
LB medium. Mutant plasmid was purified using a Qiagen Maxiprep kit (Valencia, CA) 
and sequenced to confirm the presence of the desired mutation. Expression of wild-type 
and mutant EL protein was obtained through transient transfection of 293 human 
epithelial kidney cells (293 HEK) using Lipofectamine™ reagent (Invitrogen, Carlsbad, 
CA). Briefly, 293 HEK cells were grown to >90% confluence in 100 mm dishes 
containing Dulbecco’s modified Eagles medium (DMEM), 10% fetal bovine serum 
(FBS), 50 µg/ml penicillin/streptomycin (P/S). The medium was replaced with a 
transfection mixture containing 5.85 µg ELpcDNA3.1, 52.65 µl Lipofectamine™ and 
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5.85 ml OPTI-MEM. After 5 hours, 5.85 ml DMEM, 20% FBS, P/S was added to each 
dish. After 24 hours, the medium was replaced with 6 ml serum-free DMEM, P/S and 
10U/ml heparin sulfate. After an additional 24 hours, medium was collected 30 minutes 
after addition of 10 U/ml heparin sulfate. The medium was stored at -80°C until use. 
Biotin-labeling of heparin  
Heparin >10 kDa was biotin-labeled using the method of O’Shannessy (15). Fifty 
milligrams of heparin (Sigma-Aldrich, St. Louis, MO) was dissolved in 2.5 ml sodium 
acetate buffer (0.1 M sodium acetate, 0.15 M NaCl, pH 5.5) and chilled on ice. Sodium 
m-periodate was added to a final concentration 10 mM, and the reaction incubated for 30 
minutes in the dark. The reaction was stopped using 20 mM sodium sulfite. The heparin 
solution was desalted and concentrated to 0.9 ml using Centricon-3 (Millipore, Bedford 
MA). Biotin-XX-hydrazide (EMD Chemicals, Gibbstown, NJ), 100 µl of an 8 mg/ml 
solution in dimethylformamide, was added and incubated 24 h at ambient temperature. 
Excess biotin was removed by three concentration and re-suspension cycles using tris-
buffered saline (10 mM tris-HCL, 0.15 M NaCl, pH 7.4) using Centricon-3 concentration 
devices. The degree of biotin incorporation was determined by measuring the absorbance 
at 500 nm of 0.9 ml avidin/HABA solution (6 µM avidin, 0.3 M HABA) [A1] and the 
change in absorbance [A2] after addition of 0.1 µl biotin-labeled heparin. The percent 
incorporation was then calculated: DA500 = 0.9(A1-A2); biotin (M) = DA500/3400. The 
heparin concentration, assuming an average molecular weight of 20 kDa, was determined 
by comparison to a standard curve of heparin using dimethyl methylene blue (16). The 
molar degree of biotin incorporation = [biotin]/[heparin]. 
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Enzyme-linked immunosorbent assay of EL 
A detailed description of the development of the endothelial lipase ELISA has 
been reported previously (17). Briefly, the wells of a 96-well microtiter plate were coated 
with rabbit anti-human EL antibody. Various concentrations of purified recombinant 
human EL in phosphate-buffered saline, 1% BSA, were added to the wells as a standard 
control. Conditioned medium from wild-type and mutant EL was diluted 1:1000 in 
phosphate-buffered saline and added to the wells. Specifically bound protein was 
incubated with biotin-conjugated rabbit anti-human EL antibody, followed by 
streptavidin-horseradish peroxidase conjugate, and detection with o-phenylenediamine. 
The reaction was stopped with 2.5M sulfuric acid and the plate read at 490 nm. A 
standard curve of 490 nm absorbance versus the known concentrations of EL was 
created. The concentration of EL in the conditioned medium was determined by 
comparison to the standard curve multiplied by the dilution factor. 
Equilibrium binding studies of EL, EL mutants to heparin 
Equilibrium binding studies of EL and EL mutants to heparin were performed as 
described previously (18). Briefly, biotin-heparin at 1 µg/well in phosphate-buffered 
saline (PBS), was added to a streptavidin-coated microtiter plate and incubated for 2 h at 
room temperature. After washing with PBS + 0.1% tween-20 (PBST), concentrations of 
EL between 0 and 100 nM were added to wells in triplicate. Non-specific binding was 
determined by addition of EL to blocked wells without heparin. After 2 h incubation and 
subsequent washing with PBST, 100 µl of a 1 µg/ml solution of polyclonal anti-EL 
antibody was added. After 2 h incubation and washing, 100 µl of a 1 µg/ml solution of 
goat anti-rabbit horseradish peroxidase antibody was added. After 1 h, 100 µl of a 0.42 
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mg/ml solution of ο-phenylene diamine was added. After 15 minutes, the reaction was 
stopped with 100 µl of sulfuric acid. Absorbance at 490 nm was measured on a 
Spectramax microtiter plate reader (Molecular Devices, Sunnyvale, CA). Specific 
binding was the amount of protein bound after subtraction of binding to blocked wells. 
Apparent binding affinity [KDapp] was determined using GraphPad Prism (GraphPad 
Software, San Diego, CA). 
Triglyceride lipase assay  
Triglyceride lipase activity was measured using a glycerol-stabilized emulsion of 
triolein and egg phosphatidylcholine containing glycerol-tri[9,10(n)-3H]oleate (3.3 
mCi/mmol) according to a modification of the method of Nilsson-Ehle and Schotz (19). 
Each assay tube contained 150 µl EL-conditioned medium, and 150 µl of a working 
substrate (0.05 M Tris-HCl, 0.15 M NaCl, pH 8.0, 0.75% BSA, 3.4 mM triolein, and 250 
µM phosphatidylcholine. Samples were incubated for 1 h at 37°C. Reactions were 
stopped and products were extracted according to the method of Belfrage and Vaughan 
(20). The liberated fatty acids contained in a 0.5 ml aliquot of the aqueous phase were 
quantified by scintillation counting, using a partition coefficient of 0.4. Enzyme activity 
is reported as nmol free fatty acid (FFA) liberated/h/µg protein. 
Phospholipase assay 
Phospholipase activity was measured using a glycerol-stabilized emulsion of 
cholesterol oleate, dipalmitoylphosphatidylcholine [DPPC] and [1,2-14C]DPPC as 
previously described (5). Each assay tube contained 150 µl EL-conditioned medium, 0.05 
M Tris-HCl, 0.15 M NaCl, pH 8.0, 0.75% BSA, 4.6 mM cholesteryl oleate, and 245 µM 
DPPC. Samples were incubated for 15 min at 37°C. The reactions were stopped and the 
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products extracted by the method of Belfrage and Vaughan, with the addition of 100 µg 
lysopalmitoylphosphatidylcholine [lysoPC] as carrier. The products, FFA and lysoPC, are 
quantified by scintillation counting of 0.5 ml of the aqueous phase, using a partition 
coefficient of 0.55 and dividing by two, to account for the lysoPC. Enzyme activity is 
reported as nmol free fatty acid (FFA) liberated/h/µg protein. 
Tributyrin assay 
The release of fatty acid from tributyrin by EL and EL mutants was performed 
essentially as described (21). Briefly, tributyrin, 14C labeled (American Radiolabeled 
Chemicals, St. Louis, MO) and unlabeled (Sigma-Aldrich, St. Louis, MO) (ratio 
1:40,000), were added to a final reaction mixture of 20 mM tributyrin, 50 mM Tris-HCl, 
150 mM NaCl, 2 mM CaCl2 and 2% bovine serum albumin, pH 8.5. EL wild-type and 
mutant medium, 250 µl was added to separate tubes, and the reaction run for 1 hour. 
Released fatty acid was extracted by the method of Belfrage and Vaughn and quantified 
by scintillation counting. 
Isolation of lipoprotein fractions 
Human lipoproteins were isolated from pooled plasma samples from non-fasting, 
normolipemic donors as follows: chylomicrons were obtained by centrifugation at 
d=1.006g/ml KBr for 30 min at 20,000 rpm. VLDL (d>1.006g/ml), IDL (1.006<d<1.019 
g/ml, LDL (1.019<d<1.063 g/ml), and HDL (1.063<d<1.21 g/ml) were isolated by 
sequential ultracentrifugation at 39,000 rpm for 16h in a Ti70 Beckman rotor at 10°C. 
Recovered fractions were dialyzed against phosphate-buffered saline and stored at 4°C. 
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Lipase hydrolysis of fractionated lipoprotein lipids 
 Isolated VLDL and HDL were incubated with EL-conditioned media using a 
modification of the method of Bamberger (22). Each reaction tube contained 1.25 mM 
lipoprotein phospholipids, 40 µl conditioned medium, 20 mM Tris-HCl, 0.15 M NaCl, 
pH7.4, 8 mM CaCl2 and 1% BSA in a final volume of 100 µl. Snake venom 
phospholipase A2 was used as a positive control. The tubes were incubated 4h at 37°C 
and the reaction stopped by addition of 25 mM EDTA. The released FFA was measured 
using the NEFA C kit (Wako Pure Chemical Industries, Osaka, Japan). Enzyme activity 
is reported as nmol free fatty acid (FFA) liberated/µg protein. 
 
Table 7.1.  
Primers Used for Site-Directed Mutagenesis 
 
 
 
Table 7.2.  
Concentrations of Wild-type and EL Mutants 
 
Protein      Concentration/ 
       transfection (µg/mL)* 
Wild-type 95.5 
14 ALAAPA 19 185 
292 AANA 295 12 
304 KKMRNAANSK 313 23 
427 AAIAVA 432 129 
 
*Average of 2 transfections 
 
14 KLHKPK 19 F GGACGGCTGGAAGATGCCCTCCACGCCCCCGCCGCTACACAGACTGAGG 
 R CCTCAGTCTGTGTAGCGGCGGGGGCGTGGAGGGCATCTTCCAGCCGTCC 
292 RKNR 295 F GGGATCTGTCTGAGCTGCGCCGCCAACGCCTGTAATAGCATTGGC 
 R GCCAATGCTATTACAGGCGTTGGCGGCGCAGCTCAGACAGATCCC 
304 KKMRNKRNSK 313 F GGCTACAATGCCAACAACATGCGCAACGCCGCCAACAGCAAAATG 
 R CATTTTGCTGTTGGCGGCGTTGCGCATGTTGTTGGCATTGTAGCC 
427 RRIRVK 432 F CGGGAGCTGGCCGCCCGGGCCATCGCCGTGAAGTCTGGGGAA 
 R TTCCCCAGACTTCACGGCGATGGCCCGGGCGGCCAGCTCCCG 
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Table 7.3.  
Lipoprotein Hydrolysis by Wild-type EL and EL Mutants 
 
Protein      Tributyrin Assay*     HDL#     VLDL# 
      nmol butyrate/hr/   nmol FFA/          nmol FFA/ 
     µg protein    µg protein    µg protein 
 
Wild-type 0.61  +0.010 15.5  + 3.42 7.37 + 3.56 
14 ALAAPA 19 0.61  +0.028 7.85  + 0.54 1.00 + 0.22 
292 AANA 295 0.60  +0.013 0.925 + 1.42 0 
304 KKMRNAANSK 313 0.58  +0.050 1.05  + 0.84 0 
427 AAIAVA 432 0.011 +0.006 0 0 
 
* - average of 2 experiments;  # - average of 3 experiments in triplicate 
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METHODS 
Supplements and extensions of methods presented in chapters 2, 4, 6 and 7. 
 
Computational design of stabilizing substitution R209P 
 The re-design of Arg209 of the human p53 DNA-binding domain [DBD] was 
motivated by the need to further stabilize the multi-domain p53 variants in the presence 
of DNA. At crystallographic concentrations in the range of 5 to 10 milligrams of protein 
per milliliter, the purified stable p53 variants precipitated when mixed with dsDNA, 
preventing screening of p53-DNA complexes. A visual inspection of the previously 
determined p53 DBD-DNA crystal structure (Cho et al. 1994; PDB code: 1TUP) reveals 
that Arg209 is exposed on the DBD surface opposite the DNA-binding residues, and that 
the local positive charge, in the context of a p53 multimer, might contribute to non-
specific DNA interactions (Fig. m.1). 
 
 In order to select the optimal amino-acid substitutions that would remove the 
positively charged residue, yet not disrupt the stability of the DBD, we employed a 
statistical computationally assisted design strategy [SCADS] to estimate the amino-acid 
probabilities at this site (Kono H. & Saven JG. 2001; Calhoun et al. 2003). SCADS is a 
side chain placement algorithm based on statistical mechanics and an entropy-based 
function that correlates energy levels of rotamer ensembles with amino acid identity 
occupancy probabilities (explained in chapter 5). The X-ray crystal structure used for this 
analysis is a stable variant of the human p53 DBD (Joerger et al. 2005; PDB code: 
2BIM). Of the available DBD structures, 2BIM has the best resolution (1.98 Å) and 
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shares two of the twelve stabilizing mutations with our p53 variants (V203A and 
N268D), and thus served as an ideal input structure for the calculations.  
 
 In the p53 Arg209 analysis, the value of the environmental energy was 
constrained to that of the input structure 2BIM, and the coordinates of the backbone 
atoms were fixed (Kono H. & Saven JG. 2001). Although the protein sequence was also 
fixed, rotamer sampling (via discrete residue-specific side-chain conformation libraries) 
was allowed at every position within the structure. At position 209, all amino acid 
identities and rotamer conformations were sampled. The results of the calculations (Fig. 
2.1b) show that wild-type arginine is the most probable residue with positively charged 
lysine as second most probable. The third most probable residue at position 209 is 
proline.  
 
 The side-chain structure of proline constrains the backbone dihedral angle to 
approximately −75°, providing relatively high conformational rigidity. Although proline 
can disrupt secondary structure elements; it is commonly found as the first residue of an 
α-helix and also in the edge strands of β-sheets. Indeed position 209 is located in a 
connecting strand within a β-sheet (residues 204-218) of the DBD (Fig. m.2). The R209P 
substitution into the stable p53 variants both increased melting temperature by an 
additional 15° C (described in chapter 2, Fig. 2.1a & c), and also prevented protein 
aggregation upon mixing with DNA, thus facilitating crystallographic screening of the 
p53-DNA complex.  
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Figure m.1 
 
Position of Arg209 in the DNA-binding domains bound to DNA (Cho et al. 1994; PDB code: 
1TUP). Surfaces of DBDs are shaded in blue, DNA is green and the two views are related by a 
90° horizontal rotation. The position of the positively-charged Arg209 (red) might contribute to 
non-specific DNA binding. 
 
 
 
 
 
 
Figure m.2 
 
Position of Pro209 in multi-domain p53 stable variant ST7. The same views of Fig. m.1, 
presented for the crystal structure of ST7 bound to DNA. The DBD and oligomerization domains 
are shown as blue cartoons, the DNA is green, and the four prolines at position 209 (one in each 
DBD) are shown as red sticks and labeled accordingly. 
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R209P substitution 
 The R209P substitution was introduced into the stable p53 multi-chain variants 
ST6 (described in chapter 2) using the QuikChange XL site-directed mutagenesis kit 
(Agilent Technologies, Stratagene Products Division, La Jolla, CA, USA). The primers 
used were: 
hp53P209_1 cgctGAGTATTTGGATGACccaAACACTTTTCGACATAGTGTG 
hp53P209_2 CACACTATGTCGAAAAGTGTTtggGTCATCCAAATACTCagcg 
 
Protein production and purification 
Protein expression 
 Plasmids containing the stable p53 polypeptides cloned downstream of a T7 
promoter with selectable tetracycline and ampicillin markers were used to transform E. 
coli. BL21(DE3) cells (Stratagene, La Jolla, CA, USA). Colonies were grown at 37°C 
with shaking at 220rpm in overnight LB/Amp100 starter cultures used to inoculate a final 
volume of 2.4 liters of LB/Amp100 medium the next day. The cells were grown at 37°C 
with shaking at 220 rpm to an OD of ~0.5-0.7. At the proper cell density, cells were 
pelleted by centrifugation and resuspended in fresh LB/Tet50 medium pre-warmed to 
30°C. Protein expression was induced by adding IPTG (Isopropyl β-D-1-
thiogalactopyranoside) to a final concentration of 1 mM. Cells were incubated at 30°C for 
4 to 5 hours with shaking at 220 rpm, after which the cells were pelleted, liquid medium 
removed, and pellets either stored at -20°C overnight or immediately lysed and used in 
the first purification steps. 
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Cation exchange chromatography 
 Purification of the p53 variants involves a two-step process consisting of cation 
exchange followed by gel filtration chromatography. The cells were lysed in buffer 
consisting of 25 mM bis-tris propane (BTP) [pH 6.8, 250 mM NaCl, 5 mM DTT and 
protease inhibitors], and centrifuged (Beckman Type Ti-60 fixed-angel rotor) at 50,000 
rpm for 1 hour to pellet cell debris. The cell lysate was adjusted to 100mM NaCl and 
passed over a cation exchange column (Sepharose SP column, Pharmacia Biotech, 
Uppsala, Sweden) equilibrated with buffer I [25 mM bis-tris propane (BTP) pH 6.8, 50 
mM NaCl, 5 mM DTT]. After passing the cell lysate over the column, a gradient to 100% 
buffer II [25 mM bis-tris propane (BTP) pH 6.8, 1000 mM NaCl, 5 mM DTT] was started 
and spanned the volume of 350 ml using a 2.5 ml/min flow rate and 5 ml fraction 
volumes. Fractions containing the p53 polypeptides were pooled and concentrated at 4°C 
with Vivaspin 20 MWCO 10K (Sartorius AG, Goettingen, Germany) centrifugal 
concentration devices. 
 
Gel-filtration 
 The concentrated fractions containing the p53 polypeptides purified by cation 
exchange were loaded onto a SuperDex 200 (GE Healthcare Life Sciences) size exclusion 
column equilibrated with 25 mM bis-tris propane [pH 6.8], 150 mM NaCl, 5 mM DTT 
buffer at 4°C. A flow rate of 250 µl/min, and fraction sizes of 300 µl, was used to 
separate the p53 polypeptides from the remaining bacterial proteins. Fractions containing 
the p53 polypeptides were pooled and concentrated to 5 to 15 mg/ml using Microcon 
YM-10 micro centrifugal concentration devices (Millipore, Billerica, MA, USA) at 4°C. 
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The concentrated purified p53 protein was then flash-frozen in liquid nitrogen and stored 
at -80°C until further use.  
 
Purification of p53-DNA complexes 
Oligonucleotide annealing 
 Polyacrylamide gel electrophoresis [PAGE]-purified oligonucleotides (Table m.1) 
were resuspended in TE pH 7.6 [10mM Tris, 1mM EDTA] to a final concentration of 200 
µM. Equimolar amounts of complementary oligonucleotides 1 and 2 were mixed in one 
1.5 ml screw-cap tube for each pair, and placed into a floating tube holder. One liter of 
water was brought to boil in a beaker, and the tubes containing the oligonucleotides were 
placed in the beaker at water temperature of 96°C for 5 minutes. The beaker containing 
the tubes of DNA was then removed from the heat and left to slowly equilibrate to room 
temperature on the bench top. When the beaker water temperature reached 25°C, the 
annealed oligonucleotides were removed, briefly centrifuged to collect any liquid in the 
lids, and stored at 4°C.  
 
Protein-DNA complex purification 
 All steps were performed either at 4°C or on ice. Purified stable ST p53 variants 
were mixed in molar ratios of 4:1 protein:dsDNA (100 µl final volume) on ice in order to 
form p53 tetramer-DNA complexes. The protein-DNA mix was incubated on ice for 1 
hour then loaded onto a SuperDex 200 (GE Healthcare Life Sciences) size exclusion 
column equilibrated with 25 mM bis-tris propane [pH 6.8], 150 mM NaCl, 5 mM DTT 
buffer. The complex was passed over the column at a flow rate of 250 µl/minute and 
fractions of 370 µl were collected starting 15 minutes after injection of the complex. 
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Fractions containing the complex (shown by shift in molecular size and verified by SDS-
PAGE; Figs. m.3, m.4) were then pooled, concentrated to 5-10mg/ml with Microcon 
YM-10 centrifugal concentration devices (Millipore, Billerica, MA, USA), and 
immediately used in hanging-drop crystal screening at 4°C. 
 
 
 
Figure m.3 
 
Purification of p53-DNA complexes. Two examples of DNA bound by p53 (a) and DNA not 
bound by p53 (b). p53 protein alone elutes at fraction 19, DNA alone elutes around fraction 22, 
and the p53-bound DNA complex elutes at fractions 13-15. (a) Example of a p53-DNA complex. 
Green boxes over DNA (26bp) indicate recognition sequences, chromatogram shows large 
protein-DNA peak at fractions 13-15. SDS-PAGE stained with Coomassie blue confirms that 
shifted fractions contain p53. (b) Example of an oligonucleotide too short (21bp) to interact 
stably with p53 variant ST7. Unbound p53 elutes at fraction 19 (as shown in SDS-PAGE gel 
below chromatogram), but does not complex with DNA, and is not enriched in fractions 13-15. 
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Figure m.4 
 
Elution profiles for p53, DNA and p53-DNA complexes. Three representative chromatograms 
are presented from gel filtration procedures discussed in this methods section. Fraction collection 
is always started at the same time following injection of the sample onto the Superdex 200 size 
exclusion column. Purified p53 elutes at fraction 19, DNA elutes at fraction 22, and the protein-
DNA complex elutes at fractions 13-15. Wavelengths: red curves are 254nm, blue curves are 
280nm. 
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Table m.1 
Oligonucleotide pairs, sense (upper) and anti-sense (lower), used in p53-DNA crystal 
screening. 
 
Name   Length   Sequence                                . 
p53tea211    21         GGG CATG TCT GGG CATG TCT G  
p53tea212    21         AGA CATG CCC AGA CATG CCC C 
 
p53tea221    22         GGG CATG TCT GGG CATG TCT AA  
p53tea222    22         AGA CATG CCC AGA CATG CCC TT 
 
p53tea231    23       C GGG CATG TCT GGG CATG TCT C G  
p53tea232    23       G AGA CATG CCC AGA CATG CCC G C 
 
p53tea241    24       C GGG CATG TCT GGG CATG TCT C AA  
p53tea242    24       G AGA CATG CCC AGA CATG CCC G TT 
 
p53tea251    25      AC GGG CATG TCT GGG CATG TCT CA G  
p53tea252    25      TG AGA CATG CCC AGA CATG CCC GT C 
 
p53tea261    26      AC GGG CATG TCT GGG CATG TCT CA AA  
p53tea262    26      TG AGA CATG CCC AGA CATG CCC GT TT 
 
p53tea263    26      AC GGG CATG TCT GGG CATG TCT CA GA  
p53tea264    26      TG AGA CATG CCC AGA CATG CCC GT TC 
 
p53tea265    26      AC GGG CATG TCT GGG CATG TCT CA GG  
p53tea266    26      TG AGA CATG CCC AGA CATG CCC GT CC 
 
p53tea267    26       AC GGG CATG TCT GGG CATG TCT CA CC  
p53tea268    26       TG AGA CATG CCC AGA CATG CCC GT GG 
 
p53tea2609   26   AG AC GGG CATG TCT GGG CATG TCT CA   
p53tea2610   26   CT TG AGA CATG CCC AGA CATG CCC GT 
 
p53tea2611   26      AC GGG CATG CTT GAG CATG TCT CA GA  
p53tea2612   26      TG AGA CATG CTC AAG CATG CCC GT TC 
 
p53tea2613   26      AC GGG CATG TAA TGG CATG TCT CA GA  
p53tea2614   26      TG AGA CATG CCA TTA CATG CCC GT TC 
 
p53tea2615   26      AC GGG CATG TCT GGG CAAG TCT CA GA  
p53tea2616   26      TG AGA CTTG CCC AGA CATG CCC GT TC 
 
p53tea2617   26      AC GGG CATG TCT GGG CACG TCT CA GA  
p53tea2618   26      TG AGA CGTG CCC AGA CATG CCC GT TC 
 
p53tea271    27    AC A GGG CATG TCT GGG CATG TCT CA AA  
p53tea272    27      TG AGA CATG CCC AGA CATG CCC T GT TT 
.                                                                           . 
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Crystal screening 
 All crystal screening, incubation, analysis and cryopreservation procedures were 
performed in a 4°C cold-room. The conditions promoting crystal growth were probed 
using crystal screening kits sampling a wide range of pH, anions, cations and polymers 
(Polyethylene glycols) such as the primary biased sparse matrix Crystal Screen, Index, 
PEG/Ion, SaltRX, and Natrix Screens (Hampton Research, Aliso Viejo, CA, USA) as 
well as home-made screens, in addition to screening some promising conditions with 
small-molecule additives; in all sampling over 1,000 different crystallographic conditions 
per protein or protein-DNA sample. Additionally, various protein-precipitant ratios in the 
range of 0.5:1 to 2:1 protein: precipitant were screened for most conditions. The majority 
of screens were set up in 48-well greased-edge VDX plates using 1mm thick circular 
coverslips to support the crystal drops, while some screens were performed in 96-well 
sitting drop plates (Hampton Research). Drops were manually observed and analyzed for 
the presence of crystals using a Leica stereo microscope, fitted with circular polarizers, in 
a 4°C cold-room. 
 
Colony assay 
 Saos 2 osteosarcoma cells (p53 -/-) were grown to ~60% confluency and co-
transfected (FuGene, Roche Applied Science, Indianapolis, IN, USA) with plasmids 
containing the Neo marker and one of three hp53 variants: WT, full length containing 
mutations of crystallized variant (ST), and D248Q which abolishes DNA binding.  The 
cells were exposed to various concentrations (300µg, 500µg and 800µg/ml final 
concentration) of G418 Geneticin (Gibco BRL Life Technologies, Inc), with medium 
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changes including fresh G418 every three days, over the course of two weeks. In order to 
count transformed cells (visible colonies), the cells are fixed to the 10cm plate by 
removing the media and adding 3 ml 3.7% w/w formaldehyde in phosphate-buffered 
saline [PBS with Ca2+ and Mg2+] and incubated at ambient room temperature for 5 
minutes. The PBS/formaldehyde was then removed and 3ml of 0.05% methylene blue (in 
water) was added for 10 minutes at room temperature to stain the cells. After staining, 
plates were washed four times with water, left upside down to dry, and visible colonies 
are counted.  
 
Quantitative PCR 
 Saos 2 osteosarcoma cells (p53 -/-) grown to ~60% confluency were transfected 
(FuGene, Roche Applied Science, Indianapolis, IN, USA) with plasmids containing one 
of three hp53 variants: WT, full length containing mutations of crystallized variant (ST), 
and D248Q which abolishes DNA binding. Total RNA was extracted (RNeasy, Qiagen, 
Germantown, MD, USA) from cells harvested at various time points ranging from one to 
three days after transfection and cDNA was made (PrimeScript 1st strand cDNA 
synthesis, Takara Bio Inc., Otsu, Shiga, Japan) from the extracted RNA. Quantative PCR 
was performed using primer sets for GAPDH (housekeeping), p53, p21, NoxA, SCOTIN, 
BAX and GADD45B (Roche Lightcycler 480 Real-Time PCR system) using LightCycler 
480 SYBR Green 1 Master reagents (Roche Applied Science, Indianapolis, IN, USA). 
The 10 µl reactions contained 300-400ng cDNA, and PCR temperature parameters were: 
95°C for 5 min (denaturation), then 40 amplification and detection cycles of 95°C for 15 
sec, 60°C for 20 sec, 72°C for 20 sec, followed by a final one minute 95° C to 55° C 
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melting curve analysis to confirm single-product amplification. The oligonucleotides 
used in this analysis are listed below in Table m.2.  
 
 
Table m.2 
Oligonucleotide pairs, sense (upper) and anti-sense (lower), used for qPCR 
 
Name    Product Size (bp)   Sequence                     . 
 
BAX 
RTPCR_BAXh_1  200   GCTCTGAGCAGATCATGAA 
RTPCR_BAXh_2     ATCATCCTCTGCAGCTCCA 
 
Gadd45B 
RTPCR_GADD45Bh_1 195   GGATTTTGCAATTTCTCC 
RTPCR_GADD45Bh_2    CTCGTACACCCCCACTGT 
 
GAPDH  
RTPCR_GAPDHh_1  724   TCTCTGCCCCCTCTGCTG 
RTPCR_GAPDHh_2     ACGCCTGCTTCACCACCT 
 
Human p53 
RTPCR_hp53_1  207   AGCCGCAGTCAGATCCTA 
RTPCR_hp53_2     AGCAGCCTCTGGCATTCT 
 
NoxA 
RTPCR_NOXAh_1  248   TGGAAACGGAAGATGGAA 
RTPCR_NOXAh_2     CCCAGTCTAATCACAGGT 
 
p21 
RTPCR_p21h_1  415   AGCTCTACCTTCCCACGG 
RTPCR_p21h_2     CAGGGTATGTACATGAGG 
 
Scotin 
RTPCR_SCOTINh_1 294   TGGAGCGAGGAAAGGTGTG 
RTPCR_SCOTINh_2    GGAGGCTGAGGATAAGGGG 
.            . 
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DNA binding characterization 
In vitro transcription-translation 
 [35S]-methionine-labeled full-length human wild-type p53 and the equivalent p53 
protein containing the stabilizing amino acid substitutions (ST7, Fig. 2.2, Fig. m.5) were 
expressed by using a coupled in vitro transcription-translation rabbit reticulocyte lysate 
system (Promega Corporation, Madison, WI, USA). Each 23 µl reaction was built by 
combining all ingredients (Fig. m.5) with the final addition of 2µl of [35S]-methionine to 
start the reaction. Immediately after the 1.5 hour incubation at 30°C the IVT-proteins 
were used in the DNA binding gel shift assays.  
 
DNA binding gel-shift assay 
 The radiolabeled in vitro translated p53 proteins were mixed at ambient room 
temperature with oligonucleotides containing consensus or variant p53 DNA binding 
sites (described in chapter 2, Fig. 2.5b) in reactions consisting of 1 µl IVT translated 
protein, 1 µl 50 µM dsDNA, 1 µl of 10X E-Zn buffer [100 mM Tris pH 8.0, 10 mM DTT, 
50% glycerol, 500 mM NaCl, 1 mM ZnOAc] and water to final volume of 10 µl, for 30 
minutes. The binding reaction was then analyzed on non-denaturing acrylamide tris-
glycine slab gels. The vertical gels were made with 5X Tris-glycine buffer [30.3 g Tris 
base, 144.1 g glycine, 20 ml 0.5 M EDTA] by mixing 31.5 ml water, 10 ml 5X Tris-
glycine buffer and 8.5 ml 30X acrylamide. Before sample loading, gels were pre-run at 
110V for 1.5 hours in 0.5X Tris-glycine buffer. The binding reactions were directly 
loaded into the gels and separated for 1 hour at 110V. After electrophoresis, the gels were 
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dried for 1.5 hours, and exposed to a phosphor screen that was scanned (Personal 
Molecular Imager, Bio-Rad Laboratories, Inc. Hercules, CA, USA) two days later.  
 
 
Figure m.5 
 
 
 
Representative SDS-PAGE scan of in vitro transcription-translation reactions. The luciferase 
control (green), wild-type (blue) and ST7 (orange) p53 variants are labeled on the gel with 
corresponding colored dots.  
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Introduction 
 As described in chapters 6 and 7, computational homology modeling of human 
endothelial lipase [hEL] was used to generate insights into the structural and functional 
details of this newly characterized lipase family member (1,2). Although the specificity 
of endothelial lipase towards high-density lipoprotein [HDL] has been well characterized 
experimentally, there is no structural data available to describe the mechanisms 
governing the propensity for hEL towards HDL hydrolysis. Experimental investigation of 
this lipase variant remains challenging due to the nature of post-translational 
modifications, and has rendered traditional expression systems inadequate for producing 
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the levels of pure protein required for crystallographic analysis. In the absence of a 
human endothelial lipase crystal structure, X-ray crystal structures from pancreatic and 
lipoprotein lipases were used as guides to generate an ensemble of human endothelial 
lipase models via comparative protein structure modeling for further investigation. This 
appendix is divided into some of the various topics that were investigated in this 
collaboration. 
Model Generation 
Template structures 
 The comparative protein structure modeling was performed using Modeller (3-6) 
(verions 8 through 9). Three lipase structures were used as input for the modeling 
process: 
 
 Human Pancreatic Lipase   PDB code: 1N8S 
 The pancreatic lipase (Homo sapiens)– colipase (Sus scrofa) complex7.  
 
 Human Pancreatic Lipase with Inhibitor PDB code: 1LPB 
 The pancreatic lipase (Homo sapiens) complexed with colipase (Sus scrofa) and 
 inhibited by undecane phosphonate methyl ester8:  
 
 Horse Pancreatic Lipase   PDB code: 1HPL 
 The pancreatic lipase (Equus caballus) structure9:  
 
Multiple sequence alignments were generated with human endothelial lipase and 
the three lipase structure sequences [1N8S, 1LPB, 1HPL] using ClustalW (10) (Fig. 
a1.2). From the alignments, ensembles of models (100 to 200) were created in order to 
assess structural differences among the models. Using the ten best models (lowest RMSD 
for backbone atoms among models and DOPE scores comparable to template structures) 
as input “base” structures, 5 additional activation-lid models were generated for each 
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base model. During this step, the α-helices, β-strands and β-sheets were fixed while 
allowing sampling of loop regions within this context. One representative alignment of 
10 models shows agreement in backbone conformation (Fig. a1.1). 
Figure a1.1 
 
Structural overlay of 10 models. The backbone atoms (n, ca, c, o) of 10 hEL models were 
structurally aligned. Central core regions show a high degree of similarity among models, 
whereas the solvent exposed loop regions exhibit higher positional variability. 
Model selection 
 An atomic distance-dependant statistical potential, optimized for model 
assessment and referred to as the discrete optimized protein energy method [DOPE], is 
included in the Modeller suite (11). This objective function was used to find low-scoring 
models representing DOPE scores close to those of the reference models (template 
structure). The DOPE profiles and scores for all models, in addition to the template 
structures, were calculated using MODELLER version 9v1 with a smoothing window of 15 
residues. A single lipase chain in each crystal structure was used in the calculations, 
disregarding co-lipases and in the case of the 1HPL dimer structure, disregarding one of 
the monomers. The overall DOPE score of endothelial lipase is within 87% of the score 
for 1HPL, 88% for 1N8S, and 88% for 1LPB. The residue-specific DOPE energy values 
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of the models were subsequently plotted against the DOPE profiles of representative 
template structures. The graphs generated from this analysis confirm that reasonable 
models were generated, with energy values close to those of the template structures (Fig. 
a1.3b).  
 
Four regions in the models exhibit slightly higher DOPE values than those of the 
templates (Fig. a1.3a). Amino acid numbering is for the secreted protein, after cleavage 
of the 20 amino acid signal peptide. The first, consisting of human EL residues 4-51, 
maps to the solvent exposed aminoterminal region of human endothelial lipase. The 
second region, residues 300-320, is positioned at the junction of the amino and carboxy-
terminal domains of the lipase, also exposed to solvent. The third and fourth regions, 
amino acids 339-347 and 427-440, respectively, lie on the solvent exposed far edge of the 
carboxyterminal domain. The relative variability of these regions from model to model is 
illustrated by B-factor putty in Fig. a1.3a, wider ribbons represent regions of higher 
structural variability among models. In X-ray crystallography the B-factor, also known as 
“temperature-factor”, is a term used to describe the degree to which the electron density 
for each atom is spread out, reflecting the dynamic mobility of that atom. In this case, the 
cartoon in Fig. a1.3a represents the positional variability among the models. Therefore 
the higher DOPE scores found in these regions might only reflect the increased 
flexibility, and not necessarily signify poorly modeled regions. The remaining regions of 
the models, especially those regions surrounding the conserved catalytic triad (Ser149, 
Asp173, His254) exhibit DOPE scores similar to those of the templates, demonstrating 
that the models are acceptable representations of energy minimized native states. 
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Figure a1.2 
1N8S      -----KEVCYERLG-CFSDDSPWSGITERPLHILPWSPKDVN------TRFLLYTNENP- 47 
1LPB      -----KEVCYERLG-CFSDDSPWSGITERPLHILPWSPKDVN------TRFLLYTNENP- 47 
1HPL      -----NEVCYERLG-CFSDDSPWAGIVERPLKILPWSPEKVN------TRFLLYTNENP- 47 
ELhu      MSNSVPLLCFWSLCYCFAAGSPVPFGPEGRLEDKLHKPKATQTEVKPSVRFNLRTSKDPE 20 
                 :*:  *  **: .** .   *  *.    .*: .:      .** * *.::*  
 
1N8S      -NNFQEVAADSSSISGSNFKTNRKTRFIIHGFIDKGE-ENWLANVCKNLFKVES-VNCIC 104 
1LPB      -NNFQEVAADSSSISGSNFKTNRKTRFIIHGFIDKGE-ENWLANVCKNLFKVES-VNCIC 104 
1HPL      -DNFQEIVADPSTIQSSNFNTGRKTRFIIHGFIDKGE-ESWLSTMCQNMFKVES-VNCIC 104 
ELhu      HEGCYLSVGHSQPLEDCSFNMTAKTFFIIHGWTMSGIFENWLHKLVSALHTREKDANVVV 100 
           :.    ......:....*:   ** *****:  .*  *.** .: . :.. *. .* :  
 
1N8S      VDWKGGSRTGYTQASQNIRIVGAEVAYFVEFLQSAFGYSPSNVHVIGHSLGAHAAGEAGR 164 
1LPB      VDWKGGSRTGYTQASQNIRIVGAEVAYFVEFLQSAFGYSPSNVHVIGHSLGAHAAGEAGR 164 
1HPL      VDWKSGSRTAYSQASQNVRIVGAEVAYLVGVLQSSFDYSPSNVHIIGHSLGSHAAGEAGR 164 
ELhu      VDWLPLAHQLYTDAVNNTRVVGHSIARMLDWLQEKDDFSLGNVHLIGYSLGAHVAGYAGN 160 
          ***   ::  *::* :* *:** .:* ::  **.  .:* .***:**:***:*.** **. 
 
1N8S      RTNGTIGRITGLDPAEPCFQGTPELVRLDPSDAKFVDVIHTDGAPIVPNLGFGMSQVVGH 224 
1LPB      RTNGTIGRITGLDPAEPCFQGTPELVRLDPSDAKFVDVIHTDGAPIVPNLGFGMSQVVGH 224 
1HPL      RTNGAVGRITGLDPAEPCFQGTPELVRLDPSDAQFVDVIHTDIAPFIPNLGFGMSQTAGH 224 
ELhu      FVKGTVGRITGLDPAGPMFEGADIHKRLSPDDADFVDVLHTYTRSFG--LSIGIQMPVGH 218 
           .:*::********* * *:*:    **.*.**.****:**   .:   *.:*:.  .** 
 
1N8S      LDFFPNGGVEMPGCKKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPDG-FAG 283 
1LPB      LDFFPNGGVEMPGCKKNILSQIVDIDGIWEGTRDFAACNHLRSYKYYTDSIVNPDG-FAG 283 
1HPL      LDFFPNGGKEMPGCQKNVLSQIVDIDGIWQGTRDFAACNHLRSYKYYTDSILNPDG-FAG 283 
ELhu      IDIYPNGGDFQPGCGLNDVLGSIAYG----TITEVVKCEHERAVHLFVDSLVNQDKPSFA 274 
          :*::****   ***  * :   :  .       :.. *:* *: : :.**::* *    . 
 
1N8S      FPCASYNVFTANKCFPCPSGGCPQMGHYADRYPGKTNDVGQKFYLDTGDASNFARWRYKV 343 
1LPB      FPCASYNVFTANKCFPCPSGGCPQMGHYADRYPGKTNDVGQKFYLDTGDASNFARWRYKV 343 
1HPL      FSCASYSDFTANKCFPCSSEGCPQMGHYADRFPGRTKGVGQLFYLNTGDASNFARWRYRV 343 
ELhu      FQCTDSNRFKKGICLSCRKNRCNSIGYNAKKMRNKRN---SKMYLKTRAGMPFRVYHYQM 331 
          * *:. . *. . *:.* .  * .:*: *.:  .: :   . :**.*  .  *  ::*:: 
 
1N8S      SVTLSGKK----VTGHILVSLFGNKGNSKQYEIFKGT-LKPDSTHSNEFDSDVDVGDLQM 398 
1LPB      SVTLSGKK----VTGHILVSLFGNKGNSKQYEIFKGT-LKPDSTHSNEFDSDVDVGDLQM 398 
1HPL      DVTLSGKK----VTGHVLVSLFGNKGNSRQYEIFQGT-LKPDNTYSNEFDSDVEVGDLEK 398 
ELhu      KIHVFSYKNMGEIEPTFYVTLYGTNADSQTLPLEIVERIEQNATNTFLVYTEEDLGDLLK 391 
          .: : . *    :   . *:*:*.:.:*:   :     :: : * :  . :: ::***   
 
1N8S      VKFIWYNN-VINPTLPRVGASKIIVETNVGKQFNFCSPETVREEVLLTLTPC-------- 449 
1LPB      VKFIWYNN-VINPTLPRVGASKIIVETNVGKQFNFCSPETVREEVLLTLTPC-------- 449 
1HPL      VKFIWYNN-VINLTLPKVGASKITVERNDGSVFNFCSEETVREDVLLTLTAC-------- 449 
ELhu      IQLTWEGASQSWYNLWKEFRSYLSQPRNPGRELNIRRIRVKSGETQRKLTFCTEDPENTS 451 
          ::: * .      .* :   * :    * *  :*:   ..   :.  .** *         
 
1N8S      ----------------------------- 
1LPB      ----------------------------- 
1HPL      ----------------------------- 
ELhu      ISPGRELWFRKCRDGWRMKNETSPTVELP 480 
 
Sequence Alignment of human endothelial lipase to pancreatic lipase structures. The 
sequences of three crystal structures were aligned to the hEL sequence as an initial guide for 
homology modeling. Catalytic triad Ser149, Asp173, His254, Lid region, and conserved 
disulfide bridges are highlighted accordingly. The 20-residue leader peptide (light grey) is 
cleaved from the active hEL, and the 37 carboxyterminal residues (light grey) were not modeled 
as no three-dimensional data was available for this region.  
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Function  
Catalytic triad residues 
The catalytic triad residues, required for enzymatic function, were investigated 
with attention to rotamer position in relation to the pancreatic lipase X-ray crystal 
structures. These three residues appear in similar orientation and location to the guide 
structures, providing evidence that the models are representative of a functional human 
endothelial lipase conformation. The root mean square deviations [RMSDs] for a 
representative hEL model to the human Pancreatic Lipase structure for all atoms within 
each catalytic residue were calculated with at: 
 RMSD for S149 = 0.636 Å 
 RMSD for D173 = 0.312 Å 
 RMSD for H254 = 0.475 Å 
 
 Three disulfide bridges are also present in the models formed from six conserved 
cysteine residues (Fig. a1.2). One bridge is formed by Cys232 and Cys252, located 
directly on either side of the activation lid, and potentially serves to stabilize the active 
site during catalytic lid displacement. Two other bridges, Cys277 to Cys288 and Cys291 
to Cys296, are positioned in loops located close to hinge region connecting the N-
terminal domain from C-terminal domain. 
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Figure a1.3 
 
 
Discrete optimized protein energy [DOPE] profile for representative hEL models.  
(a) B-factor putty diagram of the EL model. Four regions of slightly higher DOPE energy 
score are colored and marked with corresponding blue guide bars. The three catalytic residues: 
Ser149, Asp173, and His254 are shown as red sticks. (b) DOPE profiles of template (guide) 
structures are traced in yellow, orange and red. Representative model DOPE profiles are depicted 
with blue and green curves. Four regions of the models that exhibit slightly higher energy values 
than guide structures are highlighted with blue boxes. Locations of the three catalytic triad 
residues along the amino-acid sequence are marked with black lines. 
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Activation lid and substrate specificity 
 Reports demonstrate that triacylglyceride hydrolysis increases with increased 
amphiphacity of lid residues (12-18). Likewise, biochemical experiments probing 
substrate specificity showed that lid region mutations affected preferences for hydrolysis 
of substrates. Furthermore, it is known that the charge state of residues on the lid greatly 
affects the ability for particular lipases to recognize and properly hydrolyze its substrate 
(15,18). These studies demonstrate that lid opening or closing correlates with enzyme 
either activity, and that the size and geometry of the cleft under the lid and around the 
catalytic center relates to substrate specificity.  
 
 The hEL activation lid sequence is 232-CGLNDVLGSIAYGTITEVVKC-252. 
Conserved cysteines Cys232 and Cys252 form a disulfide bridge at the base of the 
activation lid. Residues lining the catalytic pocket opposite the activation lid help to 
stabilize the lid in the closed position over the active site. There is a local enrichment in 
large ring residues such as tryptophan, tyrosine and histidine in the cleft under the lid 
region of human endothelial lipase (Fig. a1.5a). If residues in this region were mutated to 
amino acids with smaller side chains, this might destabilize the closed conformation of 
the lid loop, possibly leading to a lipase with increased basal activity. 
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Figure a1.4 
 
  a      b    c 
   
 
Structural alignment (c) of (a) human endothelial lipase (white) with ring residues (red sticks) 
and (b) horse Pancreatic Lipase lid (yellow) with ring residues (blue sticks). 
 
Substrate specificity 
 The hEL models also provide a basis to investigate residues potentially involved in 
conferring hEL substrate specificity. The models were structurally aligned using 
MacPyMOL (version 0.96, DeLano Scientific LLC), to both horse (PDB code: 1HPL) 
and human pancreatic lipase (PDB codes: 1N8S, 1LPB) crystal structures. Residues 
within 8 Å of the center of the catalytic triad were then selected for analysis. Next, four 
different human lipase protein sequences were aligned: 
 Endothelial Lipase gi|38174526| 
 Lipoprotein Lipase gi|48146225| 
 Hepatic Lipase  gi|1695682| 
 Pancreatic Lipase gi|15679998| 
 
Given that each lipase has different substrate selectivity, and in order to find residues that 
might contribute to this substrate specificity, if a given position had identical residues 
among the four lipases, it was removed from this set.  
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 The remaining subset then contained only those residues that vary across lipase 
type (and thus could confer substrate specificity). Multi-species sequences alignments of 
endothelial lipase, 
 Homo sapiens:   gi|5174497|ref|NP_006024.1 
 Macaca mulatta:  gi|109122163|ref|XP_001090086.1 
 Rattus norvegicus: gi|60678260|ref|NP_001012759.1 
 Mus musculus:   gi|31543123|ref|NP_034850.2 
 Xenopus laevis:   gi|38174469|gb|AAH60756.1 
 
revealed the residues within this subset that vary within endothelial lipase, which were 
subsequently removed from this second subset. Residues showing substitutions through 
evolution were assumed to be less important in contributing to substrate specificity.  
 
 The remaining residues are conserved in endothelial lipase across five species, 
and are within 8 Å of the center of the catalytic triad, yet are not conserved across various 
lipase types. This analysis might suggest that these particular residues confer substrate 
specificity for endothelial lipase: W72, M74, T118, I146, Y148, V154, A155, P174, 
G176, V198, L199, Y201, T202, L208, S209, I210, I212, D227, Q229, G233, Y243, 
V250, K251, E253, E255, V258, H259, L260. Four residues in this list, Gly233, Tyr243, 
Val250 and Lys251, are located in the activation lid region between the conserved 
cysteines Cys232 and Cys252. This is in agreement with biochemical evidence 
demonstrating that the amino-acid composition of the activation lid influences substrate 
specificity.  
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Calcium coordination 
Calcium binding sites are common features of extracellular enzymes, such as 
proteases, and coordination of calcium has a large stabilizing effect. The protease 
Proteinase K from a thermophilic fungus contains two calcium binding sites, and the 
other crystallized forms of lipase also coordinate one calcium atom per monomer (7-
9,19). Calcium coordination could therefore be important to endothelial lipase stability 
and function. There is a potential calcium-binding site in the human endothelial lipase 
models that is in line with the crystal structure of horse pancreatic lipase. Using 
MacPyMOL, the human endothelial lipase models were structurally aligned to the Equus 
caballus pancreatic lipase (PDB code: 1HPL) crystal structure.  
 
Spatial analysis of residues in the hEL models (selecting residues within 4 Å of 
the calcium atom located in the 1HPL structure) revealed four residues of hEL in similar 
orientation and distance that may be involved in binding calcium. The residues used in 
horse pancreatic lipase to coordinate calcium are: Glu187 and Arg190, both through 
interactions with their backbone carbonyl, and Asp192 and Asp195. The residues in hEL 
that most probably coordinate calcium are: Ile184 (same backbone carbonyl as the horse 
Glu187), Arg187 (same backbone carbonyl as horse Arg190 and conserved in all lipases), 
Ser189 (same side-chain location as horse Asp192) and Asp192 (also in the same 
position as horse Asp195 conserved in all lipases). Furthermore, these four endothelial 
lipase residues share similar spatial distances along the sequence chain as the horse 
pancreatic lipase calcium coordinating residues. The local structure is overall very similar 
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among the crystal structures and the models in this region. Furthermore, the 
corresponding residues are conserved across various lipases.  
 
Figure a1.5 
 
Calcium coordination. Human endothelial lipase (red) aligned to horse pancreatic lipase (blue). 
Conserved residues that interact with calcium (green sphere) are shown as sticks and labeled 
according to hEL residue index.  
 
Mutations in population 
 According to the current biological data for human endothelial lipase, there are 
four mutations [G26S, T111I, T298S, N396S] associated with high levels of circulating 
HDL, implying the endothelial lipase has impaired enzymatic activity in these cases (20). 
The N396S substitution causes a two-fold reduction in activity when compared to wild-
type hEL. N396 is located very close to the glycosylation site N393, and prevention of 
N393 glycosylation is likewise known to cause a two-fold reduction in enzymatic 
activity. However, removal of another glycosylation site at N136A causes a 3-fold 
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enhanced activity of hEL. The hEL models could provide a basis to understanding how 
glycosylation might affect activity. 
 
 The four mutations were introduced, one at a time, to the wild-type sequence of 
human endothelial lipase. The sequences containing the point mutations were then used 
as input for the homology modeling process to generate theoretical structures containing 
these mutations. Representative models of each of these mutations were then aligned to 
the wild-type models. In Fig. a1.7, these alignments are graphically depicted in two 
different orientations. Green arrows highlight the mutated residues in each view. The 
wild-type sequences are shaded blue while the mutated endothelial lipase models are 
colored red. The residue of interest is likewise represented as a “stick” versus the “line” 
in the non-surface rendered monomer.  
 
 The mutations do not dramatically affect the structure (both local or global 
conformation) of the lipase when compared with wild-type models. If the endothelial 
lipase does function as a dimer, then all but the T111I mutations occur on the distal side 
of the functional area (activation lid and catalytic triad). Hypothetically, the activation lid 
opens towards the interior cavity created by the dimer. If that is indeed the case, then only 
the T111I is positioned near the dimer interface. If one or more of the other mutated 
residues are involved in allosteric regulation via glycosylation or other post-translational 
modifications, then it fits that these residues would be positioned on the distal, solvent-
exposed side of the dimer interface.  
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Figure a1.6 
   
  a 
 
  b 
 
 
 
Four mutations in human endothelial lipase (indicated by green arrows) associated with high 
levels of circulating HDL in the bloodstream. (a) View of solvent exposed surface indicating 
location of G26S (green), T298S (orange), N396S (blue), in the context of a hEL homodimer. (b) 
Position of T111I (purple), located on the side of the potential dimer interface. Residues within 5 
Å of the dimer interface are colored red.  
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Potential dimer interface residues 
 The human endothelial lipase monomer model was structurally aligned to the 
horse pancreatic lipase homodimer. The resulting human endothelial lipase dimer model 
was then used to highlight residues on one monomer within 5 Å of the opposite 
monomer. A figure from this analysis is shown in Table a1.1, with those residues near the 
interface colored in red or yellow. A list of corresponding residues is also shown below. 
Table a1.1 
 
Region 1 Region 1 Region 2 Region 3 Region 3 
42 Q 96 G 339 R 413 Q 424 Y 
43 T 97 I 342 M 414 L 452 K 
44 E 98 F 380 Q 415 T 453 S 
46 K 99 E 381 T 416 W 454 G 
47 P 100 N 403 E 417 E 455 E 
61 H 124 L   418 G 456 T 
62 E 125 P   420 S 457 Q 
63 G 128 H   421 Q 458 R 
64 C     422 S 459 K 
List of residues potentially involved in the hEL dimer interface 
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Appendix II 
p53 Supplementary Figures & Tables. 
 
 
Figure a2.1 
 
Somatic mutations in p53 – mutation affect. 24,785 total mutations. IARC TP53 mutation 
database, R13 release, November 2008 
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Figure a2.2 
 
 
 
From: Millau JF, Bastien N, Drouin R. P53 transcriptional activities: a 
 general overview and some thoughts. Mutat Res. (2009) 681:118-33. 
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Figure a2.3 
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Figure a2.4 
 
Aligned p53 DNA-binding domains. This alignment, with ST p53 sequence as the first entry, 
was used to calculate relative conservation for graphs presented in Fig. 3.7. Alignment created in 
ClustalW (EMBL-EBI) and colored by conservation in JalView (Waterhouse et al. 2009). Darker 
blue correlates with higher conservation.  
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Table a2.1 
 
p53 (and homologous) DNA-Binding domain sequences presented in multiple sequence 
alignment (Fig a2.4) 
 
Reference for composition-based statistics: 
Schaffer, Alejandro A., L. Aravind, Thomas L. Madden, 
Sergei Shavirin, John L. Spouge, Yuri I. Wolf,  
Eugene V. Koonin, and Stephen F. Altschul (2001),  
"Improving the accuracy of PSI-BLAST protein database searches with  
composition-based statistics and other refinements", Nucleic Acids Res. 29:2994-3005. 
 
Query= FILE_A 198 
     (198 letters) 
 
Database: sprot  
      510,076 sequences; 179,409,349 total letters 
 
                                                                       Score  E 
Sequences producing significant alignments:                            (bits) Value 
 
1  sp|P04637|P53_HUMAN Cellular tumor antigen p53 OS=Homo sapiens G...  370  e-102 
2  sp|Q95330|P53_RABIT Cellular tumor antigen p53 OS=Oryctolagus cu...  367  e-101 
3  sp|P13481|P53_CERAE Cellular tumor antigen p53 OS=Cercopithecus ...  361  2e-99 
4  sp|P56423|P53_MACFA Cellular tumor antigen p53 OS=Macaca fascicu...  361  2e-99 
5  sp|P61260|P53_MACFU Cellular tumor antigen p53 OS=Macaca fuscata...  361  2e-99 
6  sp|P56424|P53_MACMU Cellular tumor antigen p53 OS=Macaca mulatta...  361  2e-99 
7  sp|Q64662|P53_SPEBE Cellular tumor antigen p53 (Fragment) OS=Spe...  361  2e-99 
8  sp|Q9TTA1|P53_TUPGB Cellular tumor antigen p53 OS=Tupaia glis be...  355  9e-98 
9  sp|O36006|P53_MARMO Cellular tumor antigen p53 OS=Marmota monax ...  355  1e-97 
10 sp|P10361|P53_RAT Cellular tumor antigen p53 OS=Rattus norvegicu...  352  1e-96 
11 sp|Q8SPZ3|P53_DELLE Cellular tumor antigen p53 OS=Delphinapterus...  350  4e-96 
12 sp|Q9TUB2|P53_PIG Cellular tumor antigen p53 OS=Sus scrofa GN=TP...  349  8e-96 
13 sp|Q00366|P53_MESAU Cellular tumor antigen p53 OS=Mesocricetus a...  348  1e-95 
14 sp|O09185|P53_CRIGR Cellular tumor antigen p53 OS=Cricetulus gri...  347  2e-95 
15 sp|P79892|P53_HORSE Cellular tumor antigen p53 (Fragment) OS=Equ...  343  4e-94 
16 sp|P02340|P53_MOUSE Cellular tumor antigen p53 OS=Mus musculus G...  343  5e-94 
17 sp|P67938|P53_BOSIN Cellular tumor antigen p53 OS=Bos indicus GN...  342  1e-93 
18 sp|P67939|P53_BOVIN Cellular tumor antigen p53 OS=Bos taurus GN=...  342  1e-93 
19 sp|P51664|P53_SHEEP Cellular tumor antigen p53 OS=Ovis aries GN=...  338  1e-92 
20 sp|Q9WUR6|P53_CAVPO Cellular tumor antigen p53 OS=Cavia porcellu...  338  1e-92 
21 sp|Q29537|P53_CANFA Cellular tumor antigen p53 OS=Canis familiar...  338  2e-92 
22 sp|P41685|P53_FELCA Cellular tumor antigen p53 OS=Felis catus GN...  332  8e-91 
23 sp|Q29480|P53_EQUAS Cellular tumor antigen p53 (Fragment) OS=Equ...  285  1e-76 
24 sp|P79734|P53_DANRE Cellular tumor antigen p53 OS=Danio rerio GN...  281  2e-75 
25 sp|Q9W678|P53_BARBU Cellular tumor antigen p53 OS=Barbus barbus ...  278  2e-74 
26 sp|P10360|P53_CHICK Cellular tumor antigen p53 OS=Gallus gallus ...  275  1e-73 
27 sp|P25035|P53_ONCMY Cellular tumor antigen p53 OS=Oncorhynchus m...  275  2e-73 
28 sp|O93379|P53_ICTPU Cellular tumor antigen p53 OS=Ictalurus punc...  262  1e-69 
29 sp|P07193|P53_XENLA Cellular tumor antigen p53 OS=Xenopus laevis...  259  7e-69 
30 sp|Q92143|P53_XIPMA Cellular tumor antigen p53 OS=Xiphophorus ma...  242  1e-63 
31 sp|O57538|P53_XIPHE Cellular tumor antigen p53 OS=Xiphophorus he...  241  2e-63 
32 sp|Q9JJP2|P73_MOUSE Tumor protein p73 OS=Mus musculus GN=Tp73 PE...  239  6e-63 
33 sp|Q9XSK8|P73_CERAE Tumor protein p73 OS=Cercopithecus aethiops ...  238  1e-62 
34 sp|O15350|P73_HUMAN Tumor protein p73 OS=Homo sapiens GN=TP73 PE...  238  2e-62 
35 sp|Q9JJP6|P63_RAT Tumor protein 63 OS=Rattus norvegicus GN=Tp63 ...  236  8e-62 
36 sp|Q9H3D4|P63_HUMAN Tumor protein 63 OS=Homo sapiens GN=TP63 PE=...  236  8e-62 
37 sp|O88898|P63_MOUSE Tumor protein 63 OS=Mus musculus GN=Tp63 PE=...  236  8e-62 
38 sp|Q9W679|P53_TETMU Cellular tumor antigen p53 OS=Tetraodon miur...  234  2e-61 
39 sp|O12946|P53_PLAFE Cellular tumor antigen p53 OS=Platichthys fl...  227  3e-59 
40 sp|P79820|P53_ORYLA Cellular tumor antigen p53 OS=Oryzias latipe...  223  8e-58 
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Figure a2.5 
 
 
 
 
 
 
 
Figure a2.6 
 
 
From: Millau JF, Bastien N, Drouin R. P53 transcriptional activities: a 
 general overview and some thoughts. Mutat Res. (2009) 681:118-33. 
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Table a2.2 
 
p53 response element base pair step parameters. DNA structural parameters for were analyzed 
using the X3DNA software package (Hassan & Calladine 1998). All displacements are measured 
in Angstroms. Pictorial definitions of the step parameters are explained in Fig. a2.7. Shifted 
regions are highlighted with green boxes (p53 tetramer-DNA structure) or blue boxes (model B-
form DNA). Conserved C[A/T][A/T]G sequences are red. 
 
Multidomain p53 Oligomer bound to DNA 
   Step        Shift     Slide      Rise      Tilt      Roll     Twist 
   1 AC/GT      0.44      0.30      3.17      4.89      4.61     31.53 
   2 CG/CG     -0.07      1.89      3.27     -1.16      5.47     27.74 
   3 GG/CC     -0.77     -0.00      3.51     -5.65      1.39     37.34 
   4 GG/CC      0.88     -0.23      3.31      3.04      2.91     37.93 
   5 GC/GC     -0.12     -0.72      3.25     -1.16     -0.19     31.54 
   6 CA/TG      0.97      0.85      3.44      5.46      5.68     44.77 
   7 AT/AT      0.02     -0.30      3.16     -0.80     12.48     18.36 
   8 TG/CA     -1.16      0.36      3.58     -2.58      4.38     42.46 
   9 GT/AC     -0.19     -0.94      3.28     -1.09     -0.26     33.00 
  10 TC/GA     -0.94     -0.39      3.35     -1.23     -2.48     34.77 
  11 CT/AG     -0.41      0.66      3.37     -1.03      6.60     29.60 
  12 TG/CA     -0.10      2.62      3.17     -1.22     -3.58     44.11 
  13 GG/CC      0.50      0.32      3.20      0.61      4.28     33.30 
  14 GG/CC      0.71     -0.22      3.48      3.85     -1.63     35.95 
  15 GC/GC      0.22     -0.67      3.21      1.01     -0.59     36.01 
  16 CA/TG      1.37      0.70      3.59      2.04      4.85     41.64 
  17 AT/AT     -0.26     -0.44      2.97      1.32     12.46     17.96 
  18 TG/CA     -1.22      0.95      3.62     -3.59      5.68     43.43 
  19 GT/AC     -0.22     -0.88      3.16     -2.57      1.49     33.77 
  20 TC/GA     -0.31     -0.18      3.40     -1.37      2.71     34.35 
  21 CT/AG     -0.08     -0.68      3.30      4.03      4.79     35.29 
  22 TC/GA      0.88      1.30      3.11      3.46      1.51     32.26 
  23 CA/TG     -0.08      0.57      3.50     -4.06      7.72     41.62 
          ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
      ave.      0.00      0.21      3.32      0.10      3.49     34.73 
      s.d.      0.68      0.90      0.17      3.00      4.14      7.06 
 
B-form DNA 
   Step        Shift     Slide      Rise      Tilt      Roll     Twist 
   1 AC/GT      0.02      0.49      3.36      0.02      1.71     36.83 
   2 CG/CG      0.00      0.41      3.34      0.00      1.70     33.93 
   3 GG/CC      0.01      0.47      3.36     -0.03      1.71     35.96 
   4 GG/CC      0.01      0.47      3.36     -0.03      1.71     35.97 
   5 GC/GC     -0.00      0.54      3.38     -0.00      1.72     37.99 
   6 CA/TG     -0.04      0.44      3.35      0.01      1.71     35.09 
   7 AT/AT      0.00      0.44      3.35      0.00      1.71     35.67 
   8 TG/CA      0.04      0.44      3.35     -0.01      1.71     35.08 
   9 GT/AC     -0.02      0.49      3.36     -0.02      1.71     36.83 
  10 TC/GA      0.03      0.50      3.37      0.01      1.71     37.13 
  11 CT/AG     -0.03      0.42      3.35      0.01      1.70     34.80 
  12 TG/CA      0.04      0.44      3.35     -0.01      1.71     35.09 
  13 GG/CC      0.01      0.47      3.36     -0.03      1.71     35.96 
  14 GG/CC      0.01      0.47      3.36     -0.03      1.71     35.97 
  15 GC/GC     -0.00      0.54      3.38     -0.00      1.72     37.99 
  16 CA/TG     -0.04      0.44      3.35      0.01      1.71     35.09 
  17 AT/AT      0.00      0.44      3.35      0.00      1.71     35.67 
  18 TG/CA      0.04      0.44      3.35     -0.01      1.71     35.08 
  19 GT/AC     -0.02      0.49      3.36     -0.02      1.71     36.83 
  20 TC/GA      0.03      0.50      3.37      0.01      1.71     37.13 
  21 CT/AG     -0.03      0.42      3.35      0.01      1.70     34.80 
  22 TC/GA      0.03      0.50      3.37      0.01      1.72     37.13 
  23 CA/TG     -0.04      0.44      3.35      0.01      1.71     35.08 
          ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
      ave.      0.00      0.47      3.36     -0.00      1.71     35.96 
      s.d.      0.03      0.03      0.01      0.02      0.00      1.09 
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Figure a2.7  
 
Pictorial representation of parameters relating sequential base pair steps. The base pair 
reference frame is constructed such that the x-axis points away from the (shaded) minor groove 
edge. Image illustrates positive values of the designated parameters (Hassan & Calladine 1998; 
Dickerson et al. 1989). 
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